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1. Het maken van een op wetenschappelijk bewijs gebaseerde afweging van de voor-
en nadelen van palliatieve chemotherapie wordt bemoeilijkt door de beperkte
hoeveelheid bewijs ten aanzien van de toxiciteit en het eect op de te verwachten
levensduur.
(hoofdstuk 3 en 4 van dit proefschri)
2. Ook onder patiënten die niet meer kunnen genezen van kanker bestaat vaak een
verlangen naar informatie over de voor- en nadelen van behandelmogelijkheden,
waaronder informatie over de te verwachten levensduur.
(hoofdstuk 5 en 6 van dit proefschri)
3. De zogenoemde ‘silent misdiagnosis’ van de voorkeuren van patiënten betre
niet alleen de voorkeur voor een bepaalde behandeling, maar ook de voorkeur
voor informatie.
(hoofdstuk 6 van dit proefschri)
4. Informatie over de voor- en nadelen van palliatieve chemotherapie kan op
veilige en acceptabele wijze door een verpleegkundige middels een keuzehulp
aan patiënten met gevorderde kanker worden aangeboden.
(hoofdstuk 7 van dit proefschri)
5. Het koppelen van keuzehulpen aan richtlijnen zal de ontwikkeling en het onder-
houd, en vermoedelijk ook het gebruik van keuzehulpen ten goede komen.
(hoofdstuk 9 van dit proefschri)
6. Informatie is als medicatie — meer is niet altijd beter, het gaat om de juiste
dosering.
7. De keuze om af te zien van verdere palliatieve chemotherapie impliceert niet
zozeer dat een patiënt de hoop opgee, maar dat de hoop zich op andere aspecten
dan de behandeling richt.
8. De beste kritiek is een goede vraag.
9. Just because nobody complains doesn’t mean all parachutes are perfect.
(Benny Hill, English comedian)
10. e greatest mistake you can make in life is to be continually fearing you will
make one.
(Elbert Hubbard, American writer, publisher, artist, and philosopher)
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Part I
Setting the stage
Chapter 1
Introduction
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Background
Cancer in the palliative stage
In 2011, around 100,000 people in the Netherlands were diagnosed with cancer,
which is around 276 people every day.1 Roughly 60% of the people diagnosed with
cancer can be cured. While the other 40% of patients cannot be cured, they can
be treated with palliative intent to relieve symptoms and improve quality of life,
and if possible even increase survival.2,3 Depending on the type of cancer and the
characteristics of the cancer cells, survival gains range from weeks to months, and
nowadays for some groups of patients even years. Treatment modalities commonly
used are systemic chemotherapy and targeted therapy, while local therapy could
consist of radiotherapy and in some tumours also surgery. e focus of these
treatments is reduction or stabilisation of tumour load. All patients can benet
from best supportive care (BSC), dened as all care provided to relieve symptoms
associated with cancer (such as pain, emotional and psychosocial complaints) and
to improve quality of life.4,5 BSC does not include systemic therapy.e decision
whether or not to add systemic therapy —such as palliative chemotherapy— to
BSC deserves proper consideration of the uncertain benets against the risk of
experiencing (severe) adverse events, such as nausea and vomiting, suppression of
the immune system, and treatment-related mortality (see Figure 1.1).
Shared decision-making and decision aids
When there is no evident best treatment option, and options will vary in their impact
on the patient’s physical and psychological well-being, it is to be expected that some
patients will decide to have chemotherapy, while others will decide to refrain from
chemotherapy. To reach a decision aligned with patient’s values and preferences,
clinician and patient need to work together. Aer all, the clinician is the expert
regarding the disease, treatment options, and outcomes, while the patient knows
best how the dierent treatment optionswill aect his or herwell-being. In a seminal
publication in 1997, Charles and colleagues proposed a model for shared decision-
making (SDM) in the medical encounter.6 In this model, key characteristics of SDM
were that at least two participants are involved in the treatment decision (clinician
and patient, and perhaps other clinicians and caregivers), and that these parties
share information, take steps to build consensus about the preferred treatment, and
reach an agreement.
Pros of adding chemotherapy
Symptom prevention and relief
Prolongation of life
Cons of adding chemotherapy
(Severe) adverse events
Figure 1.1:e central treatment decision in this PhD thesis: choosing whether or not to
add palliative chemotherapy to best supportive care
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SDM can be supported by decision aids (DAs) to share information on treatment
options and the potential benets and risks of each of the alternatives, and to
structure the decision-making process. DAs are available inmany formats, including
booklets, videos, and web-based tools.7 ese aids can be used to complement the
information from the clinician, and are proven to be eective at stimulating patients
to take a more active role in decision-making,7,8 lowering decisional conict,7,9
decreasing the proportion of people remaining undecided,7 and improving patients’
knowledge regarding treatment options, without increasing anxiety or regret.7,9
e concepts of SDM and DAs t the increasing focus on patient-centred care. In
2001, the Institute of Medicine in the US named patient-centredness as one of six
goals for improving the health care system of the 21st century.10 Patient-centred
care was dened as ‘providing care that is respectful of and responsive to individual
patient preferences, needs, and values, and ensuring that patient values guide all
clinical decisions’.is goal has been embedded in legislation in the 2010 Patient
Protection and Aordable Care Act.11 Patient-centredness has also permeated the
education of medical specialists, as a framework of core competencies (CanMEDS)
described seven physician roles, one of which is the role of communicator which
emphasises patient-centred communication and SDM.12
In the Netherlands, there is a similar focus on patient-centred care. One of the
requirements in the Dutch Quality of Care Institutions Act is that health care pro-
viders oer ‘responsible’ care, which implies care of a high standard, that is provided
in an eective, ecient and patient-centred way and that meets the patient’s actual
needs.13 In recent years, many health care organisations have included the phrase
‘patient-centredness’ in their mission statements, and quality labels based on cri-
teria regarding patient-centred care have been issued by patient organisations and
insurance companies.
Shared decision-making and decision aids in the palliative treatment setting
Despite this favourable climate, questions may rise about the necessity and feas-
ibility of introducing SDM and DAs in all areas of health care. In the setting of
advanced cancer, one of the major points of discussion is whether these seriously
ill patients wish to share information on treatment options, in particular poten-
tially threatening information on expected survival.14 Nevertheless, surveys among
patients with advanced cancer have indicated that many of these patients (44%,
59%, 80%, and 88%, respectively) express a wish to receive information on expected
survival.15–18 Assuming that these results from surveys using hypothetical questions
are generalisable to patients making actual treatment decisions, this will still leave
a sizeable minority of patients who do not wish to be informed about expected
survival. It can be challenging for clinicians to tailor their information provision
to the desire of each individual patient. Studies have shown that physicians have
problems predicting patients’ preferences for information on expected survival,15
and only few patient characteristics are known to be associated with wanting sur-
vival information.15,17–19 ere are also indications that information provision is
generally not attuned to the information needs of individual patients.20
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Another major point of discussion is related to the consequences of informing
patients about their treatment options using a DA.e benets of DAs have been
demonstrated in many areas of health care, including the area of cancer treatment,
and no adverse eects have been found.7 However, clinicians oen express the
concern that in a population of patients with advanced cancer, providing survival
information may provoke anxiety.21,22
As a nal point, despite the proliferation in development and evaluation of DAs
(the last update of the Cochrane review on DAs included 86 randomised studies),7
very few to none are implemented in daily clinical practice.23 Once a DA has been
proven benecial, barriers to implementation such as lack of time and resources,
inexibility of the health care system, and clinical culture need to be overcome to
bring the benets of DAs to patients.
Study aim and research questions
is thesis focuses on the treatment decision whether or not to add palliative chemo-
therapy to best supportive care. Patients with advanced cancer can receive several
sequential lines of chemotherapy. For example, aer the diagnosis of advanced
cancer, the treatment decision arises whether or not to start a rst chemotherapeutic
approach with palliative intent, which is dened as rst-line chemotherapy. Patients
who decide to start rst-line chemotherapy will aer a certain period of time be
diagnosed with disease progression. At that moment, patients can choose whether
or not to start a subsequent second line of treatment, possibly to be followed by
further lines of treatment.
Beyond the setting of rst-line treatment, benets of chemotherapy are reduced
and also oen less clear.erefore, this thesis focuses specically on the decision
regarding second-line palliative chemotherapy. is decision will be studied in
two common types of cancer, namely colorectal and breast cancer. e research
questions addressed in this thesis are as follows:
1. What are the benets and risks of second-line chemotherapy for patients
with advanced colorectal cancer?
2. What are the benets and risks of second-line chemotherapy for patients
with advanced breast cancer?
3. Do patients with advanced cancer want to be informed about second-line
treatment options, and specically about their prognosis?
4. Is it possible to predict the information desire of individual patients based
on patient characteristics or based on the judgement of medical oncologists?
5. What is the eect of the introduction of decision aids for second-line chemo-
therapy on the well-being of patients with advanced cancer, compared with
the usual information provision?
6. What are the barriers and facilitators to implementation of these decision
aids for palliative treatment decisions in daily clinical practice?
By answering these questions, more knowledge is obtained about the necessity and
feasibility of introducing SDM and DAs in the setting of advanced cancer.
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Study design and outline of the thesis
To answer these questions, DAs on second-line palliative chemotherapy were de-
veloped (Part I) and then oered to patients in a clinical trial (Part II). In addition, a
qualitative study was performed to assess the implementation of the DAs (Part III).
ese studies are followed by a general discussion (Part IV).
Part I: Setting the stage
e study protocol in Chapter 2 describes how the DAs were developed, and how
they were oered to patients with advanced breast or colorectal cancer facing
the decision about second-line palliative chemotherapy. e treatment-related
outcomes presented in the DAs were obtained from systematic reviews of the
literature on benets and risks of second-line palliative chemotherapy for advanced
breast or colorectal cancer (Chapters 3 and 4). A nurse copy of a DA for second-line
palliative chemotherapy in advanced colorectal cancer is included in the Appendix.
Part II: Using the decision aids in the context of a clinical trial
e information desire of patients with advanced breast or colorectal cancer was
assessed by oering a DA to patients facing the decision about second-line palliative
chemotherapy. e DA contained information on three items: adverse events,
tumour response, and survival. DAs were oered to patients by a nurse, who asked
patients for each item whether the information was desired or not (Chapters 5
and 6). Oncologists were asked beforehand to make a judgement of patient’s desire
for these three information items, and this judgement was compared to the patient’s
actual information desire (Chapter 5). Data on patient characteristics potentially
associated with information desire were collected through patient questionnaires at
baseline, and inclusion and progression forms lled out by clinicians (Chapter 6).
e eects of theDAswere evaluated using random assignment of patients to receive
only usual care, or usual care plus the DA (Chapter 7).
Part III: Exploring the use of the decision aids in daily clinical practice
A qualitative study was performed to gain insight into the factors inuencing the
implementation of these DAs for palliative treatment decisions in daily clinical prac-
tice (Chapter 8). Interviews were conducted with oncologists and nurses who had
been involved in the clinical trial to explore their views on barriers and facilitators
to implementation of the DAs.
Part IV: General discussion and summaries
A general discussion of the studies presented in this PhD thesis, and the implications
for clinical practice and future research are included in Chapter 9.
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Abstract
Background ere is a continuing debate on the desirability of informing patients
with cancer and thereby involving them in treatment decisions. On the one hand,
information uptake may be hampered, and additional stress could be inicted by
involving these patients. On the other hand, even patients with advanced cancer
desire information on risks and prognosis. To settle the debate, a decision aid will be
developed and presented to patients with advanced disease at the point of decision
making.e aid is used to assess the amount of information desired. Factors related
to information desire are explored, as well as the ability of the medical oncologist
to judge the patient’s information desire.e eects of the information on patient
well-being are assessed by comparing the decision aid group with a usual care group.
Methods/Design is study is a randomised controlled trial of patients with
advanced colorectal, breast, or ovarian cancer who have started treatment with
rst-line palliative chemotherapy. e trial will consist of 100 patients in the de-
cision aid group and 70 patients in the usual care group. To collect complete data
of 170 patients, 246 patients will be approached for the study. Patients will com-
plete a baseline questionnaire on sociodemographic data, well-being measures,
and psychological measures, believed to predict information desire.e medical
oncologist will judge the patient’s information desire. Aer disease progression is
diagnosed, the medical oncologist oers the choice between second-line palliative
chemotherapy plus best supportive care (BSC) and BSC alone. Randomization
will take place to determine whether patients will receive usual care (n = 70) or
usual care and the decision aid (n = 100). e aid oers information about the
potential risks and benets of both treatment options, in terms of adverse events,
tumour response, and survival. Patients decide for each item whether they desire
the information or not. Two follow-up questionnaires will evaluate the eect of the
decision aid.
Discussion is study attempts to settle the debate on the desirability of informing
patients with cancer. In contrast to several earlier studies, we will actually deliver
information on treatment options to patients at the point of decision making.
Trial registration Netherlands Trial Registry (NTR): NTR1113
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Introduction
Introduction
Good clinical practice encompasses optimal providing of information to patients.
However, as yet the debate about the desirability of informing patients with cancer
and thereby involving them in their own care process has not been resolved. On the
one hand, it has been shown that patients with more severe disease may become
emotionally unstable and tend to leave decision making to their physician.1–3 Fur-
thermore, patients with cancer may sometimes deny their illness.4 In short, patients
may wish ‘not to know’. All these factors hamper the uptake of information. It is
conceivable that additional stress could be inicted upon patients by involving them
in decisions which are complex, emotionally hot, with high personal stakes and
have to be taken under time pressure. ese circumstances are unfavourable for
rational decision making.5 Taken these arguments together, the positive eects of
informing cancer patients with relevant information for treatment decision making
can be questioned.
On the other hand, cancer patients desire to be informed about risks and prognosis.
A systematic review of Gaston and Mitchell6 showed that almost all cancer patients
wish to be fully informed, regardless of the stage of their disease. Studies using
the questionnaire that was developed by Cassileth et al.7 showed that 83%–92% of
advanced cancer patients wanted as much information as possible, whether good
or bad.7–10 Hagerty et al.11 more specically explored the desire for prognostic
information and showed that over 80% of advanced cancer patients wanted to know
the longest time to live with treatment, 5-year survival rates, and average survival.
Unlike the aforementioned studies that probed preferences, Elit et al.12 actually
delivered information to patients with advanced gynaecological cancer. A decision
instrument was used to present information on two chemotherapeutic treatment
options and their potential risks and benets. Survival information was desired by
and provided to 92% of the women. However, these patients were asked to make
a hypothetical decision, since the treatment choice would not actually be carried
out. In the present study, we will assess patients’ information desire by oering
information in a decision aid at the point of decision making.e treatment choice
of patients will actually be carried out.
e amount of information desired may be predicted by a number of patient-related
and disease-related factors. It is known that a higher amount of information is
preferred by patients who are younger, better educated, have received the diagnosis
more recently, and are in a less advanced stage of the disease.7,9,10,13 In our study,
where we actually deliver information using a decision aid, we will examine how
various sociodemographic, medical, and psychological characteristics of the patient
are related to the patient’s information desire.
Current practice of information giving by physicians was investigated by studies in
Australia14,15 and the Netherlands,16 by audio taping the rst consult of incurable
cancer patients with their oncologists. In both Australia and the Netherlands, the
majority of patients were informed about the absence of cure (75% and 84%, respect-
ively). However, information about life expectancy or prognosis was communicated
to only 58% and 39% of Australian and Dutch patients, respectively. Only half of the
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patients in both countries were informed about the alternative to active treatment,
best supportive care (BSC). When BSC was mentioned in the Netherlands, half
of the time it was mentioned in a single sentence. Obviously, not all information
issues were covered in every rst consultation.e oncologists may have intuitively
tailored the amount and content of information to the individual patient. However,
whereas studies have indicated that over 80% of patients desire all information,
the percentages of Australian and Dutch patients receiving all information were
noticeably lower. is raises the question whether the oncologists may have un-
derestimated the amount of information desired by their patients. In the present
study, we will assess whether medical oncologists are able to judge their patients’
information desire.
A main concern of physicians is that the provision of prognostic information to
seriously ill patients may provoke patient anxiety. Our target population of patients
with incurable disease may be particularly anxiety prone. To address this issue,
the eects of the decision aid are evaluated by comparing the decision aid group
to a usual care group. e evaluation will examine eects on patient well-being,
information and decision related outcomes, and treatment choice.
In conclusion, we aim to settle the debate on the desirability of informing patients
with cancer by developing a decision aid to assess the amount of information desired
by patients with advanced cancer at the point of decision making.e study popula-
tion will consist of patients with advanced colorectal, breast, or ovarian cancer who
are treated with rst-line chemotherapy and upon disease progression will face the
choice between two equivalent treatment options.ese patients can decide to have
second-line chemotherapy in combination with BSC, or they can refrain from fur-
ther chemotherapy and opt for BSC alone. Second-line chemotherapy may induce
tumour response and prolong survival, but also entails a risk of serious adverse
events. Our research questions are: 1a) Do these patients want to be informed about
the treatment options, and specically about their prognosis? 1b) Which factors
determine whether or not these patients want to be informed? 2) Can the medical
oncologist judge whether or not the patient wants the risk information? 3) What
is the eect of the decision aid on patient outcomes (well-being, information and
decision related outcomes, treatment choice) compared to usual care?
Methods
Patients
In 11 hospitals in the Netherlands, all patients with advanced colorectal, breast, or
ovarian cancer who have started treatment with rst-line palliative chemotherapy
and upon disease progression will be faced by the choice regarding second-line
palliative chemotherapy will be included. Exclusion criteria are labile personality
structure, as assessed by the physicians, a Karnofsky performance score lower than
60, and insucient knowledge of the Dutch language.e study has been approved
by the research ethics committees of all participating hospitals.
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Procedure
e medical oncologist, or a nurse who rst consulted the medical oncologist, will
inform eligible patients in a general way that this study focuses on ‘how to involve
the opinion of patients in the treatment’. Next, he or she will ask whether the
researcher can contact the patient by phone about this study. e oncologist or
nurse is instructed not to discuss that survival information can be provided in the
study, in order not to lose patients not desiring such information. Aer the visit of
the patient, the oncologist lls in the medical history on the inclusion form. He or
she also makes a judgment whether or not the patient will desire information about
adverse events, tumour response, and median survival that will be oered in the
interview (research question 2).
In the phone call, patients are explained that data are collected by means of three
questionnaires and possibly an interview. All patients who agree to participate will
provide written informed consent. Patients will be sent a baseline questionnaire (T1)
to collect sociodemographic data, well-being measures, and measures that predict
information desire. When tumour progression is diagnosed, second-line chemo-
therapy will be oered by the oncologist and randomization will be performed.
Patients in the usual care group will receive information about the treatment choice
from their oncologist. In the intervention group, patients will receive the same
information, and will in addition be oered information in an interview using
a decision aid. At the moment of disease progression, the medical oncologist is
asked to estimate patient survival, because this is expected to be associated with the
patient’s information desire.
To evaluate the eect of the decision aid, two follow-up questionnaires will be sent to
the patients, one week (T2) and eight weeks (T3) aer the treatment choice, before
the rst evaluation of chemotherapy. Figure 2.1 displays the complete procedure.
Randomization
Randomization will be performed to determine whether the patient will receive
usual care (n = 70) or usual care plus the decision aid (n = 100). To accomplish this,
a computer generated randomization list is prepared that is stratied by hospital,
using a block size of 3. Each participating hospital will receive three sets of sealed
envelopes, related to colorectal, breast, and ovarian cancer patients. When disease
progression is diagnosed by the oncologist, a nurse will perform the randomization
by opening the appropriate envelope.
Development of the decision aids
Decision aids on second-line treatment options for patients with advanced colorec-
tal, breast, and ovarian cancer are developed. In this decision aid, the two treatment
options are explained. Next, an overview of the potential risks and benets of
the two treatment options is presented. e information on risks and benets
is obtained from systematic reviews of the literature for each tumour type. Risk
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Initial invitation by the oncologist or a nurse
• medical history
• substitute judgment of information desire Exclusion criteria
• labile personality structure
• Karnofsky performance score < 60
• insucient knowledge of the
Dutch languageAssessed for eligibility by medical oncologist
Phone call by the researcher
followed by written informed consent
Baseline questionnaire (T1)
• sociodemographic data
• well-being measures
• predictors of information desire
Diagnosis of progression: treatment choice
• estimate of survival by oncologist
Randomization
Usual care
(n = 70)
Usual care and interview
using the decision aid
(n = 100)
Follow-up questionnaire aer one week (T2)
• well-being measures
• other eects on coping, information,
knowledge, decision, and treatment
attitudes
Follow-up questionnaire aer eight weeks (T3)
• well-being measures
• other eects on coping, information,
knowledge, decision, and treatment
attitudes
Figure 2.1: Overview of study procedure
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information includes the occurrence of serious adverse events, which are dened
as grade 3 or 4 according to the Common Terminology Criteria for Adverse Events
v3.0 (CTCAE) and are presented as adverse events that can be life threatening,
can result in a hospital admission or prolongation of existing hospitalization, or
can lead to a persistent or signicant disability/incapacity. Tumour response is
dened according to WHO or RECIST criteria and classied into overall response
(complete or partial response), stable disease, and progressive disease. For both
serious adverse events and tumour response, the probability that outcomes occur
is presented in frequencies (n of 100 patients) and by means of pie charts, using a
mixed frame, e.g. ‘22 out of 100 patients will experience severe diarrhoea, 78 out
of 100 patients will not experience severe diarrhoea’. Information on survival is
presented in the format of median survival.
Interview
e decision aid is delivered by a nurse or by the researcher. First, the two treatment
options are explained.en, to familiarize patients with the general issue of trade-
os between benets and risks, an example of a risky two-attribute non-cancer
related choice is presented. Aer this example, the interviewer explains the rst
item of the decision aid regarding serious adverse events.is explanation includes
the denition of a serious adverse event and gives the patient insight in the type
of information that can be expected. Next, the patient is asked whether or not the
information on serious adverse events is desired.e same procedure is followed
for the other items on tumour response and survival. At the end of the interview,
the patient can take home a brochure with information, tailored to the information
desire of the patient.e interviewer lls in a questionnaire to register information
desire and to provide a short evaluation of the interview.
Outcome measures
Table 2.1 shows an overview of all outcome measures and the moment of measure-
ment.
Sociodemographic variables andmedical history Self-report data are collected
at T1 on demographic variables (age, marital status, having (grand)children, being
religious, working status, and education) and on previous chemotherapy, including
experienced benets and adverse events, and time since last chemotherapy. Tumour
and treatment characteristics such as primary tumour site, previous chemotherapy,
and time since diagnosis are lled in on the inclusion form by themedical oncologist.
At the moment of disease progression, the medical oncologist is asked to estimate
patient survival. Answer possibilities are 3–6 months, 6–9 months, 9–12 months,
and more than 12 months.
Well-being Patients rate their general health in the previous week on an 11-point
rating scale (0–10). Anxiety and depression are assessed with the hospital anxiety
18
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Table 2.1: Outcome measures
Subject Questionnaire Incl T1 Prog Intvw T2 T3
PATIENT’S QUESTIONS
Sociodemographic characteristics ✓
Previous chemotherapy ✓
Well-being
General Health ✓ ✓ ✓
Anxiety & Depression Hospital Anxiety and Depression Scale ✓ ✓ ✓
Cancer Worries Adapted Lerman’s Cancer Worry Scale ✓ ✓ ✓
Health-related quality of life EORTC QLQ-C15-PAL ✓ ✓ ✓
Coping
Helpless/Hopeless, Avoidance, Fighting Spirit Mental Adjustment to Cancer Scale ✓
Decision Styles Michigan Assessment of Decision Style ✓
Participation preferences Problem-Solving Decision-Making Scale ✓
Perceived participation Problem-Solving Decision-Making Scale ✓ ✓
Perceived involvement Whelan ✓ ✓
Death avoidance Death Avoidance Scale ✓
Information
Preference for information ✓
Amount of information ✓ ✓ ✓
Information from oncologist ✓
Undesired information ✓
Information desire ✓
Satisfaction with quality of information ✓ ✓
Balanced presentation of information ✓
Evaluation of information ✓ ✓
Numeracy Subjective Numeracy Scale ✓
Knowledge
General subjective knowledge ✓
Treatment subjective knowledge ✓
Objective knowledge ✓
Subjective risk ✓
Objective risk ✓
Decision
Decision satisfaction-uncertainty Decision evaluation scale ✓ ✓
Decision control Decision evaluation scale ✓ ✓
Weighing pros and cons Decision evaluation scale ✓ ✓
Treatment choice ✓ ✓
Strength of treatment preference ✓ ✓
Treatment attitudes
Valuations ✓ ✓
Treatment satisfaction ✓
Preferences for Quality/Quantity of Life QQ Questionnaire ✓
PHYSICIAN’S QUESTIONS
Tumour and treatment characteristics ✓
Substitute judgment of information desire ✓
Estimate of survival ✓
Abbreviations — Incl: Inclusion, Prog: Disease progression, Intvw: Interview
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and depression scale (HADS).17 Cancer worries are rated with three questions,
adapted from Lerman et al.18 and Stefanek et al.19: ‘Did you think of cancer last
week?’, ‘Did these thoughts aect your mood?’, and ‘Did these thoughts aect your
daily activities?’. Health-related quality of life is assessed by means of the EORTC
QLQ-C15-PAL quality of life questionnaire for cancer patients in palliative care.20
Coping Coping with cancer is assessed with the Mental Adjustment to Cancer
scale.21 ree coping strategies are assessed: helplessness/hopelessness, avoidance,
and ghting spirit.e patient’s decision style is assessed withe Michigan assess-
ment of decision style (MADS).22 e MADS covers (1) avoidance (four items, e.g.
‘I prefer not knowing the possibility that unexpected things could happen to me’);
(2) deferring responsibility (three items, e.g. ‘I would follow the recommendations
of my physician’); (3) information seeking (four items, e.g. ‘I would spend as much
time as I could gathering information’); and (4) deliberation (ve items, e.g. ‘I would
carefully consider the risks of each option as I was making a choice’).e general
participation preference at baseline is measured with the two decision-making items
from the Problem-Solving Decision-Making Scale.23 e questions are as follows:
‘When the risks and benets of the treatment options are known to you, (1) who
decides how acceptable those risks and benets are for you and (2) who decides
what treatment should be selected?’. Answers range from ‘only the physician’ to
‘only me’. Perceived participation is assessed by the same questions in past tense,
aer the decision is made. Perceived involvement is measured by asking patients
whether they felt they were oered a choice between BSC plus chemotherapy and
BSC alone.24 In addition, patients are asked whether their opinion regarding the
treatment mattered. Both questions use a yes/no response. Death avoidance will be
measured by means of the Death Avoidance Scale, which was adapted by Kaplowitz,
Campo and Chiu25 from the original Death Acceptance Scale developed by Klug
and Sinha.26 e two items are as follows: ‘I avoid discussing death when the occa-
sion presents itself ’ and ‘I make a conscious eort to avoid dwelling on thoughts
of death’, and are measured on a 5-point scale (1 = strongly disagree, 5 = strongly
agree).
Information e preferred amount of information is measured on a 11-point
scale ranging from 0 (I want to know nothing about the illness and its treatment) to
10 (I want to know everything there is to know about the illness and its treatment).8
e amount of information received about the treatment choice is measured on a
7-point scale ranging from 1 (I received way too little information), 4 (I received
exactly enough information), to 7 (I received way too much information). Informa-
tion received during the consultation with the oncologist, regarding adverse events,
tumour response, and survival, is assessed using a yes/no response. Whether pa-
tients received any undesired information is asked with a question using a yes/no
response.e key variable information desire is described under ‘Interview’ above.
Satisfaction with the quality of information is asked with three questions related to
information on adverse events, tumour response, and survival. Responses are on a
6-point scale ranging from 1 (not satised) to 6 (very much satised).e balanced
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presentation of information is evaluated on a 5-point scale from 1 (clearly in favour
of chemotherapy plus BSC), 3 (balanced), to 5 (clearly in favour of BSC alone).
Six questions are asked about unpleasant, shocking, frightening, and threatening
experiences with the information received, measured on a 5-point scale from 1 (no
negative experience) to 5 (very negative experience). Numeracy, i.e. the ability to
handle basic probability concepts, needed for the interpretation of risk information,
is measured by the subjective numeracy scale (SNS).27
Knowledge Patients rate their own knowledge (subjective knowledge) on cancer
treatments with a single question on a 10-point scale ranging from 1 (very bad) to 10
(excellent). Two questions are asked to assess the subjective knowledge with respect
to risks and benets of treatment options on a 10-point scale. Objective knowledge
will be measured with a questionnaire containing ve statements related to the two
options BSC plus chemotherapy and BSC alone.ese statements have to be judged
as right or wrong. Subjective risk perception is measured by three questions on
the chance of experiencing a serious adverse event from 1 (very high) to 5 (very
low), the chance that stable disease or a response will be achieved by BSC plus
chemotherapy, as opposed to BSC alone from 1 (much higher) to 7 (much lower),
and the chance of experiencing pain on treatment with BSC plus chemotherapy,
as opposed to BSC alone from 1 (much higher) to 7 (much lower). Objective risk
perception is asked for the chance of experiencing severe diarrhoea, and the chance
of achieving a response. Patients are asked to give a risk estimate for these two
outcomes in a range from 0% to 100%.
Decision Satisfaction and uncertainty regarding the choice between BSC plus
chemotherapy and BSC alone are assessed using ve items,28 e.g. ‘I nd it hard to
make this choice’, ‘I am satised with my decision’, measured on a 5-point scale (1
= strongly disagree, 5 = strongly agree). Patients are also asked about their feeling
of control regarding this treatment choice using ve items,28 e.g. ‘is decision is
made without me’, ‘I feel pressure from others in making this choice’, measured on a
5-point scale (1 = strongly disagree, 5 = strongly agree). Weighing of pros and cons
of the treatment options was asked with a single question ‘I weighed the pros and
cons’, on a 5-point scale (1 = strongly disagree, 5 = strongly agree). Treatment choice
is collected by asking which treatment patients prefer. Response options are: BSC
plus chemotherapy, BSC alone, don’t know. Strength of treatment preference (for
one or the other option) is asked on a 4-point Likert scale ranging from 1 (weak
preference) to 4 (very strong preference).
Treatment attitudes Valuations for each of the two treatment options are asked
on a 10-point scale ranging from 1 (very bad) to 10 (excellent). Satisfaction with
the received treatment and with the physical and emotional eect of treatment
is measured on a 6-point scale from 1 (dissatised) to 6 (very satised). Patients’
attitudes towards striving for length (quantity) or quality of life are assessed with 8
items by the ‘quality quantity questionnaire (QQ Questionnaire)’.29 High scores on
the quantity or quality scale indicate the importance of length and quality of life,
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respectively.
Substitute judgment When the medical oncologist informs patients about this
study, he or she is asked to judge whether or not the patient will desire information
about adverse events, tumour response, and median survival that will be oered in
the interview.
Sample size calculation
Our primary research question is whether or not patients want to be informed.
For study question 1a, about 100 patients in the intervention group will suce
to estimate an assumed desire rate for prognostic information of 80% with 95%
condence interval from 71% to 87%. For study question 1b, regarding factors
that determine information desire, again about 100 patients will suce to detect a
weak correlation of 0.28 between a predictor and information desire, with α = 0.05
and a power equal to 0.82. For question 2, dealing with the ability of the medical
oncologist to judge whether or not the patient wants this information, the same
analysis applies as for study question 1b. For study question 3, which addresses the
eect of the introduction of decision support compared to usual care on patient
wellbeing, the intervention group is compared to the usual care group. Because
one of the main concerns of physicians is that information on prognosis provokes
anxiety, anxiety is used as the main outcome measure. We assume that the HADS
anxiety dierence between the two groups at T3 is equal to 2.2, and the correlation
between the measurements at T1 and T3 equals 0.72.e standard deviation in each
cell is about 6, corresponding to a medium sized eect size of 0.36. With α = 0.05,
and 70 patients in each group, the power to detect the assumed eect is equal to
0.81. In conclusion, 100 patients in the intervention group and 70 patients in the
usual care group suce to answer the above research questions. Assuming that 30%
of the patients refuse to give informed consent, and that 1% of patients has died at
T3, 246 patients will have to be approached.
Statistical Analysis
In all the analyses, scale values will be calculated only if at least half of the items
are available, by imputing the mean of the available items. Question 1a about the
information desire will be answered by calculating the desire rate for prognostic
information with a 95% condence interval. For question 1b, which factors determ-
ine information desire, patients will be grouped according to information desire,
ranging from 0 (no information desired) to 3 (information on serious adverse events,
tumour response, and survival desired). en comparisons between these four
groups will be made. For categorical variables, the Chi-square test will be used.
Continuous data will also be analysed using the Chi-square test, aer a median-split
subdivision into two categories.e HADS scores will be divided by use of a clinical
cut-o point of 8.17,30,31 Bivariate analyses will be presented with p-value of vari-
ables related with information desire at the level of p < 0.2. Finally, these variables
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will be entered simultaneously in a regression model. For question 2, agreement
between the substitute judgment of the oncologist and the patient information
desire is determined. Agreement can arise from chance; a measure correcting for
chance agreement is the κ statistic, ranging from 0 to 1. A κ of 0.2, 0.5, and 0.8
indicates poor, moderate, and good agreement, respectively.32,33 In bivariate and
multivariate analyses, associations will be sought between agreement and patient
variables (sociodemographic, medical, psychological, knowledge and information).
Dichotomized variables associated with agreement at a level of p < 0.2 will be
entered simultaneously in a regression model. Question 3, which addresses the
eect of the introduction of decision support compared to usual care on patient
well-being, will be answered by comparing the intervention group with the usual
care group. Analyses of covariance corrected for dierences at baseline are used
to test the eect of the intervention. For group comparisons at a single point in
time, a t-test will be performed for continuous variables and the Chi-square test for
categorical variables.
Ethical considerations
Ethical approval for the study is obtained from the regional ethics review com-
mittee (CMO Arnhem-Nijmegen) and from the research ethics committees of all
participating hospitals. All participating patients will sign an informed consent
form.
Discussion
is study attempts to settle the debate on the desirability of informing patients with
cancer. To this end, the amount of information desired by patients with advanced
cancer is investigated by oering information in a decision aid. Furthermore, the
study will show whether it is possible to predict the amount of information desired,
either by patient and disease-related factors, or by judgment of the medical oncolo-
gist. Concerns that the information may provoke patient anxiety are addressed by
evaluating the eects of the decision aid using a randomised controlled design.e
study design has some limitations.
Selection bias could be introduced when oncologists select patients who are more
open to information or are in a better psychological state. When the data collection is
completed, the role of selection bias can be investigated by comparing the resulting
sample to other study samples, and comparing patient characteristics between
physicians that included few versus many patients. Selective patient participation
based on patients’ information desire is addressed by informing eligible patients
about the study in a general way, not mentioning the provision of (prognostic)
information.
Patients have to ll in a baseline questionnaire that includes predictors for informa-
tion desire and a baseline measurement for the eect of the information.erefore,
it is not feasible to include patients at the moment of the treatment choice; patients
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have to be included during rst-line chemotherapy. is timing may positively
aect the inclusion rate, since patients will be less distressed during rst-line che-
motherapy than at the moment of disease progression. On the other hand, due to
the interval between the baseline questionnaire and the interview, the association
between information desire and predictors may be weakened. In addition, the
correlation between the eect measures at baseline (T1) and follow-up (T2 and T3)
may be weakened.
Randomization is, for practical reasons, performed by using sealed envelopes. In
some of the 11 participating hospitals, there will be little time between the diagnosis
of disease progression and subsequent consultation with a nurse.erefore, instant
randomization will be required and envelopes are a very practical method to per-
form this.e use of envelopes leaves a possibility to subvert the randomization
procedure. However, a plain attempt to allocate a patient out of sequence will be
discovered because the envelopes are sequentially numbered and the allocation can
be compared with the predetermined sequence.e oncologist could also decide
not to randomize a patient, but this would not go unnoticed since all patients are
registered on the trial before themoment of randomization, therefore we will be able
to compare patients who were and were not randomized. Blinding of the medical
oncologists and the patients is not feasible in this type of research, because patients
may want to discuss the information from the decision aid with their oncologist.
However, patients are blinded to the intervention in that they are not aware of the
exact content of the decision aid; they are only informed that a new method of
information giving is investigated.
A major strength of this study is that, in contrast to many previous studies, we
will actually deliver information on treatment options to patients at the point of
decision making.e results of this study can be applied to improve the provision
of information in daily clinical practice. Generalization to the target population is
facilitated by the broad inclusion criteria that are used in this study and the use of
the decision aid by various nurses in the 11 participating hospitals. Furthermore, the
method used to assess patients’ information desire verymuch resembles information
giving in clinical practice, by actually providing information at the moment of the
treatment choice.
Funding
is work was supported and funded by the Dutch Cancer Society (grant number
KUN 2006-3465).e funder had no role in study design and the collection, ana-
lysis, and interpretation of data and the writing of the article and the decision to
submit it for publication.
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Abstract
is study was performed to obtain a comprehensive overview of the benets and
risks of second-line irinotecan monotherapy for advanced colorectal cancer.e
literature was systematically reviewed to identify phase II and phase III trials that
investigated the eect of second-line monotherapy with irinotecan.irty studies
were included in this review: 25 phase II studies including 32 samples and ve phase
III studies including six samples. A disease control rate of greater than or equal to
50% was found in 23 out of 32 phase II samples, and one out of two phase III samples
that reported disease control rate. Median time to progression was 2.7–6.0 months
in phase II samples and 3.0–4.3months in phase III samples. Median overall survival
ranged from 6.6 to 16.1 months in phase II samples and 9.1–10.8 months in phase
III samples.e most important severe adverse event in both phase II and phase III
trials was diarrhea (5–39 and 15–36%, respectively), followed by nausea (1–24 and
5–14%), vomiting (2–22 and 6–14%), and asthenia (0–31 and 4–21%). Treatment-
related mortality was 0–2% in phase II samples and 0–5% in phase III samples.
Quality-of-life scores in phase II studies were associated with tumor response. In
phase III studies, the quality of life while on treatment with irinotecan was similar
to that of 5-uorouracil, but better than supportive care alone.e quality of life
on the weekly schedule was similar to the 3-weekly schedule.is study provides
a comprehensive overview of the benets and risks of second-line irinotecan. In
general, second-line treatment with irinotecan is benecial to patients.
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Introduction
Introduction
Colorectal cancer is one of the three most common adult malignancies worldwide.1
Approximately 50% of patients with colorectal cancer will ultimately develop in-
curable locally recurrent or metastatic disease.2 ese patients can be treated with
palliative chemotherapy to control symptoms, maintain or improve quality of life
(QoL), and prolong survival.3 Chemotherapeutic options include uoropyrimidines,
oxaliplatin, and irinotecan. First-line treatment consists of a uoropyrimidine [intra-
venously 5-uorouracil (5-FU) or oral uoropyrimidines] in various combinations
and schedules.4 Combination chemotherapy with 5-FU, leucovorin (LV), and oxali-
platin (FOLFOX) or 5-FU, LV, and irinotecan (FOLFIRI) provides higher response
rates, longer progression-free survival and better survival than 5-FU/LV alone. As
FOLFOX is a more common choice for rst-line treatment, irinotecan is the most
likely option for second-line treatment.
Despite these recommendations for second-line palliative chemotherapy, there are
uncertainties about the balance between benets and risks.e potential benets
of irinotecan (control symptoms, maintain or improve QoL, and prolong survival)
have to be weighed against the potential risks of treatment-related mortality and
morbidity, which consists mainly of neutropenia, nausea, vomiting, diarrhea, and
asthenia.5 is decision could be supported by a comprehensive overview of benets
and risks of second-line irinotecan monotherapy.
A number of reviews, including one from the Cochrane Collaboration, have dis-
cussed the use of second-line irinotecan in advanced and metastatic colorectal
cancer.6–9 e Cochrane review used a strict methodology, including only random-
ized controlled trials, and the search strategy and characteristics of the included
studies were presented in detail.8 On account of the strict inclusion criteria, this
review included only six studies reporting on second-line irinotecan. e other
three reviews were written by experts in the eld and did not report on the search
strategy or on the characteristics of the studies that were included.6,7,9
is review will provide a comprehensive overview of the benets and risks of
second-line treatment with irinotecan, including all available evidence from phase
II and phase III studies.
Methods
Literature search
A literature search was performed in MEDLINE, EMBASE, PubMed, and the
Cochrane Controlled Trials Register for studies published between 1990 and April
2007.e search strategy for MEDLINE is shown in the Appendix.is strategy
was modied for the other bibliographic databases.e reference lists of all relevant
articles were reviewed for additional studies. Searching took place between January
andAugust 2007. Studies were included if theymet the following criteria: (i) phase II
or III clinical trial; (ii) patients with locally advanced ormetastatic colorectal cancer;
(iii) second-line palliative chemotherapy using systemically administered irinotecan
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monotherapy; (iv) outcome measures include tumor response rate, median time to
progression (TTP), median overall survival (OS), severe adverse events, and/or QoL
data; and (v) full-length articles in English, Dutch, German, or French language.
Within randomized trials, only patients groups (referred to as ‘samples’ in the
results) in whom second-line monotherapy with irinotecan was investigated were
included.
Data collection
With regard to the study design, from each sample the phase of the clinical trial
and the chemotherapeutic regimen were extracted. As for patient characteristics,
data on sex, median age, WHO performance status, tumor site (which could be
colon or rectum), involvement of more than one organ, and liver involvement were
obtained.
e following outcome data were extracted: tumor response rate, median TTP,
median OS, incidence of severe adverse events, and QoL scores. To compare tumor
response rates between phase II and phase III studies, response rates of phase II
studies (usually computed by including only assessable patients) were recomputed
using the intention-to-treat principle, following Zia et al.10 For our overview, the
outcome of interest for tumor response rate was the disease control rate (overall
response and stable disease).e incidence of grade 3 or 4 adverse events during
the course of chemotherapy and up to 30 days aer the last chemotherapy gi
was extracted. Treatment with irinotecan can cause a variety of adverse events.
erefore, a selection of severe adverse events (grades 3–4) was made based on
incidence and relevance for the patient.11,12 For alopecia, all grades of adverse events
(grades 1–4) were extracted.
Results
Literature search
e systematic literature search identied 2905 studies. Figure 3.1 presents a ow
diagram of the ensuing selection process.13 irty studies met all criteria and were
included in this review (see Table 3.1). In the 25 phase II studies included, 32 relevant
samples were identied5,14–37 and in the ve phase III studies, six relevant samples
were identied.38–42
Phase II studies
Description of studies
In the 32 samples from the phase II studies a variety of chemotherapeutic regimens
were used. In 10 study samples, irinotecan was administered 3-weekly, using a
dose of 350mg/m2.5,17,19,20,23,25,29,30,33,35 In seven study samples, irinotecan was ad-
ministered weekly for 4 consecutive weeks, using a dose of 125mg/m2, followed
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Potentially relevant studies identied and
screened for retrieval
(n = 2, 905) Studies excluded, based on title and abstract
(n = 2, 834)
• no phase II or phase III clinical trial
• no patients with colorectal cancer
• no irinotecan studied
• no second-line palliative treatment
Studies retrieved for more detailed evaluation
(n = 71) Studies excluded
(n = 41)
• retrospective design (n = 5)
• compassionate use programme (n = 1)
• other patient group or treatment (n = 5)
• no relevant data (n = 26)
• publications about the same study (n = 4)
Studies included in the review
(n = 30)
Relevant data from the included studies:
Phase II: Phase III:
25 studies including 32 samples 5 studies including 6 samples
Disease control rate 25 studies/32 samples 2 studies/2 samples
Median time to progression 18 studies/25 samples 2 studies/3 samples
Median overall survival 23 studies/30 samples 5 studies/6 samples
Severe adverse events 7–21 studies/8–27 samples 1–5 studies/1–6 samples
Quality of life 2 studies/2 samples 3 studies/4 samples
Figure 3.1: Flow diagram
by a 2-week rest period.15,16,18,22,26,35,37 e remaining 14 study samples used other
regimens, including dose variations on the 3-weekly schedule21,30 and the weekly
schedule.14,18,28,32 Furthermore, there were changes in the frequency of the sched-
ule to weekly doses without a rest period,27 or to a 2-weekly schedule,34–36 and
changes in the dose by escalation,5,31 or adapting the dose according to patient
characteristics.5,24,34
A total of 1894 patients (range 16–165) were included between 1989 and 2004. Data
on sex was reported for 31 out of 32 samples, of which 23 samples included amajority
of men (range 51–76%), six samples included a majority of women (range 51–61%),
and two samples included equal percentages of men and women. Median age was
reported for all samples, except for one sample that reported mean age, which
Table 3.1: Study characteristics
WHO
status [%]
Study n Chemotherapeutic regimen
Sex
male/
female
[%]
Age
median
(range)
[years] 0 1 2
Tu-
mour
site
colon*
[%]
>1
organ
invol-
ved
[%]
Liver
invol-
ved
[%]
PHASE II STUDIES
Shimada et al.14 67 A: 100 mg/m2 weekly (n = 31)
B: 150 mg/m2 every 2 weeks (n = 32) 59/41 57 (24–72) 38 35 22 — — 63
Rothenberg et al.15 48 150 mg/m2 (n = 9) and 125 mg/m2 (n = 39)
every week for 4 weeks, 2-week rest
54/46 63 (29–78) 60 38 2 — — 67
Pitot et al.16 90 125 mg/m2 every week for 4 weeks, 2-week rest 64/36 63 (32–82) 38 48 14 74 — —
Rougier et al.17 165 350 mg/m2 every 3 weeks 56/44 60 52 35 13 73 69 79
Rothenberg et al.18 64 125 mg/m2 every week for 4 weeks, 2-week rest 50/50 61 (42–84) 59 33 8 — 84 80
102 100 mg/m2 every week for 4 weeks, 2-week rest 49/51 64 (25–84) 44 51 5 — 79 72
Van Cutsem et al.19 107 350 mg/m2 every 3 weeks 59/41 58 (28–72) Median:
1 (0–2)
68 — —
Ratanatharathorn et al.20 16 350 mg/m2 every 3 weeks 69/31 56 (41–68) 88 13 0 69 44 33
Ulrich-Pur et al.21 38 175 mg/m2 on days 1 and 10 every 3 weeks 76/24 65 (31–75) 24 63 13 58 76 74
Michael et al.22 65 125 mg/m2 every week for 4 weeks, 2-week rest 51/49 56 8 77 15 68 71 75
See et al.23 33 350 mg/m2 every 3 weeks 73/27 58 (39–70) — — — 55 — —
Tsavaris et al.24 90 350 mg/m2 every 3 weeks (WHO 0) or
250 mg/m2 every 3 weeks (WHO 1) 61/39 66 (42–70) 49 51 0 — — 79
Antón et al.25 60 350 mg/m2 every 3 weeks 62/38 58 (37–70) 53 42 5 67 38 73
Cassinello et al.26 69 125 mg/m2 every week for 4 weeks, 2-week rest 49/51 63 (37–79) 45 49 6 57 36 71
Cerea et al.27 16 125 mg/m2 weekly 44/56 63 (42–74) Median:
0 (0–1)
— — 76
Karaoğlu et al.28 36 100 mg/m2 every week for 4 weeks, 2-week rest 61/39 53 (33–72) Median:
0 (0–2)
66 19 61
Méndez et al.29 115 350 mg/m2 every 3 weeks 62/38 61 (32–75) 40 55 5 64 36 73
Tsavaris et al.30 60 350 mg/m2 every 3 weeks 57/43 64 (48–70) 60 40 0 32 — 78
60 175 mg/m2 on days 1 and 10 every 3 weeks 60/40 62 (46–70) 65 35 0 35 — 82
Viéitez et al.31 35 250 mg/m2 every 3 weeks,
increased by 50 mg/m2 in each cycle 63/37 63 (42–75) 5 45 48 — 46 —
Benavides et al.32 34 100 mg/m2 every week for 4 weeks, 2-week rest 38/62 60 (34–75) 0 71 29 68 26 53
Hartmann et al.33 50 350 mg/m2 every 3 weeks 42/58 59 (39–77) 40 56 4 46 52 88
Saigi et al.34 45 250 mg/m2 every 2 weeks (high risk) 58/42 64 (31–77) — — — 56 — 67
51 250 mg/m2 every 2 weeks (low risk) 69/31 65 (31–79) 100 0 0 82 — 87
Schoemaker et al.35 41 350 mg/m2 every 3 weeks 56/44 60 (28–75) 29 68 2 54 29 85
37 125 mg/m2 every week for 4 weeks, 2-week rest 46/54 58 (41–71) 35 54 11 65 46 84
46 250 mg/m2 every 2 weeks 59/41 62 (35–74) 46 52 2 59 35 72
García-Girón et al.36 63 250 mg/m2 every 2 weeks —/— Mean:
63 (41–75)
46 48 6 60 — 66
Van Cutsem et al.5 36 350 mg/m2 every 3 weeks 50/50 60 (29–71) 50 44 6 64 — 70
62 250 mg/m2 every 3 weeks
(increasing to 350 mg/m2 and 500 mg/m2) 71/29 59 (33–70) 60 36 5 66 — 79
66 500 mg/m2 , 350 mg/m2 , or 250 mg/m2 ,
based on toxicity risk factors
62/38 60 (30–70) 46 53 2 67 — 80
Graeven et al.37 27 125 mg/m2 every week for 4 weeks, 2-week rest 74/26 67 (53–78) 37 56 7 48 — 74
PHASE III STUDIES
Cunningham et al.38 189 350 mg/m2 every 3 weeks 68/32 59 (22–75) 47 39 14 53 57 80
Rougier et al.39 127 350 mg/m2 every 3 weeks 57/43 58 (30–75) 57 35 8 56 52 79
Aravantinos et al.40 62 350 mg/m2 every 3 weeks 65/35 63 (23–75) 53 36 11 79 66 69
Fuchs et al.41 95 125 mg/m2 every week for 4 weeks, 2-week rest 62/38 < 70 : 66%† 48 46 5 78 44 73
196 350 mg/m2 every 3 weeks 58/42 ≥ 70 : 34%† 43 45 11 76 54 70
Chau et al.42 339 350 mg/m2 every 3 weeks 59/41 62 (29–80) 27 61 12 62 — 73
—data not reported
* versus rectum
† Owing to stratication by age, both samples contained equal percentages of patients < 70 vs. ≥ 70.
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ranged from 53 to 67 years of age. WHO performance status was reported for 30
samples, of which 27 reported on the percentage of patients with a status of 0, 1, or
2. Except for one sample including relatively few patients (50%) with a performance
status of 0 or 1, the remaining 26 samples included 73–100% of patients with a
status of 0 or 1. Out of 25 samples reporting on disease location, in 21 samples more
patients with a tumor in the colon, as opposed to the rectum, were included (54–
82%). Involvement of multiple organs, which was reported for 16 out of 32 samples,
ranged from 19 to 84%. Twenty-seven out of 28 samples included a majority of
patients with liver involvement (53–88%). With regard to earlier treatment, 92–100%
of patients had undergone surgery earlier, 0–44% had received radiotherapy earlier,
and almost all patients included in these samples had received chemotherapy with
uoropyrimidines earlier, most of them in the palliative setting.
Outcomes
Table 3.2 presents an overview of disease control rate, median TTP, and median OS.
Disease control rate could be computed for all 32 samples, and ranged from 25.9 to
72.6%. Twenty-three samples reported a disease control rate of at least 50%. Median
TTP was reported in 25 samples and ranged from 2.7 to 6.0 months. Median OS
was reported in 30 samples, which showed a wide range of 6.6–16.1 months. Eleven
samples reported a median OS shorter than 9 months, whereas 19 samples reported
a median OS of 9 months or longer.
An overview of severe adverse events is provided in Table 3.3. All samples reported
on the incidence of severe adverse events, but ve samples reported the incidence of
events for each cycle and not for each patient.20,24,25,30 erefore, Table 3.3 presents
no data for these ve samples, except for alopecia and treatment-related mortality.
Most severe adverse events (grades 3–4) were gastrointestinal.e highest incidence
was reported for severe diarrhea (5–39%). Nausea (1–24%) and vomiting (2–22%)
were also frequently observed, whereas lower incidence rates were observed for
anorexia (0–12%), constipation (0–6%), and mucositis (0–3%). With regard to other
severe adverse events, severe asthenia was frequently observed (0–31%). Alopecia
(grades 1–4) was observed in 32–100% of patients. A treatment-related mortality
of 2% was seen in two samples, whereas the other 13 out of 15 samples reported no
treatment-related mortality.
QoL was reported in two samples. In the rst sample, Van Cutsem et al.19 (n = 107)
used the European Organization for Research and Treatment of Cancer Quality of
Life Questionnaire (EORTCQLQ-C30),43 which was lled in at baseline and before
each 3-weekly cycle. Questionnaire return rate was not reported. e median
Global Health Status improved with successive cycles, probably because of the
selection of patients with treatment benet. In patients who had a partial response,
median Global Health Status was 75.9, compared with 63.1 in nonresponders, and
58.3 in patients with progression as a best response. In the second sample, Michael
et al.22 (n = 65) used the EORTC QLQ-C30 version 2.0, which was lled in every 6
weeks. Questionnaire return rate was 98% at baseline and 93% during treatment.
At baseline, there were signicant role and physical impairments, with a marked
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Table 3.2: Disease control rate, median time to progression, and median overall survival
Tumour response
Study n OR [%] SD [%] PD [%] N/A% DCR*
Median TTP
[months]
Median OS
[months]
PHASE II STUDIES
Shimada et al.14 67 25.4 28.4 25.4 20.9 53.8 — 9.3
Rothenberg et al.15 48 20.8 31.3 37.5 10.4 52.1 — 10.4
Pitot et al.16 90 13.3 57.8 26.7 2.2 71.1 — 8.3
Rougier et al.17 165 13.9 26.7 29.1 30.3 40.6 4.2 10
Rothenberg et al.18 64 14.1 43.8 — — 57.9 5.1 10.6
102 8.8 38.2 — — 47 3.3 9.3
Van Cutsem et al.19 107 12.1 39.3 32.7 15.9 51.4 3.9 10.4
Ratanatharathorn et al.20 16 6.3 43.8 50.0 0 50.1 2.7 16.1
Ulrich-Pur et al.21 38 21.1 50.0 28.9 0 71.1 — —
Michael et al.22 65 7.7 35.4 27.7 29.2 43.1 — 7.2
See et al.23 33 21.2 27.3 42.4 9.1 48.5 — 9.5
Tsavaris et al.24 90 20.0 43.3 36.7 0 63.3 3.2 6.6
Antón et al.25 60 13.3 41.7 38.3 6.7 55 4.4 10.5
Cassinello et al.26 69 17.4 27.5 52.2 2.9 44.9 5.2 13.3
Cerea et al.27 16 12.5 31.3 56.3 0 43.8 4 —
Karaoğlu et al.28 36 13.9 36.1 — — 50 4 12
Méndez et al.29 115 18.3 36.5 33.0 12.2 54.8 4.8 13.6
Tsavaris et al.30 60 21.7 35.0 43.3 0 56.7 4.5 7
60 25.0 36.7 38.3 0 61.7 6 9
Viéitez et al.31 35 8.6 51.4 40.0 0 60 3 8
Benavides et al.32 34 20.6 38.2 41.2 0 58.8 5.5 8.3
Hartmann et al.33 50 12.0 46.0 32.0 10.0 58 3.0 7.9
Saigi et al.34 45 8.9 33.3 44.4 13.3 42.2 3.2 7.1
51 15.7 56.9 25.5 2.0 72.6 5.3 11.7
Schoemaker et al.35 41 7.3 43.9 46.3 2.4 51.2 2.7 9.4
37 5.4 62.2 18.9 13.5 67.6 3.5 7.1
46 10.9 54.3 32.6 2.2 65.2 3.8 8.6
García-Girón et al.36 63 17.5 46.0 23.8 12.7 63.5 4.5 8.8
Van Cutsem et al.5 36 8.3 50.0 27.8 13.9 58.3 4.1 12.5
62 12.9 41.0 29.0 17.7 53.9 4.2 12.1
66 9.1 36.4 48.5 6.1 45.5 3.0 10.9
Graeven et al.37 27 11.1 14.8 48.1 25.9 25.9 — 10.7
PHASE III STUDIES
Cunningham et al.38 189 — — — — — — 9.2
Rougier et al.39 127 4.7 — 36.2 — — — 10.8
Aravantinos et al.40 62 6.5 48.4 32.3 12.9 54.9 4.3 9.6
Fuchs et al.41 95 — — — — — 4.0 9.9
196 — — — — — 3.0 9.9
Chau et al.42 339 9.4 33.0 57.5 0 42.4 — 9.1
Abbreviations — OR: overall response, SD: stable disease, PD: progressive disease, N/A: not eli-
gible/not assessable, DCR: disease control rate, OS: overall survival, TTP: time to progression
—data not reported
* e outcome of interest for tumour response is disease control rate, which is computed by combining
the overall response and stable disease.
Table 3.3: Severe adverse events (grades 3–4)
Nausea
Vomit-
ing
Nausea
and/or
vomit-
ing
Diar-
rhea
Consti-
pation
Ano-
rexia
Muco-
sitis/
Stoma-
titis
Asthe-
nia/
Fatigue
Alopecia
(grades
1–4)
Treat-
ment
related
mortality
Study n n (%) n (%) n (%) n (%) n (%) n (%) n (%) n (%) n (%) n (%)
PHASE II STUDIES
Shimada et al.14 67 — — 8 (13%) 8 (13%) — — — — 39 ( 62%) —
Rothenberg et al.15 48 5 (10%) 8 (17%) — 18 (38%) — — — 3 ( 6%) — —
Pitot et al.16 90 22 (24%) 14 (16%) — 33 (36%) 1 ( 1%) 11 (12%) 2 (2%) 9 ( 7%) 63 ( 70%) —
Rougier et al.17 165 — — 36 (22%) 64 (39%) — — 0 (0%) — 128 ( 88%) —
Rothenberg et al.18 64 — 14 (22%) — 21 (33%) — — — 10 (16%) 36 ( 56%) 0 (0%)
102 — 2 ( 2%) — 24 (24%) — — — 17 (17%) 57 ( 56%) 0 (0%)
Van Cutsem et al.19 107 — — 20 (19%) 28 (26%) 0 ( 0%) 3 ( 3%) 2 (2%) 9 ( 8%) 97 ( 91%) 0 (0%)
Ratanatharathorn et al.20 16 × × × × × × × × × 0 (0%)
Ulrich-Pur et al.21 38 — — 0 ( 0%) 2 ( 5%) 0 ( 0%) 0 ( 0%) — 0 ( 0%) 24 ( 63%) —
Michael et al.22 65 — — 14 (21%) 17 (26%) — — — 10 (15%) — 0 (0%)
See et al.23 33 — 5 (17%) — 2 ( 7%) — — — — 30 (100%) —
Tsavaris et al.24 90 × × × × × × × × 90 (100%) 0 (0%)
Antón et al.25 60 × × × × × × × × 50 ( 80%) —
Cassinello et al.26 69 1 ( 1%) 7 (10%) — 10 (15%) 1 ( 1%) 1 ( 1%) — 1 ( 1%) — —
Cerea et al.27 16 — — 0 ( 0%) 6 (38%) — — — — — —
Karaoğlu et al.28 36 8 (22%) 3 ( 8%) — 10 (28%) 2 ( 6%) 1 ( 3%) 0 (0%) — 14 ( 39%) 0 (0%)
Méndez et al.29 115 — — 12 (10%) 22 (19%) 3 ( 3%) — 1 (1%) 3 ( 3%) — 2 (2%)
Tsavaris et al.30 60 × × × × × × × × × —
60 × × × × × × × × × —
Viéitez et al.31 35 — — 2 ( 6%) 6 (17%) — — 0 (0%) — 11 ( 32%) —
Benavides et al.32 34 2 ( 6%) 2 ( 6%) — 10 (29%) — — 1 (3%) — — —
Hartmann et al.33 50 2 ( 4%) 4 ( 8%) — 12 (24%) 2 ( 4%) — 1 (2%) 1 ( 2%) — —
Saigi et al.34 45 2 ( 4%) 3 ( 7%) — 8 (18%) — — 0 (0%) 14 (31%) — 0 (0%)
51 4 ( 8%) 1 ( 2%) — 7 (14%) — — 1 (2%) 4 ( 8%) — 0 (0%)
Schoemaker et al.35 41 6 (15%) 4 (10%) — 4 (10%) — 0 ( 0%) — 3 ( 7%) 29 ( 71%) —
37 2 ( 5%) 1 ( 3%) — 9 (24%) — 0 ( 0%) — 1 ( 3%) 16 ( 43%) —
46 4 ( 9%) 4 ( 9%) — 6 (13%) — 0 ( 0%) — 2 ( 4%) 31 ( 67%) —
García-Girón et al.36 63 6 (10%) 7 (11%) — 12 (19%) — — 1 (2%) — — 0 (0%)
Van Cutsem et al.5 36 4 (11%) 5 (14%) — 11 (31%) — — — 3 ( 8%) — 0 (0%)
62 7 (11%) 10 (16%) — 13 (21%) — — — 7 (11%) — 1 (2%)
66 7 (11%) 6 ( 9%) — 18 (27%) — — — 8 (12%) — 0 (0%)
Graeven et al.37 27 2 ( 7%) 1 ( 4%) — 5 (19%) 1 ( 4%) 0 ( 0%) 0 (0%) — 17 ( 63%) 0 (0%)
PHASE III STUDIES
Cunningham et al.38 189 26 (14%) 26 (14%) — 42 (22%) 19 (10%) 9 ( 5%) 4 (2%) 28 (15%) — 2 (1%)
Rougier et al.39 127 14 (11%) 18 (14%) — 28 (22%) 10 ( 8%) 7 ( 6%) 3 (2%) 17 (13%) — 0 (0%)
Aravantinos et al.40 62 — — 0 ( 0%) 9 (15%) — — — 2 ( 4%) 53 ( 86%) 2 (3%)
Fuchs et al.41 95 5 ( 5%) 6 ( 6%) — 34 (36%) 1 ( 1%) 1 ( 1%) — 11 (12%) — 5 (5%)
196 20 (11%) 24 (13%) — 36 (19%) 0 ( 0%) 6 ( 3%) — 21 (11%) — 3 (2%)
Chau et al.42 339 — — 18 ( 5%) 53 (16%) — — — 72 (21%) — —
—data not reported×incidence of severe adverse events reported for each cycle and not for each patient
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reduction in overall QoL. On treatment, there was a signicant improvement in
social functioning and pain intensity. ere were nonsignicant trends towards
improved global QoL score and emotional functioning, reduction of fatigue, and
anorexia, and worsening of diarrhea.
Phase III studies
Description of studies
Within the phase III studies that were included, randomized comparisons were
made between irinotecan and best supportive care,38 irinotecan and uorouracil
by continuous infusion,39 and weekly irinotecan and 3-weekly irinotecan.41 Fur-
thermore, one sample presented a selection of patients from Greece from a large
international phase III study evaluating the benet of adding granulocyte colony-
stimulating factor to irinotecan.40 In the remaining sample, the patients who
achieved an objective response or disease stabilization aer 24 weeks of irinotecan
were randomized to either stop or continue irinotecan.42
In these six samples fromphase III studies, only the 3-weekly regimens (ve samples)
and the weekly regimen (one sample) were used. A total of 1008 patients (range
62–339) were included between 1995 and 2003. All samples included a majority
of men (range 57–68%) and median age, which was reported in four samples,
ranged from 58 to 63 years of age. Furthermore, 86–94% of patients had a WHO
performance status of 0 or 1. In all six samples, the disease was more oen located
in the colon, as opposed to the rectum (53–79%). Next, 44–66% of patients had
multiple organ involvement and 69–80% had liver involvement. With regard to
earlier treatment, 91–99% of patients had undergone surgery earlier, 8–28% had
received radiotherapy earlier, and almost all patients had received chemotherapy
earlier with uoropyrimidines, most of them in the palliative setting.
Outcomes
Disease control rate, which could be computed in two phase III samples, was 42.4
and 54.9%, respectively. Median TTP was reported in three samples and ranged
from 3.0 to 4.3 months. All six samples reported a median OS of more than 9
months (range 9.1–10.8).
Severe adverse events (grades 3–4) were reported for all six samples. Most of the
reported severe adverse events were gastrointestinal, including diarrhea (15–36%),
nausea (5–14%), and vomiting (6–14%). Furthermore, severe asthenia was observed
in 4–21% of patients. One sample reported that 86% of patients experienced some
grade of alopecia. Treatment-related mortality ranged from 0 to 5%.
QoL was reported in four samples. Cunningham et al.38 (n = 189) used the EORTC
QLQ-C30, which was lled in at baseline, at 3 weeks, 6 weeks, and then every 6
weeks. Aer discontinuation of treatment in the irinotecan group, the patients
continued to ll in the QLQ-C30 questionnaires every 6 weeks as in the supportive-
care group. Questionnaire return rate at baseline was approximately 80% in both
39
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groups and decreased during the study to approximately 50%. Questionnaire return
rate decreased more rapidly in the supportive-care group, which the investigators
attributed to earlier deterioration in the patients. All signicant dierences were
in the favor of the irinotecan group, except for diarrhea score. In the sample of
Rougier et al.39 (n = 127) the EORTC QLQ-C30 was lled in at baseline, at 3 weeks,
and at 6 weeks, then every two visits up to 1 year. Aer the treatment was stopped
the questionnaire was lled in every 6 weeks in both the groups.e questionnaire
return rate was similar in both the groups: 67% in the irinotecan group and 70%
in the uorouracil group. QoL scores were also similar in both the groups. In
the two samples of Fuchs et al.41 (n = 95 and n = 196) the EORTC QLQ-C30
version 2.0 was lled in at baseline, every 6 weeks during treatment and at treatment
discontinuation. Questionnaire return rate was similar in the two groups: 81% in
the weekly irinotecan group and 86% in the every-3-weeks irinotecan group.ere
were no signicant dierences in the QoL scores between the treatment groups.
Discussion
Our study provides a comprehensive overview of the benets and risks of second-
line irinotecan. A disease control rate of at least 50% was reported in 23 out of 32
phase II samples and one out of two phase III samples. Median TTP was 2.7–6.0
months in phase II samples and 3.0–4.3 months in phase III samples. Median OS
was 6.6–16.1 months in phase II samples and 9.1–10.8 months in phase III samples.
e most important severe adverse event in both phase II and phase III studies
was diarrhea, followed by nausea, vomiting, asthenia, and alopecia (grades 1–4).
Treatment-related mortality was 0–2% in phase II samples and 0–5% in phase III
samples. QoL scores in phase II studies were in accordance with tumor response:
highest scores were observed for patients with an objective response, followed by
patients with stable disease, followed by patients with progressive disease. Random-
ized phase III studies showed that QoL on treatment with irinotecan was similar
to 5-FU, but better than supportive care alone. In addition, a similar QoL was
observed for the weekly and 3-weekly irinotecan schedule.
In this review, an extensive search was undertaken by using a highly sensitive search
strategy in multiple databases, followed by an additional search of the reference lists.
Sucient studies were available to provide an overview of the benets and risks of
irinotecan, but there is a possibility of a publication bias, as studies nding a lack of
benet or a high incidence of severe adverse events may have been abandoned by
scientists or rejected by editors.
e available data originate from a variety of phase II and phase III studies. Dif-
ferences in study design may hamper the comparability of studies. An important
factor in the study design is the phase of the clinical trial. In this review, the phase
III studies that were included reported higher treatment-related mortality than
the included phase II studies. A plausible explanation would be the selection of
patients with good prognostic factors for phase II studies, but no obvious dierences
were observed in this review between the patients included in phase II and phase
40
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III studies regarding sex, median age, WHO performance status, tumor site, in-
volvement of more than one organ, liver involvement, and pretreatment. A second
factor in the study design is the regimen of irinotecan used. Two of the studies
that were included, a randomized phase II study35 and a randomized phase III
study,41 compared the weekly and the 3-weekly regimen. Similar disease control
rates, median TTP, and median OS were found. However, a higher incidence of
severe diarrhea was reported with the weekly regimen compared with the 3-weekly
regimen in both the phase II study, which reported the incidence in percentage of
cycles, and the phase III study (36 vs. 19%, respectively; P = 0.002). In this review
also higher incidence of severe diarrhea was seen in the weekly regimen compared
with the 3-weekly regimen, in both phase II (27.1 vs. 22.2%) and phase III studies
(36.2 vs. 18.7%).
When extending the results of our review to patients with colorectal cancer who are
eligible for second-line irinotecan as encountered in daily clinical practice, there
are a number of limitations. First, because of selective recruitment of patients for
clinical trials, trial participants may have more favorable prognostic factors than
the nonparticipants.44 Meanwhile, a compassionate use program in 40 hospitals in
e Netherlands including 112 patients showed results that are comparable with the
results of this review.45 In addition, a retrospective chart review in one institution
among all nontrial patients treated with irinotecan showed that toxicity rates in
nontrial patients were not statistically dierent from the rates reported in published
clinical trials.46 Second, not all patients included in the clinical trials received irino-
tecan as second-line treatment; in some of the samples irinotecan was administered
as rst-line treatment (aer an adjuvant treatment including uoropyrimidines) or
as third-line or fourth-line treatment.
is review focused on irinotecan monotherapy, whereas during the last decade
a number of targeted agents have been developed.e addition of these targeted
agents to irinotecan monotherapy may improve ecacy. A retrospective evaluation
on bevacizumab and a phase III trial on cetuximab have shown that the addition of
either of these targeted agents to irinotecan improves ecacy, with a tolerable safety
prole.47,48 Second, panitumumab has been investigated in the rst-line setting and
in patients refractory to standard chemotherapy, but no trials in the second-line
setting have been published yet.
Another factor associated with the outcome of irinotecan is the genetic variation of
proteins involved in irinotecan metabolism.ese variations are important when
comparing populations with dierent races. In particular, polymorphisms aecting
UGT1A1 expression or activity are being investigated. e evidence is currently
insucient to recommend the routine use of UGT1A1 genotyping.49
In conclusion, for irinotecan in second line, an extensive search was undertaken.
irty relevant studies were found.e results in general reect more than accept-
able disease control rates, median TTP, and OS durations, whereas in a randomized
phase III study OS and QoL with irinotecan were superior to best supportive care
alone.erefore, in general, second-line treatment with irinotecan is benecial to
the patient. However, decision making for individual patients may be inuenced by
medical factors and personal preferences. As only aggregated data were available in
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this review, it was not possible to identify those patients who were most likely to
benet from the treatment with irinotecan.is information could only be obtained
by conducting a meta-analysis of individual patient data. Furthermore, the results
from this review can be used as reference values for the design of future clinical
studies on second-line schedules with new agents.
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Appendix
MEDLINE search strategy
(1) Exp lode ’COLORECTAL−NEOPLASMS’ ( s e a r c h ed C o l o r e c t a l Neoplasms ) / a l l
s ubhe ad ing s
(2) ’RECTAL NEOPLASMS ’ / a l l s ubhe ad ing s
(3) Exp lode ’SIGMOID−NEOPLASMS’ ( s e a r c h ed Sigmoid Neoplasms ) / a l l
s ubhe ad ing s
(4) CARCINOMA* nea r (COLORECTAL or COLON* or RECT* or INTESTIN* or LARGE
BOWEL or BOWEL)
(5) NEOPLASIA* nea r (COLORECTAL or COLON* or RECT* or INTESTIN* or LARGE
BOWEL or BOWEL)
(6) NEOPLASM* nea r (COLORECTAL or COLON* or RECT* or INTESTIN* or LARGE
BOWEL or BOWEL)
(7) ADENOCARCINOMA* nea r (COLORECTAL or COLON* or RECT* or INTESTIN* or
LARGE BOWEL or BOWEL)
(8) CANCER* nea r (COLORECTAL or COLON* or RECT* or INTESTIN* or LARGE BOWEL
or BOWEL)
(9) Tumour * nea r (COLORECTAL or COLON* or RECT* or INTESTIN* or LARGE
BOWEL or BOWEL)
(10) Tumor* nea r (COLORECTAL or COLON* or RECT* or INTESTIN* or LARGE BOWEL
or BOWEL)
(11) # 1 or #2 or #3 or #4 or #5 or #6 or #7 or #8 or #9 or # 10
(12) CAMPTOTHECIN
(13) I r i n o t e c a n
(14) CPT− 1 1
(15) CPT11
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(16) CPT 1 1
(17) # 1 2 or # 1 3 or # 14 or # 1 5 or # 16
(18) RANDOMIZED−CONTROLLED−TRIAL in PT
(19) ’ Randomized−Con t r o l l e d −T r i a l s ’ / a l l SUBHEADINGS in MIME.MJME. PT
(20) CONTROLLED−CLINICAL−TRIAL in PT
(21) ’ Con t r o l l e d −C l i n i c a l −T r i a l ’ /WITHOUT SUBHEADINGS in MIME.MJME. PT
(22) CLINICAL−TRIAL in PT
(23) ’ C l i n i c a l −T r i a l ’ /WITHOUT SUBHEADINGS in MIME.MJME. PT
(24) ’ C l i n i c a l −T r i a l −Phase−I I ’ /WITHOUT SUBHEADINGS in MIME.MJME. PT
(25) ’ C l i n i c a l −T r i a l −Phase− I I I ’ /WITHOUT SUBHEADINGS in MIME.MJME. PT
(26) ’ C l i n i c a l −T r i a l −Phase−IV ’ /WITHOUT SUBHEADINGS in MIME.MJME. PT
(27) e xp l ode CLINICAL−TRIALS / a l l s ubhe ad ing s
(28) ( c l i n * nea r t r i a l * ) in TI
(29) ( c l i n * nea r t r i a l * ) in AB
(30) ( s i n g l * or doubl * or t r e b l * or t r i p l * ) nea r ( b l i n d * or mask * )
(31) (# 30 in TI ) or (# 30 in AB)
(32) ’ S i n g l e −Bl ind −Method ’ /WITHOUT SUBHEADINGS in MIME.MJME. PT
(33) ’Double−Bl ind −Method ’ /WITHOUT SUBHEADINGS in MIME.MJME. PT
(34) PLACEBOS
(35) p l a c e bo * in TI
(36) p l a c e bo * in AB
(37) random * in TI
(38) random * in AB
(39) RESEARCH−DESIGN
(40) COMPARATIVE−STUDY in PT
(41) e xp l ode EVALUATION−STUDIES / a l l s ubhe ad ing s
(42) FOLLOW−UP−STUDIES
(43) PROSPECTIVE−STUDIES
(44) c o n t r o l * or p r o s p e c t i v * or v o l u n t e e r *
(45) (#44 in TI ) or (#44 in AB)
(46) ’ Mu l t i c e n t e r −S t u d i e s ’ / a l l SUBHEADINGS
(47) ’ I n t e r v e n t i o n −S t u d i e s ’ /WITHOUT SUBHEADINGS
(48) ’ Cohort−S t u d i e s ’ /WITHOUT SUBHEADINGS
(49) ’ Case−Contro l−S t u d i e s ’ /WITHOUT SUBHEADINGS in MIME.MJME. PT
(50) ’ Cross−Over−S t u d i e s ’ /WITHOUT SUBHEADINGS in MIME.MJME. PT
(51) ’ L on g i t u d i n a l −S t u d i e s ’ /WITHOUT SUBHEADINGS in MIME.MJME. PT
(52) ’ R i sk−Fa c t o r s ’ /WITHOUT SUBHEADINGS in MIME.MJME. PT
(53) ’ Treatment−Outcome ’ /WITHOUT SUBHEADINGS in MIME.MJME. PT
(54) # 1 8 or # 19 or #20 or #2 1 or #22 or #23 or #24 or #25 or #26 or #27 or
#28 or #29 or # 3 1 or #32 or # 3 3 or #34 or # 3 5 or #36 or #37 or #38
or #39 or #40 or #41 or #42 or #43 or #45 or #46 or #47 or #48 or
#49 or #50 or # 5 1 or #52 or # 5 3
(55) (TG=ANIMALS) not ( (TG=HUMANS) and (TG=ANIMALS) )
(56) #54 not # 5 5
(57) # 1 1 and # 1 7 and # 5 6 .
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Abstract
No standard monotherapy or combination palliative chemotherapy currently exists
for patients with advanced breast cancer pretreated with anthracyclines and taxanes.
In this systematic review we assess the current knowledge on the ecacy and safety
of palliative single-agent chemotherapy drugs —capecitabine, vinorelbine, gem-
citabine, and liposomal doxorubicin— commonly used in daily clinical practice.
We identied 22 studies, of which ten investigated capecitabine, nine investigated
vinorelbine, three investigated gemcitabine, and one investigated liposomal dox-
orubicin.e greatest amount of information was available for capecitabine and
vinorelbine.ese two drugs showed good ecacy.e disease control rate diered
signicantly between the four drugs, which is relevant in terms of how well tumour
symptoms can be improved and whether quality of life can be maintained or even
improved. To obtain more evidence of the ecacy and safety of chemotherapeutic
agents used in this pretreated population of advanced breast cancer patients, ran-
domised comparisons of the various drugs, as monotherapy and in combination
with targeted agents, are needed.
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Introduction
Introduction
Breast cancer is the most common malignant disease among women in developed
countries. In Europe in 2008, an estimated 421 000 incident cases of breast cancer
were diagnosed and 129 000 deaths from this disease were reported.1 Despite the
advances in diagnostic techniques, surgery, and adjuvant treatment, 30–70% of
patients have recurrent disease or develop metastases and, ultimately, die of the
disease. An additional 6% present with metastatic disease at diagnosis.2
When metastases are seen, cure is no longer an option.e aim of the treatment
becomes palliative and median survival is about 2 years.3,4 e method of treatment
depends on hormone-receptor status and whether HER2 (also known as ErbB-2)
is overexpressed. For patients with tumours negative for hormone receptors or
who have not responded to endocrine treatment, chemotherapy is the appropriate
treatment option.2 Several chemotherapeutic agents are used in the treatment of
breast cancer, of which anthracyclines and taxanes are two of the most eective.5 Ac-
cording to the European Society for Medical Oncology clinical recommendations,2
only taxane-based regimens have level 1 evidence for use as rst-line therapy in
patients progressing aer adjuvant anthracycline-based chemotherapy. No standard
approaches for second-line or further chemotherapy have particular recommenda-
tions because no data show any particular regimen to be better than any other.2 In
daily practice, capecitabine, vinorelbine, gemcitabine, and liposomal doxorubicin
are widely used as monotherapy. A regimen might, therefore, be selected on the
basis of the characteristics of an individual patient and tumour,6 the patient’s and
clinician’s preferences for the method of administration, side-eects, costs, or a
combination of these features.
In view of the palliative aim of the treatment, the benets of chemotherapy have
to be weighed against the risk of toxic eects. For rst-line treatment, the use
of a taxane in combination with another chemotherapeutic agent has improved
response rates and survival compared with a taxane alone, although the rate of toxic
eects has increased.5 Randomised comparisons suggest that sequential therapy is
as eective as combination chemotherapy.5,7 Sequential monotherapy is, therefore,
the preferred choice in patients with advanced disease, in the absence of rapid
clinical progression, life-threatening visceral metastases, and the need for control
of acute symptoms.8
Although reviews have been published on treatment options for patients pretreated
with anthracyclines and taxanes,9–11 they have not compared the dierent regimens
and have assessed only a selection of the available evidence. Jassem and colleagues9
limited their search to randomised and non-randomised controlled trials, and
Moreno-Aspitia and colleagues10,11 only included studies relevant to clinical practice
at the time. We aim in this Review, therefore, to provide a comprehensive synthesis of
the information on the ecacy and safety of agents commonly used as monotherapy
for advanced breast cancer in patients who have previously received anthracyclines
and taxanes.
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Methods
A literature search was performed in PubMed for papers published from January,
1966, to April, 2010, with the search terms “xeloda”, “caelyx”, “gemzar”, “navelbine”,
“breast”, “mamma”, “advanced”, “metastatic”, followed by the addition of “capecita-
bine”, “vinorelbine”, “gemcitabine”, and “liposomal doxorubicin”.e reference lists
of all relevant articles were searched for additional studies. Studies were included if
they met the following criteria: phase 2 or 3 clinical trial; at least 80% of enrolled
patients with advanced breast cancer pretreated with anthracyclines and taxanes;
palliative chemotherapy with capecitabine, vinorelbine, gemcitabine, or liposomal
doxorubicin monotherapy; and the report was a full-length paper published in
English, Dutch, German, or French. For randomised trials we only included pa-
tients from study groups in which one of the four relevant study drugs had been
used. Article selection was decided by one researcher (LJMO) and a random sample
comprising 5% of papers was checked independently by another researcher (PBO).
Data extraction
e following data were extracted from the selected reports: study phase, chemo-
therapeutic agents, dosing scheme, inclusion period, number of patients, patients’
age, WHO performance status, and the proportion of patients pretreated with an-
thracyclines and taxanes. To enable assessment of outcome data on ecacy, we
extracted the most frequently reported endpoints in breast cancer studies, which are
tumour response rate, median time to progression (TTP), median progression-free
survival (PFS), and median overall survival (OS).12 To compare tumour response
rates between studies we converted data into intention-to-treat response data when
necessary, with the number of enrolled patients as the denominator.13 e outcome
of interest for tumour response rate was the disease control rate, which we dened
as overall response plus stable disease. For outcome data on safety, we extracted the
incidence of serious adverse events (grades 3–4) and of severe alopecia.
Data synthesis
For each drug, a summary of the outcome data was obtained by computation of
means for disease control rate, median TTP, median PFS, median OS, and the
number of serious adverse events, weighted according to the number of patients
included in the studies. Ecacy outcomes were compared between study drugs
with a random eects model to take into account heterogeneity across studies. We
used univariate ANOVA, which used weighted least squares, and again weighted by
the number of patients in the studies. With this conservative method of weighting,
the analysis was based on the number of studies included and not on the number
of patients included. All analyses were performed with SPSS (version 16.0).
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Results
4079 potentially relevant studies screened for retrieval
(all identied through database searching)
3984 studies excluded on the basis of title and abstract
95 studies retrieved to assess in more detail
73 studies excluded on the basis of full-length article
16 no phase 2 or 3 clinical trial
40 < 80% of patients pretreated with anthracyclines
and taxanes
6 combination treatment
1 because other publications on same study identied
10 no relevant data
22 studies included
Figure 4.1: Selection process for articles
Results
Description of studies
e initial systematic literature search identied 4079 potentially relevant studies.
e addition of generic drug names to this search strategy did not yield additional
studies, nor did the checking of 200 randomly selected studies. e review of
the reference lists from all retrieved studies did not reveal any further suitable
studies.e reporting of the selection process (Figure 4.1) followed the PRISMA
statement.14 22 studies met all criteria and were included in the systematic review
(Table 4.1). Ten studies investigated capecitabine,15–24 nine vinorelbine,16,25–32 three
gemcitabine,33–35 and one liposomal doxorubicin.36 One randomised, phase 2 study
investigated capecitabine in one treatment group and vinorelbine in the other.16
ese 22 studies included a total of 2046 patients; the earliest was started in 1993
and the latest nished in 2009. Ecacy and safety data are presented in Tables 4.2
and 4.3.
Capecitabine
Among the studies of capecitabine three were phase 3 trials15,17,19 and seven were
phase 2 trials,16,18,20–24 and they involved a total of 1404 patients. A regimen of
1250mg/m2 twice daily for 14 days every 3 weeks was used in all but two studies,
where the dose was 1255mg/m2. e studies were done between 1996 and 2006,
and the median ages ranged from 48 years to 56 years. Most of the included patients
(55% in one study, 93–100% in the other nine studies) hadWHO performance status
scores of 0 or 1.
Table 4.1: Characteristics of the included studies
WHO performance status
0 1 2
Study
Phase
and design Dosing scheme
Inclusion
period n
Age in years
median (range) n (%) n (%) n (%)
Pretreated
with
anthracyclines
n (%)
Pretreated
with
taxanes
n (%)
CAPECITABINE
Cameron et al.15 3, randomised 1250 mg/m2 twice daily for 14 days every 3 weeks 2004–06 201 51 (28–83) 118 ( 59%) 83 (41%) 0 199 (>99%) 199 (>99%)
Pajk et al.16 2, randomised 1250 mg/m2 twice daily for 14 days every 3 weeks 2002–04 23 50 (31–70) 23 (100%)* .. 0 23 (100%) 23 (100%)
Thomas et al.17 3, randomised 1250 mg/m2 twice daily for 14 days every 3 weeks 2003–06 377 52 (25–79) 237 ( 63%) 136 (36%) 1 ( 1%) 365 ( 97%) 363 ( 96%)
Lin et al.18 2, single arm 1250 mg/m2 twice daily for 14 days every 3 weeks 2001–03 37 52 (34–84) 22 ( 60%) 13 (35%) 2 ( 5%) 37 (100%) 37 (100%)
Miller et al.19 3, randomised 1250 mg/m2 twice daily for 14 days every 3 weeks 2000–02 230 Mean 52 (30–77) 115 ( 50%) 115 (50%) 0 ≥227 (≥99%) ≥227 (≥99%)
Fumoleau et al.20 2, single arm 1250 mg/m2 twice daily for 14 days every 3 weeks 1998–2001 126 54 (30–80) 55 ( 44%) 61 (49%) 9 ( 7%) 121 ( 96%) 125 ( 99%)
Lee et al.21 2, single arm 1250 mg/m2 twice daily for 14 days every 3 weeks 1999–2002 38 48 (31–66) 21 ( 55%)* .. 17 (45%) 38 (100%) 38 (100%)
Reichardt et al.22 2, single arm 1250 mg/m2 twice daily for 14 days every 3 weeks 1999–2000 136 56 (32–77) 94 ( 69%) 36 (27%) 5 ( 4%) 127 ( 93%) 134 ( 99%)
Blum et al.23 2, single arm 1255 mg/m2 twice daily for 14 days every 3 weeks 1997–99 74 Mean 53 (29–77) 74 (100%)* .. 0 71 ( 96%) 74 (100%)
Blum et al.24 2, single arm 1255 mg/m2 twice daily for 14 days every 3 weeks 1996–96 162 Mean 56 (26–78) 162 (100%) .. 0 147 ( 91%) 162 (100%)
VINORELBINE
Seo et al.25 2, single arm 25 mg/m2 weekly 2004–09 26 47 (37-71) 21 ( 81%)* .. 5 (19%) 24 ( 92%) 24 ( 92%)
Pajk et al.16 2, randomised 30 mg/m2 days 1 and 8 every 3 weeks 2002–04 24 54 (31-71) 24 (100%) .. 0 24 (100%) 24 (100%)
Martín et al.26 3, randomised 30 mg/m2 days 1 and 8 every 3 weeks 2001–05 126 57 (35-80) 45 ( 36%) 58 (46%) 21 (17%) 126 (100%) 126 (100%)
Papaldo et al.27 2, dual arm 25 mg/m2 weekly 2000–04 33 57 (35-74) 29 ( 88%) 3 ( 9%) 1 ( 3%) 33 (100%) 29 ( 88%)
Toi et al.28 2, single arm 25 mg/m2 days 1 and 8 every 3 weeks 2001–03 50 55 (37-71) 38 ( 76%) 7 (14%) 5 (10%) 50 (100%) 50 (100%)
Jara-Sánchez et al.29 2, single arm 8 mg bolus, followed by 8 mg/m2 days 1–4, every 3 weeks 1996–99 47 54 (34-78) 47 (100%)† .. .. 44 ( 94%) 39 ( 83%)
Zelek et al.30 2, single arm 30 mg/m2 weekly 1997–99 40 49 (39-69) 40 (100%)† .. .. ≥33 (≥81%) 40 (100%)
Udom et al.31 2, single arm 25 mg/m2 every 2 weeks 1997–98 20 47 (23-71) 3 ( 15%)‡ 2 (10%)‡ 7 (35%)‡ 19 ( 95%) 19 ( 95%)
Livingston et al.32 1–2, single arm 30 mg/m2 weekly, dose escalation up to 35 mg/m2 1993–95 40 Mean 48 (33-73) 40 (100%)* .. 0 40 (100%) 40 (100%)
GEMCITABINE
Modi et al.33 2, single arm 800 mg/m2 weekly for 3 weeks, 1-week rest 1998–2001 22 54 (36-70) 10 ( 45%) 11 (50%) 1 ( 5%) 21 ( 95%) 22 (100%)
Rha et al.34 2, single arm 850 mg/m2 weekly for 3 weeks, 1-week rest 2000–02 41 47 (30-69) 11 ( 27%) 21 (51%) 9 (22%) 41 (100%) 41 (100%)
Smorenburg et al.35 2, single arm 1200 mg/m2 weekly for 3 weeks, 1-week rest NR 23 53 (31-70) 6 ( 26%) 16 (70%) 1 ( 4%) 23 (100%) 23 (100%)
LIPOSOMAL DOXORUBICIN
Keller et al.36 3, randomised 50 mg/m2 every 4 weeks NR 150 56 (33-87) 150 (100%)† .. .. 124 ( 83%) 150 (100%)
Abbreviation — NR: not reported
* Reported as WHO status of 0–1
† Reported as WHO status 0–2
‡ Numbers include patients with a WHO status of 3 (25%) or unknownWHO status (15%)
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Table 4.2: Ecacy data from studies selected for systematic review, by study drug
Number (%) of patients with tumour response*
Median [months]
Study n
Overall
response
Stable
disease
Progressive
disease
Not
assessable
Disease
controlled TTP PFS OS
CAPECITABINE
Cameron et al.15 201 28 (14%) 59 (29%) 47 (23%) 67 (33%) 87 (43%) 4.3 NR 15.3
Pajk et al.16 23 2 ( 9%) 5 (22%) 10 (44%) 6 (26%) 7 (30%) NR 2.8 9.3
Thomas et al.17 377 54 (14%) 175 (46%) 102 (27%) 46 (12%) 229 (60%) NR 4.2 NR
Lin et al.18 37 12 (32%) 17 (46%) NR NR 29 (78%) NR 5.9 9.5
Miller et al.19 230 21 ( 9%)
44 (19%)†
NR NR NR NR NR 4.2 14.5
Fumoleau et al.20 126 35 (28%) 44 (35%) 47 (37%) 0 79 (63%) 4.9 NR 15.2
Lee et al.21 38 10 (26%) 13 (34%) 13 (34%) 2 ( 5%) 23 (60%) 4.6 NR 18.1
Reichardt et al.22 136 21 (15%) 63 (46%) 52 (38%) 0 84 (62%) 3.5 NR 10.1
Blum et al.23 74* 19 (26%) 23 (31%) NR NR 42 (57%) 3.2 NR 12.2
Blum et al.24 162‡ 27 (20%) 54 (40%) 46 (34%) 8 ( 6%) 81 (60%) 3.1 NR 12.6
Weighted mean .. .. .. .. .. 57 3.9 4.2 13.5
VINORELBINE
Seo et al.25 26 5 (19%) 9 (35%) 10 (38%) 2 ( 8%) 14 (54%) NR 3.7 10.4
Pajk et al.16 24 3 (13%) 5 (21%) 8 (33%) 8 (33%) 8 (33%) NR 2.6 11.0
Martín et al.26 126 33 (26%) 32 (25%) 58 (46%) 3 ( 2%) 65 (51%) NR 4.0 16.4
Papaldo et al.27 33 9 (27%) 12 (36%) 12 (36%) 0 21 (63%) 6.0 NR 22
Toi et al.28 50 10 (20%) 19 (38%) 18 (36%) 3 ( 6%) 29 (58%) 3.8 NR NR
Jara-Sánchez et al.29 47 9 (19%) 5 (11%) 32 (68%) 1 ( 2%) 14 (30%) 2.4 NR 7.7
Zelek et al.30 40 10 (25%) 9 (23%) 21 (53%) 0 19 (48%) NR NR 6
Udom et al.31 20 7 (35%) 3 (15%) 10 (50%) 0 10 (50%) 2.8 NR NR
Livingston et al.32 40 10 (25%) NR NR 0 NR 3.0 NR 7.6
Weighted mean .. .. .. .. .. 49 3.6 3.8 12.6
GEMCITABINE
Modi et al.33 22 3 (14%)§ 1 ( 5%) 14 (64%) 4 (18%) 4 (19%) NR NR 9.5
Rha et al.34 41 8 (20%) 12 (29%) 18 (44%) 3 ( 7%) 20 (49%) NR 4.5 11
Smorenburg et al.35 23 0 6 (26%) NR NR 6 (26%) 1.9 NR 7.8
Weighted mean .. .. .. .. .. 35 1.9 4.5 9.8
LIPOSOMAL DOXORUBICIN
Keller et al.36 150¶ 11 (10%) 32 (28%) 37 (32%) 35 (30%) 43 (38%) NR 2.9 10.4
Abbreviations—NR: not reported, TTP: time to progression, PFS: progression-free survival, OS: over-
all survival
* e outcome of interest was disease control rate, which is computed by combining overall response
and stable disease.
† e study’s independent review facility determined a response rate of 9%, whereas the investigators
determined a response rate of 19%.
‡ 135 patients had measurable disease and could be assessed for response.
§ Response unconrmed.
¶ 115 of 150 patients were eligible according to the protocol, and response data for only these patients
are provided.
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Table 4.3: Safety data from studies selected for systematic review, by study drug
Study Nausea Vomiting Diarrhoea
Consti-
pation Fatigue
Hand-foot
syndrome Stomatitis Alopecia Death
CAPECITABINE
Cameron et al.15 2 ( 1%) 2 ( 1%) 10 ( 5%) NR 4 ( 2%) 14 ( 7%) NR NR NR
Pajk et al.16 1 ( 4%) 1 ( 4%) 0 0 1 ( 4%) 1 ( 4%) NR NR 0
Thomas et al.17 6 ( 2%) 7 ( 2%) 33 ( 9%) 1 (0%) 12 ( 3%) 62 (17%) 4 ( 1%) 0 3 (1%)
Lin et al.18 NR 6 (16%) 5 (14%) NR NR 7 (19%) 5 (14%) NR 0
Miller et al.19 4 ( 2%) NR 23 (11%) 0 14 ( 7%) 52 (24%) 1 ( 1%) NR 2 (1%)
Fumoleau et al.20 NR NR 13 (10%) NR NR 26 (21%) NR NR 0
Lee et al.21 0 0 1 ( 3%) NR NR 2 ( 5%) 1 ( 3%) NR 0
Reichardt et al.22 4 ( 3%) 5 ( 4%) 11 ( 8%) NR NR 18 (13%) NR 0 0
Blum et al.23 7 (10%) 4 ( 6%) 14 (19%) NR 6 ( 8%) 16 (22%) 9 (12%) NR 0
Blum et al.24 7 ( 4%) 6 ( 4%) 23 (14%) 2 (1%) 12 ( 7%) 16 (10%) 4 ( 3%) 0 0
Total number
(weighted mean)
31 ( 3%) 31 ( 3%) 133 (10%) 3 (0%) 49 ( 5%) 214 (16%) 24 ( 3%) 0 ( 0%) 5 (1%)
VINORELBINE
Seo et al.25 0 0 NR NR NR NR 0 NR 0
Pajk et al.16 0 0 0 1 (4%) 3 (13%) 0 NR NR 0
Martín et al.26 3 ( 2%)* 3 ( 2%)* NR 2 (2%) 21 (17%) NR 2 ( 2%) 21 (17%) 1 (1%)
Papaldo et al.27 0 0 1 ( 3%) NR NR NR 1 ( 3%) NR NR
Toi et al.28 1 ( 2%) 1 ( 2%) 0 NR 2 ( 4%) NR 0 NR 0
Jara-Sánchez et al.29 3 ( 6%)* 3 ( 6%)* NR NR 6 (13%) NR 6 (13%) NR 1 (2%)
Zelek et al.30 NR NR NR NR NR NR NR NR NR
Udom et al.31 NR NR NR NR NR NR NR NR 0
Livingston et al.32 NR NR NR NR NR NR NR 0 0
Total number
(weighted mean)
7 ( 2%) 7 ( 2%) 1 ( 1%) 3 (2%) 32 (13%) 0 ( 0%) 9 ( 3%) 21 (13%) 2 (1%)
GEMCITABINE
Modi et al.33 0 0 NR 1 (5%) 2 ( 9%) NR 0 0 0
Rha et al.34 0 0 1 ( 2%) 1 (2%) NR NR NR 0 0
Smorenburg et al.35 3 (14%)* 3 (14%)* NR NR 1 ( 5%) NR 0 0 0
Total number
(weighted mean)
3 ( 4%) 3 ( 4%) 1 ( 2%) 2 (3%) 3 ( 7%) NR 0 ( 0%) 0 ( 0%) 0 (0%)
LIPOSOMAL DOXORUBICIN
Keller et al.36 5 ( 3%) 6 ( 4%) 1 ( 1%) 0 8 ( 5%) 28 (19%) 11 ( 8%) 0 NR
Data are number of patients with adverse event (%).
Abbreviation — NR: not reported
* Nausea and vomiting reported as the combined variable severe nausea or vomiting.
e disease control rate could be calculated for nine of the ten studies, in 1174
patients: the lowest rate was 30% and the highest rate was 78%. Median TTP was
reported in six studies involving 737 patients, and ranged from 3.1 to 4.9 months.
e other four studies reported on median PFS in 667 patients, which ranged from
2.8 to 5.9 months. Median OS was reported in nine of ten studies, in 1027 patients,
and ranged from 9.3 to 18.1 months. Weighted mean values were 57% for disease
control rate, 3.9 months for median TTP, 4.2 months for median PFS, and 13.5
months for median OS.
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Results
e most important serious adverse events associated with capecitabine were
diarrhoea, which aected 0–19% of patients (weighted mean 10%) and hand-foot
syndrome, which aected 4–24% of patients (weighted mean 16%).
Vinorelbine
One phase 3 study,26 seven phase 2 studies,16,25,27–31 and one phase 1–2 study32 were
identied. Various dosing schemes were used: 25–30mg/m2 was administered
weekly,25,27,30,32 every 2 weeks,31 or on days 1 and 8 every 3 weeks.16,26,28 In the study
by Jara-Sánchez and co-workers29 patients received a bolus of 8mg/m2 followed
by 8mg/m2 on days 1–4 of every third week. A total of 406 patients were included
and studies were done between 1993 and 2009.e median ages ranged from 47 to
57 years. WHO performance status scores varied: in two studies all patients’ scores
were between 0 and 2, in one only 25% of patients had scores of 0 or 1, and in the
other six studies scores were 0 or 1 in 81–100% of patients.
Disease control was achieved in a total of 366 patients (rate range 30–63%). Median
TTP values were reported in five studies in 190 patients, and ranged from 2.4 to
6.0 months.ree studies reported median PFS times of 2.6, 3.7, and 4.0 months,
respectively, in a total of 176 patients. Median OS was reported for seven of nine
studies (n = 336), the minimum duration was 6months and the maximum duration
was 22 months.e weighted means were 49% for disease control rate, 3.6 months
for median TTP, 3.8 months for median PFS, and 12.6 months for median OS.
Vinorelbine was mainly associated with serious fatigue (range 4–17%, weighted
mean 13%), and one study reported severe alopecia in 17% of patients.
Gemcitabine
ree phase 2 studies33–35 used gemcitabine at doses of 800, 850 or 1200mg/m2
weekly for 3 weeks, followed by 1 week of rest. e total number of patients was
86. Median ages were 54, 47, and 53 years, and 78–96% of all patients had WHO
performance status scores of 0 or 1.
ese three studies showed disease control rates of 19%, 49%, and 26%, respectively.
One study reported a median TTP of 1.9 months, and another a median PFS of
4.5 months. All three studies reported median OS times (Table 4.2).e weighted
mean values were 35% for disease control rate, 1.9 months for median TTP, 4.5
months for median PFS, and 9.8 months for median OS.
One study reported serious nausea, vomiting, or both, in 14% of patients, and two
studies reported serious fatigue in 9% and 5% of patients, respectively.
Liposomal doxorubicin
One phase 3 study on liposomal doxorubicin was identied.36 is study included
150 patients and used a dosing scheme of 50mg/m2 every 4 weeks. e median
age was 56 years, and all patients had WHO performance status scores of 0–2 (a
requirement for study entry).
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Figure 4.2: Disease control and weighted disease control rates by drug
e study showed a disease control rate of 38%, a median PFS of 2.9 months and a
median OS of 10.4 months.e most notable adverse events were serious hand-foot
syndrome (19%) and serious stomatitis (8%).
Comparison of drugs
e disease control rates diered signicantly between study drugs (d f = 20,
R2 = 0.293, p = 0.031). e weighted mean disease control rates were highest
in capecitabine, followed by vinorelbine, liposomal doxorubicin, and gemcitabine
(Figure 4.2). For the other ecacy outcomes, median TTP,median PFS, andmedian
OS, the observed dierences were not signicant.
Discussion
e overall disease control rates were most favourable for capecitabine and vinorel-
bine.e longest median TTP and PFS values were reported for vinorelbine and
capecitabine, respectively, but individually these outcomes did not dier signic-
antly between study drugs. Median OS was longer than 12 months for capecitabine
and vinorelbine but not for gemcitabine or liposomal doxorubicin.e dierences
in OS between study drugs, however, were also not signicant.
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Safety of chemotherapy is of particular importance in the palliative setting. All
drugs were associated with more than one type of serious adverse event.e safety
data for alopecia are noteworthy. For vinorelbine severe alopecia was seen in 0–17%
of patients; the prescribing information indicates that 12% of patients experience
a grade of alopecia, and that in less than 1% of these alopecia will be severe.37 By
contrast, for gemcitabine no patients developed any alopecia, but, although the
prescribing information reports severe alopecia in less than 1% of patients, 15% will
experience a grade of alopecia.38
Limitations and strengths
e systematic search that was undertaken for this Review could be subject to
publication bias. If studies in which ecacy was poor or the frequency of serious
adverse events was high were not reported, the ecacy and safety of the drugs
assessed would be overoptimistic. If the same extent of bias is assumed for all agents,
however, the comparison of drugs in this Review would be less aected.
A limitation was the inadequate reporting of safety data.e assessment of safety is
one of the main objectives of phase 2 studies and, therefore, the main toxic eects
should be reported.e reporting of safety data was, however, incomplete and there
was a lack of uniformity in the reporting of grades. Such inadequate reporting of
safety is a well-known problem in randomised, controlled trials.39–41 Safety data
could be improved if the CONSORT statement extension for harm-related data was
rigorously applied by authors and journals.42
e analysis has several other limitations. First, except for the study of Pajk and
colleagues,16 all reports provided information from only one study group and,
therefore, no dierences could be assessed or ratios calculated, and standard meta-
analytical techniques were not applicable. Heterogeneity is probably higher in
non-randomised than in randomised studies, which is why we used a random-
eects model to incorporate heterogeneity.e degree of heterogeneity could not
be quantied, however, because data on variance were not routinely reported in the
included studies. Sources of heterogeneity could not be explored by relating design
features to study outcome, because few features were noted and the reporting of
them was non-uniform (Table 4.1). Heterogeneity could also have been caused
by variability in study populations. e median ages and WHO performance
status scores of patients did not seem to dier between drugs, but several relevant
variables were insuciently reported and could not be compared. For instance, data
on previous treatment, such as endocrine therapy, number of chemotherapy lines in
the metastatic setting, and response to previous endocrine and chemotherapeutic
treatments, were missing. Many studies also did not provide data on HER2 and
hormone-receptor status. Although these tumour markers have been reported to be
useful in the prediction of outcomes in patients receiving neoadjuvant chemotherapy
for breast cancer, such usefulness has not been conrmed for chemotherapy in
metastatic breast cancer,43 probably because, in the course of time, most tumours
dedierentiate, aggressiveness increases, and response to treatment decreases.44
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We were unable to compute disease control rates for two studies because data on
stable disease were not reported.19,32 We contacted the authors of these reports,
who informed us that the data were not available. Sensitivity analyses were done to
explore the eect of theMiller study19 on the ANOVA results. We used the weighted
mean stable disease rate of the other studies on capecitabine and estimated the
missing disease control rate to be 48%, which rose to 57% when the disease control
rate was predicted from the strong relationship (R = 0.932) of median PFS with
disease control rate across all drugs.ese results suggest that our conclusions are
not substantially altered by the lack of availability of disease status data in some
studies.
Multiple outcomes were assessed per study drug and, therefore, the risk of false-
positive results is increased.e signicant nding for disease control was, however,
consistent with the results for the other ecacy outcomes, where capecitabine
had the greatest ecacy, followed by vinorelbine, liposomal doxorubicin, and
gemcitabine.
Strengths of this systematic review were the literature search, for which we used a
broad strategy, and the selection of studies that included at least 80% of patients pre-
treated with anthracyclines and taxanes, which ensured homogeneous pretreatment
among populations.
Agreements and disagreements with other studies
We found two reports in which ecacy and safety were compared directly between
drugs. First, in the randomised phase 2 study of Pajk and colleagues,16 capecitabine
was compared with vinorelbine (in 23 vs. 24 patients).at study was prematurely
discontinued because of poor accrual and, therefore, no formal conclusions could
be made.e limited data from the study suggested, however, that the antitumour
activities of capecitabine and vinorelbine were similar. In relation to safety, cape-
citabine seemed to be less toxic than vinorelbine. Our systematic review showed
that capecitabine and vinorelbine were the most ecacious drugs overall, but that
outcomes were consistently in favour of capecitabine. is indication of better
ecacy was not conrmed by statistical testing, however, nor could it be conrmed
by the ndings of Pajk and colleagues.16
Second, in a randomised, phase 3 study, Keller and colleagues36 compared liposomal
doxorubicin with the commonly used regimens vinorelbine or mitomycin C plus
vinblastine. e mixed control group meant that this study arm did not meet
the inclusion criteria for the present Review, but 85% of patients in the control
group received vinorelbine. e ecacy of both regimens was similar, and the
haematological safety prole of liposomal doxorubicin was favourable compared
with that of vinorelbine.36 In most of the studies of vinorelbine we selected, ecacy
was better than that for liposomal doxorubicin, although the comparison was
hampered by only one study including the latter drug.
e review of Jassem and colleagues9 included one study in which capecitabine was
assessed, one study in which vinorelbine was assessed, and one in which liposomal
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doxorubicin was investigated. None of the drugs was signicantly more eective
for tumour response, PFS, or OS than the others. In the reviews of Moreno-Aspitia
and colleagues10,11 none of the treatment options proved better than the other and,
therefore, in the absence of evidence-based guidelines, the treatment choice should
be based on the patient’s personal circumstances.
Other treatment options
Chemotherapeutic drugs that are being investigated are ixabepilone, vinunine,
abraxane (paclitaxel albuminbound particles), pemetrexed, trabectedin, and eri-
bulin.45 Only ixabepilone, trabectedin, and eribulin have been investigated in a popu-
lation of patients with breast cancer pretreated with anthracyclines and taxanes.46–48
So far the ecacy of these agents has not surpassed that for the drugs included in
this Review.
Although sequential monotherapy is recommended, combination therapy might
be an option for selected patients. Combination therapy with cyclophosphamide,
methotrexate, and 5-uorouracil is widely used, although evidence to support use
of this regimen is lacking for patients previously treated with anthracyclines and
taxanes, as studies were done before the introduction of taxanes. A randomised,
controlled trial published in 2009 did show that in the adjuvant setting a regimen of
cyclophosphamide, methotrexate, and 5-uorouracil was better than capecitabine
alone in women with early-stage breast cancer who were aged 65 years or older.49
In addition, a randomised, controlled trial of cyclophosphamide, methotrexate,
and 5-uorouracil as rst-line therapy showed similar ecacy to that seen for
capecitabine.50 ese results warrant further investigation of cyclophosphamide,
methotrexate, and 5-uorouracil in patients pretreated with anthracyclines and
taxanes, in comparison with capecitabine and vinorelbine.e safety of cyclophos-
phamide, methotrexate, and 5-uorouracil, which might be associated with a raised
risk of haematological adverse events, should also be assessed.
Two phase 3 studies included in this systematic review compared capecitabine17 and
vinorelbine26 monotherapy with combination therapy. Treatment with combined
capecitabine and ixabepilone resulted in better response rates and longer median
PFS, but not better OS, than did capecitabine monotherapy.17,51 On the basis of
the study by Hortobagyi and colleagues,51 the FDA has approved the combination
of capecitabine and ixabepilone for patients with metastatic or locally recurrent
breast cancer who no longer benet from conventional regimens.52 Combination
therapy was, however, associated with a raised risk of toxic eects and a higher
number of deaths from treatment-related adverse events, and increased rates of
treatment discontinuation.e European Medicines Agency has, therefore, refused
a marketing authorisation for ixabepilone, because of concerns that the benets
do not outweigh the risks.53 Another phase 3 study compared vinorelbine with
vinorelbine plus gemcitabine and showed prolonged median PFS but no improve-
ment in response rates or OS.e risk of toxic eects was slightly raised with the
combination regimen.26
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e addition of targeted agents to chemotherapy drugs could improve ecacy.
Agents are available now that target epidermal growth factor receptor, HER2, and
vascular endothelial growth factor.e use of these agents raises the risk of addi-
tional toxic eects. Agents targeting epidermal growth factor receptor can lead to
dermatological and gastrointestinal events, and those targeting vascular endothelial
growth factor have been associated with bleeding episodes, thrombosis, hyperten-
sion, and proteinuria.54
Conclusions
Our systematic review shows that of the four chemotherapeutic drugs most com-
monly used for advanced breast cancer pretreated with anthracyclines and taxanes,
capecitabine and vinorelbine were most ecacious. We found only limited evidence
for the eectiveness of gemcitabine and liposomal doxorubicin. Rates of disease
control diered signicantly between agents, which might be relevant to the quality
of life of patients. To obtain more evidence of the ecacy and safety of agents used
in patients with metastatic breast cancer pretreated with anthracyclines and taxanes,
randomised comparisons of the various chemotherapeutics and targeted agents are
needed.
Funding
is work was supported and funded by the Dutch Cancer Society (grant number
KUN 2006-3465).e funder had no role in study design and the collection, ana-
lysis, and interpretation of data and the writing of the article and the decision to
submit it for publication.
Disclosure
e authors have no conicts of interest to disclose.
References
1. Ferlay J, Parkin DM and Steliarova-Foucher E. Estimates of cancer incidence and
mortality in Europe in 2008. Eur J Cancer. 2010; 46(4): 765–781. doi: 10.1016/j.ejca.
2009.12.014. pmid: 20116997.
2. Cardoso F, Senkus-Konefka E, Falloweld L, Costa A, Castiglione M and the ESMO
Guidelines Working Group. Locally recurrent or metastatic breast cancer: ESMO
Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2010;
21(Suppl 5): v15–v19. doi: 10.1093/annonc/mdq160. pmid: 20555067.
3. Largillier R, Ferrero J-M, Doyen J et al. Prognostic factors in 1,038 women with meta-
static breast cancer. Ann Oncol. 2008; 19(12): 2012–2019. doi: 10.1093/annonc/mdn424.
pmid: 18641006.
63
References
4. Saad ED, Katz A and Buyse M. Overall survival and post-progression survival in
advanced breast cancer: a review of recent randomized clinical trials. J Clin Oncol.
2010; 28(11): 1958–1962. doi: 10.1200/JCO.2009.25.5414. pmid: 20194852.
5. Amar S, Roy V and Perez EA. Treatment of metastatic breast cancer: looking towards
the future. Breast Cancer Res Treat. 2009; 114(3): 413–422. doi: 10.1007/s10549-008-
0032-3. pmid: 18465221.
6. Jones SE. Considerations in treatment choice formetastatic breast cancer.Breast Cancer.
2008; 15(1): 35–39. doi: 10.1007/s12282-007-0005-0. pmid: 18224392.
7. European School ofOncology (ESO)-MBCTask Force.Metastatic breast cancer. Recom-
mendations proposal from the European School of Oncology (ESO)-MBC Task Force.
Breast. 2007; 16(1): 9–10. doi: 10.1016/j.breast.2006.11.002. pmid: 17390420.
8. Cardoso F, Bedard PL, Winer EP et al. International guidelines for management of
metastatic breast cancer: combination vs sequential single-agent chemotherapy. J Natl
Cancer Inst. 2009; 101(17): 1174–1181. doi: 10.1093/jnci/djp235. pmid: 19657108.
9. Jassem J, Carroll C, Ward SE, Simpson E and Hind D.e clinical ecacy of cytotoxic
agents in locally advanced or metastatic breast cancer patients pretreated with an
anthracycline and a taxane: a systematic review. Eur J Cancer. 2009; 45(16): 2749–2758.
doi: 10.1016/j.ejca.2009.05.035. pmid: 19615886.
10. Moreno-Aspitia A and Perez EA. Treatment options for breast cancer resistant to
anthracycline and taxane.Mayo Clin Proc. 2009; 84(6): 533–545. doi: 10.1016/S0025-
6196(11)60585-5. pmid: 19483170.
11. Moreno-Aspitia A and Perez EA. Anthracycline- and/or taxane-resistant breast cancer:
results of a literature review to determine the clinical challenges and current treatment
trends. Cliner. 2009; 31(8): 1619–1640. doi: 10.1016/j.clinthera.2009.08.005.
pmid: 19808124.
12. Saad ED and Katz A. Progression-free survival and time to progression as primary end
points in advanced breast cancer: oen used, sometimes loosely dened. Ann Oncol.
2009; 20(3): 460–464. doi: 10.1093/annonc/mdn670. pmid: 19095776.
13. Zia MI, Siu LL, Pond GR and Chen EX. Comparison of outcomes of phase II studies
and subsequent randomized control studies using identical chemotherapeutic regimens.
J Clin Oncol. 2005; 23(28): 6982–6991. doi: 10.1200/JCO.2005.06.679. pmid: 161925
85.
14. Moher D, Liberati A, Tetzla J, Altman DG and the PRISMA Group. Preferred re-
porting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ.
2009; 339: b2535. doi: 10.1136/bmj.b2535. pmid: 19622551.
15. Cameron D, Casey M, Press M et al. A phase III randomized comparison of lapatinib
plus capecitabine versus capecitabine alone in women with advanced breast cancer
that has progressed on trastuzumab: updated ecacy and biomarker analyses. Breast
Cancer Res Treat. 2008; 112(3): 533–543. doi: 10.1007/s10549-007-9885-0. pmid:
18188694.
16. Pajk B, Cufer T, Canney P et al. Anti-tumor activity of capecitabine and vinorelbine in
patients with anthracycline- and taxane-pretreated metastatic breast cancer: ndings
from the EORTC 10001 randomized phase II trial. Breast. 2008; 17(2): 180–185. doi:
10.1016/j.breast.2007.09.002. pmid: 17976988.
64
Ch
ap
te
r4
.
Se
co
nd
-li
ne
ch
em
ot
he
ra
py
fo
ra
dv
an
ce
d
br
ea
st
ca
nc
er
17. omas ES, Gomez HL, Li RK et al. Ixabepilone plus capecitabine for metastatic breast
cancer progressing aer anthracycline and taxane treatment. J Clin Oncol. 2007; 25(33):
5210–5217. doi: 10.1200/JCO.2007.12.6557. pmid: 17968020.
18. Lin P-C, Wang W-S, Yang M-H, Yen C-C, Chao T-C, Hsiao L-T and Chen P-M. Se-
quential therapy with capecitabine followed by vinorelbine/cisplatin in patients with
anthracycline/taxane-refractory metastatic breast cancer. J Chin Med Assoc. 2006;
69(7): 304–309. doi: 10.1016/S1726-4901(09)70263-1. pmid: 16903643.
19. Miller KD, Chap LI, Holmes FA et al. Randomized phase III trial of capecitabine
compared with bevacizumab plus capecitabine in patients with previously treated
metastatic breast cancer. J Clin Oncol. 2005; 23(4): 792–799. doi: 10.1200/JCO.2005.
05.098. pmid: 15681523.
20. Fumoleau P, Largillier R, Clippe C et al.Multicentre, phase II study evaluating capeci-
tabine monotherapy in patients with anthracycline- and taxane-pretreated metastatic
breast cancer. Eur J Cancer. 2004; 40(4): 536–542. doi: 10.1016/j.ejca.2003.11.007.
pmid: 14962720.
21. Lee S-H, Lee J, Park J et al. Capecitabine monotherapy in patients with anthracycline-
and taxane-pretreated metastatic breast cancer.Med Oncol. Fall 2004; 21(3): 223–231.
doi: 10.1385/MO:21:3:223. pmid: 15456949.
22. Reichardt P, Von Minckwitz G,uss-Patience PC et al.Multicenter phase II study of
oral capecitabine (Xeloda®) in patients with metastatic breast cancer relapsing aer
treatment with a taxane-containing therapy. Ann Oncol. 2003; 14(8): 1227–1233. doi:
10.1093/annonc/mdg346. pmid: 12881384.
23. Blum JL, Dieras V, Lo Russo PM, Horton J, Rutman O, Buzdar A and Osterwalder
B. Multicenter, phase II study of capecitabine in taxane-pretreated metastatic breast
carcinoma patients. Cancer. 2001; 92(7): 1759–1768. pmid: 11745247.
24. Blum JL, Jones SE, Buzdar AU et al. Multicenter phase II study of capecitabine in
paclitaxel-refractory metastatic breast cancer. J Clin Oncol. 1999; 17(2): 485–493. pmid:
10080589.
25. Seo HY, Lee HJ, Woo OH et al. Phase II study of vinorelbine monotherapy in anthra-
cycline and taxane pre-treated metastatic breast cancer. Invest New Drugs. 2011; 29(2):
360–365. doi: 10.1007/s10637-009-9357-y. pmid: 19943080.
26. Martín M, Ruiz A, Muñoz M et al. Gemcitabine plus vinorelbine versus vinorelbine
monotherapy in patients with metastatic breast cancer previously treated with anthra-
cyclines and taxanes: nal results of the phase III Spanish Breast Cancer Research
Group (GEICAM) trial. Lancet Oncol. 2007; 8(3): 219–225. doi: 10 . 1016 / S1470 -
2045(07)70041-4. pmid: 17329192.
27. Papaldo P, Fabi A, Ferretti G et al.A phase II study on metastatic breast cancer patients
treated with weekly vinorelbine with or without trastuzumab according to HER2
expression: changing the natural history of HER2-positive disease. Ann Oncol. 2006;
17(4): 630–636. doi: 10.1093/annonc/mdj110. pmid: 16410363.
28. Toi M, Saeki T, Aogi K et al. Late phase II clinical study of vinorelbine monotherapy in
advanced or recurrent breast cancer previously treated with anthracyclines and taxanes.
Jpn J Clin Oncol. 2005; 35(6): 310–315. doi: 10.1093/jjco/hyi090. pmid: 15930037.
65
References
29. Jara-Sánchez C, Martín M, García-Sáenz JA et al. Vinorelbine as a 96-hour continuous
infusion in heavily pretreated patients with metastatic breast cancer: a cooperative
study by the GEICAM group. Clin Breast Cancer. 2003; 3(6): 399–404. doi: 10.3816/
CBC.2003.n.004. pmid: 12636884.
30. Zelek L, Barthier S, Riofrio M, Fizazi K, Rixe O, Delord JP, Le Cesne A and Spielmann
M.Weekly vinorelbine is an eective palliative regimen aer failure with anthracyclines
and taxanes in metastatic breast carcinoma. Cancer. 2001; 92(9): 2267–2272. doi: 10.10
02/1097-0142(20011101)92:9<2267::AID-CNCR1572>3.0.CO;2-Q. pmid: 11745280.
31. Udom DI, Vigushin DM, Linardou H, Graham H, Palmieri C and Coombes RC. Two
weekly vinorelbine: administration in patients who have received at least two prior
chemotherapy regimes for advanced breast cancer. Eur J Cancer. 2000; 36(2): 177–182.
doi: 10.1016/S0959-8049(99)00219-1. pmid: 10741275.
32. Livingston RB, Ellis GK, Gralow JR,WilliamsMA,White R, McGuirt C, Adamkiewicz
BB and Long CA. Dose-intensive vinorelbine with concurrent granulocyte colony-
stimulating factor support in paclitaxel-refractorymetastatic breast cancer. J Clin Oncol.
1997; 15(4): 1395–1400. pmid: 9193331.
33. Modi S, Currie VE, Seidman AD et al. A phase II trial of gemcitabine in patients with
metastatic breast cancer previously treated with an anthracycline and taxane. Clin
Breast Cancer. 2005; 6(1): 55–60. doi: 10.3816/CBC.2005.n.009. pmid: 15899073.
34. Rha SY,MoonYH, JeungHC et al.Gemcitabinemonotherapy as salvage chemotherapy
in heavily pretreated metastatic breast cancer. Breast Cancer Res Treat. 2005; 90(3):
215–221. doi: 10.1007/s10549-004-2468-4. pmid: 15830134.
35. Smorenburg CH, Bontenbal M, Seynaeve C, van Zuylen C, de Heus G, Verweij J and
deWit R. Phase II study of weekly gemcitabine in patients with metastatic breast cancer
relapsing or failing both an anthracycline and a taxane. Breast Cancer Res Treat. 2001;
66(1): 83–87. doi: 10.1023/A:1010679127390. pmid: 11368414.
36. Keller AM, Mennel RG, Georgoulias VA et al. Randomized phase III trial of pegylated
liposomal doxorubicin versus vinorelbine or mitomycin C plus vinblastine in women
with taxane-refractory advanced breast cancer. J Clin Oncol. 2004; 22(19): 3893–3901.
doi: 10.1200/JCO.2004.08.157. pmid: 15459210.
37. GlaxoSmithKline. NAVELBINE® (vinorelbine tartrate) Injection — Prescribing informa-
tion. U.S. Food and Drug Administration (FDA). 2002. url: http://www.fda.gov/
ohrms/dockets/ac/04/briefing/4021b1_10_vinorelbine%20label.pdf (accessed
2011 Mar 10th).
38. Eli Lilly. GEMZAR® (gemcitabine hydrochloride) Injection — Prescribing Information.
U.S. Food and Drug Administration (FDA). 1996. url: http://www.accessdata.fda.
gov/drugsatfda_docs/label/2010/020509s064lbl.pdf (accessed 2011 Mar 10th).
39. Ioannidis JP and Lau J. Completeness of safety reporting in randomized trials: an
evaluation of 7 medical areas. JAMA. 2001; 285(4): 437–443. doi: 10.1001/jama.285.
4.437. pmid: 11242428.
40. Loke YK and Derry S. Reporting of adverse drug reactions in randomised controlled
trials — a systematic survey. BMC Clin Pharmacol. 2001; 1: 3. doi: 10.1186/1472-
6904-1-3. pmid: 11591227.
66
Ch
ap
te
r4
.
Se
co
nd
-li
ne
ch
em
ot
he
ra
py
fo
ra
dv
an
ce
d
br
ea
st
ca
nc
er
41. Pitrou I, Boutron I, Ahmad N and Ravaud P. Reporting of safety results in published
reports of randomized controlled trials.Arch InternMed. 2009; 169(19): 1756–1761. doi:
10.1001/archinternmed.2009.306. pmid: 19858432.
42. Ioannidis JPA, Evans SJW, Gøtzsche PC, O’Neill RT, Altman DG, Schulz K, Moher
D and the CONSORT Group. Better reporting of harms in randomized trials: an
extension of the CONSORT statement. Ann Intern Med. 2004; 141(10): 781–788. doi:
10.7326/0003-4819-141-10-200411160-00009. pmid: 15545678.
43. Hamilton A, Larsimont D, Paridaens R et al. A study of the value of p53, HER2, and
Bcl-2 in the prediction of response to doxorubicin and paclitaxel as single agents in
metastatic breast cancer: a companion study to EORTC 10923. Clin Breast Cancer.
2000; 1(3): 233–40, 233–40. doi: 10.3816/CBC.2000.n.020. pmid: 11899648.
44. Corle DK, Sears ME and Olson KB. Relationship of quantitative estrogen-receptor
level and clinical response to cytotoxic chemotherapy in advanced breast cancer. An
extramural analysis. Cancer. 1984; 54(8): 1554–1561. pmid: 6478397.
45. Fernández Y, Cueva J, Palomo AG et al.Novel therapeutic approaches to the treatment
of metastatic breast cancer. Cancer Treat Rev. 2010; 36(1): 33–42. doi: 10.1016/j.ctrv.
2009.10.001. pmid: 19883980.
46. Zelek L, Yovine A, Brain E, Turpin F, Taamma A, Riofrio M, Spielmann M, Jimeno J
andMisset JL. A phase II study of Yondelis® (trabectedin, ET-743) as a 24-h continuous
intravenous infusion in pretreated advanced breast cancer. Br J Cancer. 2006; 94(11):
1610–1614. doi: 10.1038/sj.bjc.6603142. pmid: 16736024.
47. omas E, Tabernero J, Fornier M et al. Phase II clinical trial of ixabepilone (BMS-
247550), an epothilone B analog, in patients with taxane-resistant metastatic breast
cancer. J Clin Oncol. 2007; 25(23): 3399–3406. doi: 10.1200/JCO.2006.08.9102. pmid:
17606975.
48. Vahdat LT, Pruitt B, Fabian CJ et al. Phase II study of eribulin mesylate, a halichondrin
B analog, in patients with metastatic breast cancer previously treated with an anthra-
cycline and a taxane. J Clin Oncol. 2009; 27(18): 2954–2961. doi: 10.1200/JCO.2008.
17.7618. pmid: 19349550.
49. Muss HB, Berry DA, Cirrincione CT et al. Adjuvant chemotherapy in older women
with early-stage breast cancer. N Engl J Med. 2009; 360(20): 2055–2065. doi: 10.1056/
NEJMoa0810266. pmid: 19439741.
50. O’Shaughnessy JA, Blum J, Moiseyenko V et al. Randomized, open-label, phase II trial
of oral capecitabine (Xeloda®) vs. a reference arm of intravenous CMF (cyclophosph-
amide, methotrexate and 5-uorouracil) as rst-line therapy for advanced/metastatic
breast cancer. Ann Oncol. 2001; 12(9): 1247–1254. pmid: 11697835.
51. Hortobagyi GN, Gomez HL, Li RK et al. Analysis of overall survival from a phase
III study of ixabepilone plus capecitabine versus capecitabine in patients with MBC
resistant to anthracyclines and taxanes. Breast Cancer Res Treat. 2010; 122(2): 409–418.
doi: 10.1007/s10549-010-0901-4. pmid: 20454927.
52. U.S. Food and Drug Administration (FDA). FDA approves Ixempra for advanced
breast cancer patients. 2007. url: http://www.fda.gov/NewsEvents/Newsroom/
PressAnnouncements/2007/ucm109015.htm (accessed 2011 Mar 10th).
67
References
53. European Medicines Agency (EMA). Questions and answers on recommendation for
the refusal of the marketing authorization for Ixempra. 2008. url: http://www.ema.
europa.eu/docs/en_GB/document_library/Summary_of_opinion_- _Initial_
authorisation/human/000930/WC500014746.pdf (accessed 2011 Mar 10th).
54. Gerber DE. Targeted therapies: a new generation of cancer treatments. Am Fam Physi-
cian. 2008; 77(3): 311–319. pmid: 18297955.
Appendix A
Nurse copy of a decision aid 
for second-line chemotherapy 
in advanced colorectal cancer
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Introduction
Explaining the goal of the study
You are participating in a study exploring ways to inform patients like you about
their treatment options. As a part of this study, we have collected information on the
available treatment options and developed this decision aid.e aid is designed for
patients with colorectal cancer, for whom cure is not an option. You have previously
been treated with chemotherapy and now you are faced with a decision about two
treatment options. Both treatment options aim to reduce your complaints as much
as possible. We would like to involve you in this treatment decision.
Explaining the course of the consultation
During this consultation we will present you with information on the two dierent
treatment options, including the adverse events and results associated with these
two options.e information is intended to support your treatment decision. You
can decide for yourself which information you want or do not want to receive.
is decision aid presents the chance that certain adverse events and results will
occur.ese chances are based on studies among large numbers of patients. It is
not possible to predict whether you will actually experience these adverse events
and results.
e information that is presented during the consultation is included in a take home
brochure. You may want to discuss the information with others. Should you have
any questions about the decision aid, please give us a call.e contact details can
be found in the take home brochure.⇒ Do you have any questions at this moment? Please feel free to ask any questions
that may arise during the consultation.
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Treatment options
If you have previously been treated with chemotherapy, two dierent treatment op-
tions are available.e goal of both treatment options is to reduce your complaints
as much as possible.
Treatment option 1: best supportive care without chemotherapy
With this treatment option, your complaints will be managed using best supportive
care, which may include drugs and in some cases also radiation therapy or surgery.
Best supportive care is intended to cause as few adverse events as possible. You will
not receive any chemotherapy.
Treatment option 2: best supportive care with chemotherapy
With this treatment option, you will not only receive best supportive care, but also
chemotherapy using the drug ‘irinotecan’.
As described above, your complaints will be managed using best supportive care,
which may include drugs and in some cases also radiation therapy or surgery.
Alongside best supportive care, you will also receive chemotherapy in an attempt
to kill cancer cells or slow down the growth of cancer cells. If successful, your
complaints may be reduced. It is also possible that chemotherapy lengthens your
life. On the other hand, chemotherapy can cause adverse events, which in some
cases can be life threatening.
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Example of information in this decision aid
e information presented in this decision aid is meant to help you choose between
the two treatment options. As is oen the case with decisions, there is a trade-o
between pros and cons. An example of such a trade-o is presented below. e
information in this example is ctitious.
When you are going on holiday, you can decide to either stay in the Netherlands, or
to go abroad.⇒ lay down the cards for the patient according to the scheme below:
Holiday destination
the Netherlands abroad
Weather conditions
Number of people who have nice weather
30 of 100 do
70 of 100 don’t
60 of 100 do
40 of 100 don’t
Food poisoning
Number of people who experience food
poisoning
1 of 100 does
99 of 100 don’t
15 of 100 do
85 of 100 don’t
As you can see, there is a trade-o between the positive outcome (nice weather)
and the negative outcome (food poisoning). Similar trade-os can be made when it
comes to treatment decisions.roughout this decision aid, we will use the same
format to present you with information on the available treatment options, to enable
a trade-o between the dierent options.
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Information on adverse events
On the next page you can nd information on adverse events related to the two
dierent treatment options.
In both treatment groups, severe and less severe adverse events can occur. Less
severe events can cause discomfort, but for the sake of clarity, this decision aid will
only present severe adverse events. Severe adverse events can lead to a hospital
admission or prolongation of an admission. On rare occasions, severe adverse
events can be life threatening.
e length of chemotherapy treatment is on average 4 months.is decision aid
shows the chance of severe adverse events occurring within this 4 month period.
e aid only shows severe adverse events for which the rate of occurrence is found
to be dierent between the two treatment options. In addition, the decision aid
presents the chance that a person dies as a result of a severe adverse event.⇒Do you want to receive the information on adverse events?
If the patient decides that the information is not desired, please proceed with the next
item ‘response of the cancer’
Should the patient be interested in severe adverse events with an equal occurrence
in both groups, these include: constipation, fatigue, mouth ulcers, loss of appetite,
skin complaints, neurological complaints, cardiovascular complaints, pain, abdominal
pain, and infections.
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⇒ lay down the cards for the patient according to the scheme below:
best supportive care
without
chemotherapy
with
chemotherapy
severe nausea
you are so nauseated that your intake of
food and uid is insucient
3 of 100 do
97 of 100 don’t
14 of 100 do
86 of 100 don’t
severe vomiting
you have to vomit at least 6 times a day
sometimes intravenous uids and intra-
venous feeding are needed
8 of 100 do
92 of 100 don’t
14 of 100 do
86 of 100 don’t
severe diarrhoea
you have an increase of at least 7 stools
per day, and may also have problems con-
trolling your bowels
6 of 100 do
94 of 100 don’t
22 of 100 do
78 of 100 don’t
severe hair loss
you lose all your hair (on your head)
0 of 100 do
100 of 100 don’t
44 of 100 do
56 of 100 don’t
death
you die as a result of a severe adverse event
0 of 100 do
100 of 100 don’t
1 of 100 does
99 of 100 don’t
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Information on the response of the cancer
e next page contains information on the response of the cancer for both treatment
options.
Chemotherapy is used in an attempt to kill cancer cells or slow down the growth of
cancer cells. If successful, your complaints may be reduced. During the course of
chemotherapy treatment, you will have regular check-ups to monitor the response
of the cancer.
ere are three possible ways for the cancer to respond to treatment:
• the size of the cancer is reduced
e cancer is reduced to half or less than half of its initial size.
• the size of the cancer remains stable
ere are no signicant changes in the size of the cancer.
• the size of the cancer is increased
e cancer does not respond to treatment and continues to grow.
Please note that any reduction or stabilisation of the cancer will only be temporary.
In the end, the cancer will always start to grow again.⇒Do you want to receive the information on the response of the cancer?
If the patient decides that the information is not desired, please proceed to the last
item ‘survival’
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⇒ lay down the cards for the patient according to the scheme below:
best supportive care
without
chemotherapy
with
chemotherapy
the size of the cancer is reduced
(in the pie diagram this part is displayed
in white)
0 of 100 4 of 100
the size of the cancer remains stable
(in the pie diagram this part is displayed
in grey)
6 of 100 52 of 100
the size of the cancer is increased
(in the pie diagram this part is displayed
in black)
94 of 100 44 of 100
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Information on survival
e next page contains information on survival for both treatment options.
As a result of the cancer, people will die prematurely. is decision aid presents
how many months will pass from today until half of the people are alive, for both
treatment options.is can give you insight in the gain that can be expected from
chemotherapy treatment.
Again, we would like to emphasize that it is not possible to predict your individual
survival.⇒Do you want to receive the information on survival?
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⇒ lay down the cards for the patient according to the scheme below:
best supportive care
without
chemotherapy
with
chemotherapy
Aer this number of months,
50 out of 100 people are still alive and
50 out of 100 people will have died
6months 9months
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Treatment decision
You have received information on the two dierent treatment options and the ad-
verse events and results associated with these options.is information is intended
to support the treatment decision about the two options. If you want to be involved
in this decision, you canmake a trade-o between the pros and cons of both options.
An overview of all information is now laying on the table in front of you.

Part II
Using the decision aids
in the context of a clinical trial
Chapter 5
Expected survival with 
and without second-line 
palliative chemotherapy: 
who wants to know?
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Abstract
Background According to surveys, many patients with advanced cancer wish to
receive survival information.
Objective is study investigated information preferences by oering patients a
decision aid (DA) with information on expected survival for two treatment options:
supportive care with or without second-line palliative chemotherapy. Predictors of
accepting survival information were explored.
Design Eligible patients in this multicentre prospective study were oered second-
line chemotherapy for advanced breast or colorectal cancer. A nurse presented a
DA on second-line treatment and asked patients whether they desired information
on (i) adverse events, (ii) tumour response and (iii) survival. Data on 50 clinical
and psychosocial patient characteristics were collected from inclusion forms and
patient questionnaires.
Results Seventy-seven patients received a DA; median age 62 years (range 32–
80), 61% female, 77% colorectal cancer. Fiy-seven patients (74%; 95% CI 64–84)
desired survival information. Four psychosocial characteristics (e.g. deliberative
decision style) independently predicted information desire. However, the use of
these characteristics to predict information desire hardly outperformed a simple
prediction rule.
Conclusions Many patients desired information on expected survival when de-
ciding about second-line treatment. However, our exploratory analysis indicated
that patients desiring this information could not be identied based on their clinical
or psychosocial characteristics.ese ndings can help encourage candid discus-
sions about expected survival. Health professionals should be careful not to make
implicit assumptions of information desire based on patient characteristics, but to
explicitly ask patients if survival information is desired, and act accordingly.
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Introduction
A central component of the communication with patients with advanced cancer is
the discussion of prognosis, including expected survival. Health professionals may
be concerned that providing survival information could be contrary to patients’
wishes or best interests.1 While patients with advanced cancer indeed fear bad news,
many wish to receive survival information to make treatment decisions and plan the
future.2 Candid conversations about prognosis can establish an open atmosphere,
improve patients’ sense of control and facilitate more realistic expectations.3 Surveys
found that many patients with advanced cancer (44, 59, 80 and 88%, respectively)
stated a desire for survival information.4–7 It remains unclear, however, how many
patients will accept survival information when it is actually oered by a health
professional.8
Previous studies have tried to characterize patients desiring survival informa-
tion. In these studies, patients were asked whether they desired to discuss ex-
pected survival6,7,9 or whether they desired these discussions had taken place.4,10
Among patients with advanced cancer, a higher information desire was observed
for men4,10 and for patients with higher education,7 more pain,7 or more symptoms
of depression.6 In addition, among patients with cancer across all disease stages,
stating a desire for survival information was associated with lower age, lower death
avoidance and worse prognosis.9
is study will assess preferences of patients with advanced breast or colorectal
cancer for receiving survival information when deciding whether or not to start
second-line palliative chemotherapy. Patients’ information desire will be assessed
by actually oering information of the expected benets and risks of chemother-
apy, using a decision aid (DA). Clinical and psychosocial patient characteristics
associated with desiring survival information will be explored.
Methods
Design
is study was part of a randomized trial (Netherlands Trial Registry; NTR1113)
conducted in 17 hospitals in the Netherlands which was described in detail else-
where.11 In short, the target population consisted of patients with advanced breast or
colorectal cancer facing the decision whether or not to start second-line palliative
chemotherapy. To identify these patients, patients who were in remission aer
rst-line chemotherapy or were receiving rst-line chemotherapy were preselected.
Exclusion criteria were labile personality structure, a Karnofsky score lower than 60,
and insucient Dutch language prociency.e study was approved by the regional
ethics review committee and the research ethics committees of all participating
centres.
Procedure
e medical oncologist or nurse assessed the potential eligibility of consecutive
patients. Professionals were instructed not to mention that explicit survival inform-
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ation could be provided, to avoid losing patients not desiring such information.
Professionals asked patients for permission to be approached by the researcher, who
obtained written informed consent.
At inclusion, patients were sent a baseline questionnaire with sociodemographic
and psychosocial variables hypothesized to be associated with information desire.
ese patients were monitored for disease progression and the ensuing treatment
decision whether or not to start second-line palliative chemotherapy. Patients who
were oered second-line treatment were randomly assigned to receive (i) the usual
treatment-related information from the oncologist (control group) or (ii) the usual
treatment-related information followed by a DA from a nurse (intervention group)
(1:2 ratio).
is study focused on the patients in the intervention group, who received the DA in
a subsequent consultationwith a nurse, typically within aweek aer the consultation
with the oncologist whomentioned disease progression and treatment options. DAs
were developed for 11 chemotherapeutic regimens commonly used as second-line
treatment for advanced breast or colorectal cancer, based on systematic reviews
of the literature for the two tumour types.12,13 In the systematic review on benets
and risks of second-line irinotecan for advanced colorectal cancer, 25 phase II and
5 phase III studies were identied. Median survival was established using the single
direct randomized comparison between patients receiving best supportive care
(BSC) plus second-line irinotecan and patients receiving BSC alone.12 In the vast
body of literature on second-line chemotherapy for breast cancer, no randomized
studies comparing any of the second-line chemotherapeutic regimens to BSC alone
were found. A meta-analysis was performed to establish the median survival for
each of the selected chemotherapeutic regimens; no dierences in eectiveness
were found between the regimens.13 In the DAs, the median expected survival of
12 months with chemotherapy was presented together with a question mark for
expected survival without chemotherapy, and an explanation that it is not known
whether, or in what way, the survival of patients with advanced breast cancer
is inuenced by second-line chemotherapy. Figure 5.1 shows a summary of the
information provided in a DA for colorectal cancer, and a full DA is available in the
online supplement.
e consultation started with an introduction in which the DA, the two treatment
options (supportive care with or without second-line palliative chemotherapy),
and an example of risk information were presented.en, the nurse proceeded to
oer information on risks and benets in three separate items: (i) adverse events;
(ii) tumour response; and (iii) survival. For each item, the nurse rst elaborated
on the type of information that could be expected (e.g. implications of a serious
adverse event, the temporary nature of tumour response, the concept of median
survival) and then asked the patient whether the information was desired or not.
If desired, the nurse provided the information. e instructions for the nurse,
including the explanation of the concept of median survival, are included in the
online supplement.
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Without
chemotherapy
With
chemotherapy
ADVERSE EVENTS
Severe nausea
You are so nauseated that your intake of food
and uid is insucient
3 of 100 do
97 of 100 don’t
14 of 100 do
86 of 100 don’t
Severe vomiting
You have to vomit at least 6 times a day
sometimes intravenous uids and intraven-
ous feeding are needed
8 of 100 do
92 of 100 don’t
14 of 100 do
86 of 100 don’t
Severe diarrhoea
You have an increase of at least 7 stools per
day, and may also have problems controlling
your bowels
6 of 100 do
94 of 100 don’t
22 of 100 do
78 of 100 don’t
Severe hair loss
You lose all your hair (on your head)
0 of 100 do
100 of 100 don’t
44 of 100 do
56 of 100 don’t
Death
You die as a result of a severe adverse event
0 of 100 do
100 of 100 don’t
1 of 100 does
99 of 100 don’t
RESPONSE OF THE CANCER
e size of the cancer is reduced (white) 0 of 100 4 of 100
e size of the cancer remains stable (grey) 6 of 100 52 of 100
e size of the cancer is increased (black) 94 of 100 44 of 100
SURVIVAL
Aer this number of months
50 out of 100 people are still alive and
50 out of 100 people will have died
6months 9months
Figure 5.1: Example of the summary page of a decision aid for colorectal cancer
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Measures
Table 5.1 gives an overview of the measurements of information desire and potential
predictors.
Information desire
During the interview with the DA, the nurse registered the main outcome measure:
whether or not the patient wanted to see the information on survival (see above in
‘Procedure’).
Potential predictors of information desire
Sociodemographic variables were collected through the baseline questionnaire and
the inclusion form (Table 5.1). Oncologists were instructed to record tumour and
treatment characteristics on the inclusion form and to estimate patient survival on
the progression form. At the start of the interview, the nurse asked for the patient’s
treatment preference and if applicable, the strength of this preference. Measures on
well-being included general health, anxiety and depression,14 cancer worries15 and
health-related quality of life.16 Questions on coping included coping with cancer,17
decision style,18 participation preference19 and death avoidance.9,20 Information-
related measures included the amount of information preferred,21 the amount of
information received and numeracy22,23 (i.e. the ability to handle basic probability
concepts). Patients rated their own baseline knowledge (subjective knowledge)
on cancer and on benets and risks of treatment options. Patients’ attitudes were
measured with questions on striving for length (quantity) and quality of life,24
questions on the patients’ perceived amount of benets and risks experienced during
rst-line chemotherapy and a question on the time since last chemotherapeutic
treatment.
Statistical analysis
To examine selective attrition, the characteristics of patients receiving the DA were
compared with patients experiencing progressive disease who were not randomized,
using an independent samples t-tests or chi-square test. As themain outcome of this
study, we calculated the percentage of patients, including the 95% condence interval
of that percentage, who accepted the survival information. Next, an extensive
exploratory analysis of potential predictors of accepting survival information was
performed. Patients desiring survival information were compared with patients
not desiring that information, using chi-square tests. In case of missing data, scale
values were calculated only if at least half of the items were available, by imputing the
mean of the available items. Data were dichotomized by a median split, except for
HADS anxiety and depression scales which were dichotomized using a clinical cut-
o point of 8.25 Patient characteristics associated with desiring survival information
at a level of P < 0.2 in a bivariate analysis were entered stepwise in a multivariable
logistic regression model, adding additional variables with a P value of < 0.05.e
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Table 5.1: Overview of measurements of information desire and predictors
Timing of
measurements
Variable Operationalization Inclusion
Interview
with DA
Information desire P
PREDICTORS OF INFORMATION DESIRE
Sociodemographics (n = 8)
Age P
Living situation P
Working status P
Having children P
Having grandchildren P
Education P
Religion P
Gender O
Tumour and treatment characteristics (n = 7)
Date of initial diagnosis of disease O
Date of diagnosis metastatic disease O
Tumour location O
Tumour status O
Previous palliative chemotherapy O
First-line chemotherapy in study setting O
Estimate of patient survival 3–6, 6–9, 9–12, >12 months O*
Decision-related measures (n = 2)
Treatment preference Chemotherapy+BSC / BSC alone / do not know P
Strength of treatment preference 1–4 (not strong – very strong)† P
Well-being (n = 13)
General health 0–10 (worst – best imaginable) P
Anxiety and depression HADS Anxiety and Depression Scale P
Cancer Worries Adapted Lerman’s Cancer Worry Scale P
Health-related quality of life (n = 9)‡ EORTC QLQ-C15-PAL P
Coping (n = 9)
Coping with cancer (n = 3)§ Mental Adjustment to Cancer Scale P
Decision style (n = 4)¶ Michigan Assessment of Decision Style P
Participation preference Problem-Solving Decision-Making Scale P
Death avoidance Death Avoidance Scale P
Information-related measures (n = 5)
Information preference 0–10 (I want to know nothing – everything
there is to know)
P
Amount of information received 1–7 (way too little – way too much) P
Subjective numeracy (n = 3)∥ Subjective Numeracy Scale P
Knowledge-related measures (n = 1)
Subjective knowledge 1–10 (very bad – excellent) P
Treatment attitudes (n = 5)
Striving for length or quality of life (n = 2)** QQ Questionnaire P
Perceived benefits and harms
of first-line chemotherapy (n = 2)†† 1–4 (much – none) P
Time since last chemotherapy 1–5 (currently under treatment – more
than a year ago)
P
Abbreviations — P: patient-reported, O: oncologist-reported, BSC: best supportive care, DA: decision aid
* Reported on the progression form when disease progression occurred.
† For patients who were undecided, strength of the treatment preference was scored as ‘0’.
‡ Including physical and emotional functioning, fatigue, nausea and vomiting, pain, dyspnoea, insom-
nia, appetite loss, constipation.
§ Including helplessness/hopelessness, cognitive avoidance, ghting spirit.
¶ Including decision avoidance, deferring responsibility, information seeking, deliberation.∥ Including the total scale and the ability and preference subscales.
**Including striving for length of life and striving for quality of life.
††Including benets and harms of rst-line palliative chemotherapy.
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use of a higher value of P for the selection of variables in the bivariate analysis is
generally recommended because the use of the traditional value of P < 0.05 can
result in missing important predictors, concealed by confounding.
Results
Participants
Of 441 patients assessed for potential eligibility, 86 (20%) did not meet the inclusion
criteria, and 34 patients (8%) were not approached and therefore the inclusion
criteria could not be veried (see Figure 5.2). Of the 321 patients asked for the study,
263 (82%) gave informed consent. Of them, 92 patients (35%) were not faced with
the decision on second-line palliative chemotherapy and therefore did not belong
to the target population of this study. Another 43 patients (16%) faced the treatment
decision but were not randomized and dropped out of the study. Of the 128 patients
who experienced disease progression and were randomized, 83 were assigned to
the intervention group, of which 77 (93%) received the DA.
No signicant dierences were found between the 43 patients with progressive
disease who were not randomized and the 77 patients who received the DA on
the variables of gender (60 vs. 61% female; P = 0.872), age (mean 59.6 vs. 61.0;
P = 0.470), education (college education 25 vs. 30%; P = 0.592), employment (45
vs. 41%; P = 0.751), information preference at baseline (mean scores 8.3 vs. 8.5;
P = 0.458) and general health (mean scores 6.7 vs. 6.4; P = 0.422). However, non-
randomized patients more oen had a tumour of the breast (vs. colon or rectum)
than patients receiving the DA (43 vs. 23%; P = 0.027).
Information desire
Of 77 patients receiving the DA, 74 (96%) desired the information on adverse events,
70 (91%) desired the information on tumour response, and 57 (74%; 95% CI 64–84)
desired the information on survival.
Potential predictors of information desire
Of 50 patient characteristics considered, 15 (30%) were associated with information
desire at the level P < 0.2 (see Table 5.2). Patients who desired survival information
were more likely to be unemployed or male, more recently received the initial
diagnosis of disease, andmore oen had a tumour of the colon or rectum (vs. breast).
In addition, desiring survival information was associated with more symptoms of
nausea and vomiting, pain and dyspnoea. Patients desiring survival information
employed less cognitive avoidant and ghting spirit cancer coping styles, deferred
less responsibility and deliberated more regarding decision making. Desire for
survival information was higher in patients with a lower perceived numerical ability,
lower subjective knowledge and perception of greater benet and lesser harm from
rst-line chemotherapy.
Consultation with oncologist during rst-line treatment:
441 patients assessed for eligibility
Not asked for the study
• Did not meet inclusion criteria (N = 86)
• Other reasons (e.g. patient not asked in time) (N = 34)
Asked for the study
(N = 321)
Did not give informed consent (N = 58)
Gave informed consent
(N = 263)
Not faced with the decision on second-line chemotherapy
• No disease progression within
the follow-up of the study (N = 40)
• Bad medical condition or died (N = 47)
• Already decided not to want any
further chemotherapy (N = 5)
Not randomized
• Missed at disease progression (N = 35)
• Refused further participation in study (N = 6)
• Other reasons (e.g. went to another hospital) (N = 2)
Preselection of patients who started rst-line palliative chemotherapy
Random assignment
(N = 128)
Randomly assigned to receive usual care
plus the decision aid (N = 83) Randomly assigned to receive usual care(N = 45)
Did not receive the decision aid
• No time before start of
chemotherapy (N = 2)
• Patient refusal (N = 4)
Received the decision aid from the nurse
(N = 77)
Figure 5.2: Patient ow chart
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Table 5.2: Patient characteristics associated with information desire at P < 0.2
Acceptance of survival information Bivariate analysis
yes
n = 57 (74%) non = 20 (26%) χ2 OR (95% CI) P
SOCIODEMOGRAPHICS
Working status
Unemployed 24 (80%) 6 (20%) 4.4 0.3 (0.1– 0.9) 0.037
Employed 11 (52%) 10 (48%)
Gender
Male 26 (87%) 4 (13%) 4.4 0.3 (0.1– 1.0) 0.037
Female 31 (66%) 16 (34%)
TUMOUR AND TREATMENT CHARACTERISTICS
Time since initial diagnosis of disease
Short (< 35 months) 33 (87%) 5 (13%) 5.9 0.3 (0.1– 0.8) 0.015
Long (≥ 35 months) 24 (63%) 14 (37%)
Tumour location
Breast 11 (61%) 7 (39%) 1.9 2.3 (0.7– 7.0) 0.165
Colon or rectum 46 (78%) 13 (22%)
WELL-BEING: HRQOL
HRQoL: nausea and vomiting
Low (0) 32 (68%) 15 (32%) 3.3 2.9 (0.9– 9.9) 0.068
High (> 0) 25 (86%) 4 (14%)
HRQoL: pain
Low (< 16.7) 32 (70%) 14 (30%) 1.9 2.2 (0.7– 6.9) 0.167
High (≥ 16.7) 25 (83%) 5 (17%)
HRQoL: dyspnoea
Low (0) 34 (69%) 15 (31%) 2.5 2.5 (0.7– 8.6) 0.117
High (> 0) 23 (85%) 4 (15%)
COPING
Coping with cancer: cognitive avoidance
Low (< 2.5) 30 (88%) 4 (12%) 6.1 0.2 (0.1– 0.8) 0.014
High (≥ 2.5) 27 (64%) 15 (36%)
Coping with cancer: fighting spirit
Low (< 3) 31 (86%) 5 (14%) 4.7 0.3 (0.1– 0.9) 0.031
High (≥ 3) 26 (65%) 14 (35%)
Decision style: deferring responsibility
Low (< 4.7) 40 (80%) 10 (20%) 1.9 0.5 (0.2– 1.4) 0.169
High (≥ 4.7) 17 (65%) 9 (35%)
Decision style: deliberation
Low (< 4.4) 23 (62%) 14 (38%) 6.5 4.1 (1.3–13.1) 0.011
High (≥ 4.4) 34 (87%) 5 (13%)
INFORMATION-RELATED MEASURES
Subjective Numeracy: ability subscale
Low (< 5) 30 (83%) 6 (17%) 2.6 0.4 (0.1– 1.2) 0.108
High (≥ 5) 27 (68%) 13 (33%)
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Table 5.2: (continued)
Acceptance of survival information Bivariate analysis
yes
n = 57 (74%) non = 20 (26%) χ2 OR (95% CI) P
KNOWLEDGE-RELATED MEASURES
Subjective knowledge
Low (< 6.3) 31 (86%) 5 (14%) 4.0 0.3 (0.1– 1.0) 0.045
High (≥ 6.3) 26 (67%) 13 (33%)
TREATMENT ATTITUDES
Perceived benefits first-line chemotherapy
Low (< 2) 13 (54%) 11 (46%) 8.3 5.1 (1.6–15.8) 0.004
High (≥ 2) 42 (86%) 7 (14%)
Perceived harms first-line chemotherapy
Low (< 2) 10 (91%) 1 ( 9%) 1.9 0.3 (0.0– 2.3) 0.172
High (≥ 2) 47 (73%) 17 (27%)
Abbreviations — OR: odds ratio, CI: condence interval
* selection of 51 patients below the age of 65 (retirement age in the Netherlands at the time of the
study)
e multivariable model was tted twice; once with all 15 predictors and once with
14 predictors, as the variable ‘employment status’ was only available for a subgroup
of patients under age 65 (retirement age in the Netherlands at the time of the
study) (n = 53). Both models showed that greater perceived benet of rst-line
chemotherapy (OR 7.4; 95% CI 1.8–30.8), lower cognitive avoidance (OR 0.1; 95%
CI 0.0–0.7), lower ghting spirit (OR 0.2; 95% CI 0.0–0.8) and higher deliberation
decision style (OR 4.9; 95% CI 1.1–21.1) were four independent predictors of desiring
survival information.e odds ratios presented are derived from the model tted
with 14 predictors.
Applying these four characteristics, desiring survival information was correctly
predicted in 60 of 72 patients with complete data (83% correct). Incorrect predic-
tions included overestimations for eight patients (11%) and underestimations for
four patients (6%). By way of comparison, simply assuming that all 72 patients
would accept survival information already correctly identied 55 patients desiring
information (76%).
Discussion
is study showed that the large majority of patients with advanced breast or colo-
rectal cancer (74%) desired to be informed about survival when facing a decision on
second-line palliative treatment. An extensive exploration of patient characteristics
associated with actual acceptance of survival information yielded four patient char-
acteristics, related to past experience and coping with cancer and decision-making
styles, associated with desiring survival information. However, these characteristics
were not very helpful in correctly identifying patients desiring survival information.
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Simply assuming that all patients desire survival information would already identify
most of these patients correctly.
Previous studies reported that a large proportion of patients with advanced cancer
(44, 59, 80 and 88%, respectively) stated a desire for survival information.4–7 In the
present study, we went a step further by oering treatment-related information to
patients who faced a palliative treatment decision.is information was oered by
a nurse using a DA. We found that a high percentage of patients (74%) wished to
receive the information when it was actually oered to them.
Some of the patient characteristics associated with acceptance of survival informa-
tion have previously been reported to be associated with a stated desire for survival
information.is includes the nding that men4,10 and patients with more pain7
were more likely to desire survival information. Likewise, our data mildly sugges-
ted that patients experiencing more nausea, vomiting and dyspnoea desired more
information. We will not elaborate on these ndings because of the limited prac-
tical value for predicting information desire. Reported predictors of preferences
for survival information not conrmed in this study include higher education,7,9
higher depression scores6 and lower death avoidance.9 Furthermore, the previously
reported relation between higher desire for survival information and worse patient-
reported prognosis9 was not conrmed when oncologists’ estimate of survival was
used. Age was not found to be related to desiring survival information; previous
studies showedmixed results for age.7,9 Hypothesized predictors of desiring survival
information that were not conrmed in this study included (strength of) patients’
treatment preference, cancer worries, information and participation preferences,
and striving for length vs. quality of life.
Despite extensive modelling, patients desiring survival information could not be
identied using psychosocial and clinical characteristics. We do not recommend
that any of the characteristics are used to decide whether or not to oer survival
information to a patient. Apart from the fact that the identied characteristics are
not easily assessable, (at least) 11% of patients would receive undesired survival
information, while another 6% would be denied desired information.
e main strength of this study is that patients’ desire for survival information was
investigated by oering information to patients who actually faced a treatment
decision. To minimize selection bias, we preselected patients who would potentially
face the treatment decision, applying few exclusion criteria, and instructed profes-
sionals not to tell patients beforehand that detailed survival information would be
oered in the DA. A satisfactory informed consent rate of 82% was achieved.
A limitation to the generalizability of the results is that we selected only patients
with advanced breast or colorectal cancer, deciding about second-line palliative
chemotherapy. For both tumour types, a substantial majority of patients (78% of
colorectal and 61% of patients with breast cancer, respectively) desired survival
information. e generalizability of our ndings to patients with other tumour
types or patients facing other palliative treatment decisions needs further study.
e exploration of predictors of accepting survival information was extensive, but
has several limitations. Patients lled out the baseline questionnaire several months
(median 3; IQR 0–9) before the survival information was oered. It is possible that
95
C
onclusion
certain patient characteristics (e.g. well-being) changed over these months.us,
the predictive performance of the model might have been better had more recent
patient data been used. However, a lengthy questionnaire at the time of disease
progression was judged to be infeasible.e generalizability of the identied patient
characteristics to other populations is questionable. First, there is the issue of
multiple testing. In the bivariate analysis, 15 of 50 patient characteristics (30%)
were found to be associated with information desire, while 10 characteristics (20%;
P < 0.2) were expected to be found due to chance alone. Second, the multivariable
regression model is likely overtted, for instance due to the high number of patient
characteristics in relation to the number of patients.26 Larger studies are needed to
conrm the ndings on patients’ information desire and potential predictors.
e nding that many patients wanted to receive information on expected sur-
vival regarding second-line chemotherapy can help encourage candid discussions
between health professionals and patients. Our recommendation to health profes-
sionals is not to make implicit assumptions of information desire based on patient
characteristics, but to explicitly ask patients if survival information is desired, and
then act accordingly.e use of open-ended questions can help to elicit a patient’s
most important questions and concerns as well as the preferred level of candidness,
to guide the provision of information by the clinician.27 For example, a physician
might ask ‘How much would you like to know?’ or more specically ‘Do you want
me to tell you how long patients can live with this kind of cancer with or without
chemotherapy? What kind of information do you want me to cover?’.3,28
DAs can support health professionals and patients in conversations about treatment
options by providing numerical estimates of expected survival, including visual aids,
for each treatment option. DAs are proven to be eective at improving knowledge
and realistic perceptions of outcomes and increasing patients’ involvement.29 In
the current study, DAs were oered to patients by nurses, because nurses usually
spend more time with patients than physicians, and some nurses are already highly
involved in supporting treatment decisions.30,31 A possible amendment to the DAs
used in this study, as recommended in a recent study exploring preferences of
people with a cancer experience, is the presentation of three survival scenarios (best
case, worst case and typical survival) instead of median survival.32 ese scenarios
would better convey the variation in survival duration and help patients to hope for
the best while planning for the worst.
Conclusion
Our ndings indicate that many patients with advanced breast or colorectal cancer
want to receive survival information when deciding about second-line palliative
chemotherapy. It is, however, dicult to identify those patients who desire the
information. Candid conversations about expected survival are particularly relevant
in the context of treatment decisions, when the potential benets of treatment have
to be weighed up against the risks. Decision aids can be valuable tools to support
health professionals and patients in these conversations.
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Abstract
Communication about palliative treatment options requires a balance between
providing patients with sucient information and not providing unwanted inform-
ation. Surveys have indicated that many patients with advanced cancer express
a wish to receive detailed information. In this prospective multicenter study the
information desire of patients with advanced breast or colorectal cancer was further
investigated by oering treatment-related information to patients using a decision
aid (DA). In addition, this study explored oncologists’ awareness of their patients’
information desire. Seventy-seven patients with advanced breast or colorectal can-
cer facing the decision whether to start second-line palliative chemotherapy were
oered a DA by a nurse.is DA contained information on adverse events, tumor
response and survival.e nurse asked the patient whether each information item
was desired. Ninety-ve percent of patients chose to receive information on adverse
events, 91% chose to receive information on tumor response, and 74% chose to
receive information on survival. Oncologists’ judgment of patients’ information de-
sire was 100%, 97%, and 81%, respectively. For all three information items together,
oncologists correctly judged the information desire of 62% of patients.is study
conrms that many patients with advanced cancer wish to receive detailed informa-
tion on the benets and risks of palliative treatment options when the information
is actually available. Oncologists were adequately aware of this high information
desire, but had some diculty judging the information desire of individual patients.
A stepped approach to giving information (‘preview, ask, tell, ask’) may help to
better meet patients’ information needs.
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Introduction
Introduction
Palliative chemotherapy aims at prevention and relief of disease symptoms. e
impact of treatment on length of life is oenmodest or uncertain, and the occurrence
of adverse events can negatively impact quality of life. erefore, the decision
whether to start palliative chemotherapy involves a personal trade-o between
the potential benets and risks of treatment.1 When informing patients about this
treatment option, information provision needs to be balanced in order to meet
informed consent, while not providing any unwanted information.2
In daily clinical practice, achieving this balance may be dicult. Findings from
surveys suggest that many patients in the palliative treatment setting wish to re-
ceive detailed treatment-related information.3,4 Little is known about the ability of
physicians to judge patients’ information desire. One study in the palliative setting
showed that physicians had diculty predicting patients’ stated preferences for
information on expected survival.5 Likewise, studies on treatment decision making
showed poor concordance between patients’ preferences and physicians’ percep-
tions of these preferences.5–9 Reference has been made to the ‘silent misdiagnosis’
of patients’ treatment preferences.10
e present study will focus on the treatment decision whether or not to start
second-line palliative chemotherapy. Beyond rst-line treatment for advanced
disease, benets of subsequent lines of chemotherapy are reduced and also oen
less clear, emphasizing the preference-sensitive nature of this decision. Furthermore,
the study will focus on two common types of cancer, i.e. colorectal and breast cancer.
Unlike previous studies using hypothetical scenarios, patients’ information desire
will be assessed by actually oering information about the benets and risks of
treatment options to patients, using a decision aid (DA). e aim of the study
is to investigate patients’ desire for information about the benets and risks of
second-line treatment, and to explore their oncologists’ awareness of this desire.
Methods
Study design
e study described here was part of a multicenter randomized trial; this trial
was registered in the Netherlands Trial Registry (NTR1113) and details have been
published in the study protocol.11 In short, the target population consisted of patients
with advanced breast or colorectal cancer facing the treatment decision whether
or not to start second-line palliative chemotherapy. To identify these patients, we
recruited patients who had started or were starting rst-line palliative chemotherapy
for advanced breast or colorectal cancer. Exclusion criteria were labile personality
structure (as assessed by the physician), a Karnofsky performance score lower than
60, and insucient knowledge of the Dutch language.e study was approved by
the regional ethics review committee (CMO Arnhem-Nijmegen) and the research
ethics committees of all participating centers.
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e medical oncologist or nurse assessed the potential eligibility of consecutive
patients. Health professionals were instructed to introduce the study topic as ‘how
to involve the opinion of patients in their treatment’. Patients were not to be told
that detailed risk information (e.g. on survival) could be provided in this study, to
avoid selection of patients based on information desire. Health professionals asked
patients for permission to be approached by the researcher, who obtained written
informed consent.
Aer inclusion, patients were monitored for disease progression and the subsequent
decision whether or not to start second-line palliative chemotherapy. Patients who
were proposed second-line treatmentwere randomly assigned to receive (1) the usual
treatment-related information from the oncologist (control group) or (2) the usual
treatment-related information from the oncologist plus a DAwith information from
a nurse (intervention group) in a 1:2 ratio. Treatment allocation was concealed using
sealed envelopes which were opened by the nurse aer the oncologist mentioned
disease progression and oered second-line treatment. Unequal randomization was
employed because the control group was only needed to evaluate the DAs (results of
the randomized comparison are reported in a separate manuscript), while data from
the intervention group were also used to address questions on patients’ information
desire.11
Outcome measures
For each patient included in the study, the oncologist completed an inclusion form
with patient and disease characteristics, and stated a judgment of whether the patient
would desire information for each of the three items in the DA: (1) adverse events;
(2) tumor response; and (3) survival. Patients completed a baseline questionnaire
on sociodemographic variables.
When disease progression occurred and the oncologist had proposed second-line
chemotherapy, patients in the intervention group received the DA in a subsequent
consultation with a nurse, typically within a week.e data on risks and benets
presented in the DAwere obtained from systematic reviews of the literature for the
two tumor types.12,13 DAs were developed for 11 chemotherapeutic regimens com-
monly used as second-line treatment for patients with advanced breast or colorectal
cancer. All DAs were reviewed and approved by the participating oncologists.
Patients’ information desire was obtained as follows. Using the DA, information
on the three items was presented in a stepwise fashion (See Figure 6.1).e nurse
rst explained the type of information that could be expected and then asked the
patient whether the information item was desired or not. If desired, the information
was provided.e nurse asked the patient for each item whether any information
on that item had been provided by the oncologist, to explore whether patients’
information desire was associated with the perception of previously having received
information on these items from the oncologist.
105
M
ethods
Introduction
e nurse introduces the decision aid
e nurse introduces the aim of treatment and the two treatment options:
• best supportive care
• best supportive care plus second-line chemotherapy
e nurse gives a non-health related example of the presentation of risk information
Information
Adverse events
(1) e nurse explains the implications of a severe adverse event (e.g. hospital
admission), and explains the selection of adverse events that has been made
(2) e nurse asks the patient whether the information on severe adverse events
is desired
(3) If desired, the nurse provides the information
Tumor response
(1) e nurse explains the dierent ways in which the tumor can respond to
treatment, including the temporary nature of this response
(2) e nurse asks the patient whether the information on tumor response is
desired
(3) If desired, the nurse provides the information
Survival
(1) e nurse explains the concept of median survival, and emphasizes that it is
not possible to predict an individual patient’s survival
(2) e nurse asks the patient whether the information on expected survival is
desired
(3) If desired, the nurse provides the information
Wrap-up
e nurse explains that the information can be used to make a treatment choice
e nurse gives the patient a brochure with the information the patient desired to
see
Figure 6.1: Interview with the nurse using the decision aid
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Statistical analysis
Descriptive statistics were used to summarize patients’ information desire and
oncologists’ judgment. Concordance between these two outcome measures was
examined by calculating the percentage overall concordance, positive agreement
(concordance for wanting the information), and negative agreement (concordance
for not wanting the information). Associations between patients’ information desire
and perceptions of having previously received information from the oncologist were
explored using chi square tests. All analyses were performed using SPSS version 20.
Results
Participating patients and oncologists
Patient ow is depicted in Figure 6.2. Out of 441 patients assessed for potential
eligibility, 55 (12%) did not meet the inclusion criteria, 31 (7%) were excluded, and
34 (8%) were not approached by the oncologist and therefore the inclusion criteria
could not be veried. Of the 321 patients approached to participate in this study, 263
(82%) gave informed consent. From this group, 92 patients (35%) were not faced
with the decision on second-line chemotherapy and therefore did not belong to
the target population of this study. Another 43 patients (16%) faced the treatment
decision but were not randomized and dropped out of the study. Of the 128 patients
who were randomized, 83 patients were randomized to the intervention group,
and 77 (93%) completed the intervention interview with the nurse using the DA.
Oncologists’ judgment of information desire was available for 74 of these patients.
Table 6.1 lists the characteristics of the 77 patients who received the DA and the 40
participating oncologists from 17 hospitals.
Information on adverse events, tumor response, and survival
During the interview, 95% of patients chose to receive information on adverse events,
91% chose to receive information on tumor response, and 74% chose to receive
information on survival.ere were no dierences in information desire between
patients who perceived or did not perceive to have received any information on
this topic from the oncologist. Oncologists thought that of 74 patients, all would
want information on adverse events (100%), 97% would want information on tumor
response, and 81% would want information on survival.
Concordance between oncologists’ judgment and patients’ information desire
Table 6.2 shows the concordance between oncologists’ judgment and patients’ in-
formation desire. Depending on the item, oncologists correctly judged the informa-
tion desire of 47 to 70 out of 74 patients (64–95%). For all three information items
together, oncologists’ judgments were concordant with the information desire of
62% of patients. Positive agreement for wanting to see information on adverse
Consultation with oncologist during rst-line chemotherapy
Assessed for eligibility (n = 441)
Included in the study and monitored for disease progression
(n = 263)
Consultation with oncologist about second-line chemotherapy
Randomized (n = 128)
Allocated to receive usual care plus the
decision aid (n = 83)
• Received the decision aid (n = 77)
• Did not receive the decision aid (n = 6)
– No time before start of
chemotherapy (n = 2)
– Refusal patient (n = 4)
Allocated to receive usual care (n = 45)
Excluded (n = 120)
• Did not meet inclusion criteria (n = 55)
• Labile personality structure (n = 12)
• Karnofsky score lower than 60 (n = 14)
• Insucient Dutch language prociency (n = 5)
• Other reasons (e.g. patient not asked in time) (n = 34)
• Declined to participate (n = 58)
Excluded (n = 135)
• Not faced with the decision on second-line
chemotherapy (n = 92)
– No disease progression within the follow-up of the
study (n = 40)
– Bad medical condition or died (n = 47)
– Already decided not to want any further
chemotherapy (n = 5)
• Not randomized (n = 43)
– Missed at disease progression (n = 35)
– Refused further participation in study (n = 6)
– Other reasons (e.g. went to another hospital) (n = 2)
Recruitment of patients who started rst-line palliative chemotherapy
Figure 6.2: Patient ow chart
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Table 6.1: Patient and oncologist characteristics
PATIENT CHARACTERISTICS (n = 77)
Male sex, n (%) 30 (39%)
Age, median (range) 62 (32–80)
Living with partner, n (%) 59 (79%)
Employed*, n (%) 21 (41%)
College education or more, n (%) 22 (29%)
Colorectal cancer (vs. breast cancer), n (%) 59 (77%)
Information preference, mean (SD)† 8.5 (1.6)
ONCOLOGIST CHARACTERISTICS (n = 40)
Male sex, n (%) 18 (45%)
Academic hospital (vs. peripheral), n (%) 13 (33%)
Number of judgments made per oncologist, mean (range) 2 (1–8)
Abbreviation — SD: standard deviation
* selection of patients <65 years of age, retirement age in the Netherlands in 2012
† rating scale from 0 (I want to know nothing about the illness and its treatment) to 10 (I want to
know everything there is to know about the illness and its treatment)
events and tumor response was 97% and 94%, respectively, and 77% for wanting to
see information on survival. Negative agreement for not wanting to see information
on the three items ranged between 0 and 18%.
Discussion
is study sought to determine whether the high information desire as stated by
patients with advanced cancer in surveyswould also hold truewhen actually oering
treatment-related information in a DA.e ndings conrm that almost all patients
with advanced breast or colorectal cancer wished to receive information on adverse
events and tumor response rates, and that three quarters of patients wished to
receive detailed survival information related to second-line treatment options.
e oncologists in this study were adequately aware of their patients’ high informa-
tion desire.ey were generally capable of identifying patients wanting information
about adverse events and tumor response, but had more diculty identifying pa-
tients wanting information about survival and patients not wanting the available
information. ese results are in line with the previously described ‘silent mis-
diagnosis’ of patients’ information preferences,5 and treatment and participation
preferences.5–10 e majority of patients in this study wished to receive all available
information from the DA, including detailed survival information. However, audio-
recordings of consultations on rst-line palliative chemotherapy in the Netherlands
and Australia have shown that 61% and 58% of patients, respectively, are not given
survival information.14,15 In addition, a systematic review illustrated that communic-
ation on prognosis is characterized by lack of clarity, lack of an estimate of expected
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Table 6.2: Oncologists’ judgment versus patients’ actual information desire
Patients’ desire (n = 77)
Wanted
information
Did not want
information
Overall
con-
cordance
Positive
agreement†
Negative
agreement‡
ITEM 1: ADVERSE EVENTS
Oncologists’ judgment (n = 74)
wants information 70* 4
does not want information 0 0*
concordance 95% 97% 0%
ITEM 2: TUMOR RESPONSE
Oncologists’ judgment (n = 74)
wants information 65* 7
does not want information 2 0*
concordance 88% 94% 0%
ITEM 3: SURVIVAL
Oncologists’ judgment (n = 74)
wants information 44* 16
does not want information 11 3*
concordance 64% 77% 18%
* overall concordance
† positive agreement (concordance for wanting the information) = 2a/(2a+b+c)
‡ negative agreement (concordance for not wanting the information) = 2d/(2d+b+c)
survival, and avoidance of this topic by focusing on active treatment options.16
Perhaps not surprisingly, studies have shown that more than two-thirds of patients
who had started rst-line palliative chemotherapy did not seem to understand that
the goal of treatment was not cure,17 and that only 49% of patients with advanced
cancer were fully aware of their prognosis.4 Oncologists might be hesitant to impart
survival information, possibly fearing a negative impact on the patient.18 Such fear,
however, may not be warranted. For instance, in patients with advanced cancer, full
prognostic discussion was associated with lower levels of depression and did not
impact on anxiety.19 In the same vein, prognostic information could be provided to
patients without taking away hope,20 and end-of-life discussions did not inict psy-
chological distress.21 On the contrary, not discussing prognosis may cause distress
and may preclude patients from reorganizing and adapting their lives.22 It was also
found that patients reporting not having had end-of-life discussions received more
aggressive medical care near death and later hospice referral, resulting in worse
quality of life.21
What can be done to help clinicians to better meet patients’ desire for information?
A stepped approach to giving information, as employed in this study, could help to
tailor information to patients’ desire by (1) rst giving the patient a preview of the
type of information available; (2) asking whether the information is desired; and
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(3) then following the patient’s desire. is stepwise approach is consistent with
recommendations on the communication of prognosis to patients with advanced
disease.23 DAs can help to implement this approach by providing numerical estim-
ates of benets and risks of treatment options; previous studies showed that DAs
can improve understanding.24 e clinician can further promote understanding by
asking what the patient understands and feels about the information provided.25
Methodological strengths of our study are that information desire was assessed
by providing treatment-related information to patients at the point of decision-
making. Generalisability is facilitated by the recruitment of patients using broad
inclusion criteria, before the moment of disease progression. To prevent selective
patient participation, physicians were instructed to recruit consecutive patients and
not to mention that detailed risk information could be provided.is study has a
number of limitations. Ideally, oncologists’ judgment of their patients’ information
desire would be recorded between the diagnosis of disease progression and the
treatment discussion with the patient. However, recording oncologists’ judgment
in this narrow window of opportunity was expected to result in a large amount of
missing data. Asking oncologists for a retrospective judgment, as was done in a
previous study on palliative treatment decisions,5 would introduce the risk of recall
bias. We therefore decided to record the oncologists’ judgment beforehand (median
time of 5 months before the treatment discussion), knowing that most oncologists
in this study had a long-standing relationship with their patients (as an indication,
median time since rst diagnosis of disease and diagnosis of metastatic disease
were 23 and 10 months, respectively). While our ndings are in line with previous
studies, they will need to be conrmed by further studies of real-world treatment
decisions. It is also worth noting that the accuracy of predicting patient’s desire for
survival information may vary between doctors, but this could not be analyzed due
to the small number of judgments made per doctor. In hindsight, it would have
been worthwhile to also ask the patients in the control arm of the randomized trial
about their information desire, without oering the information, to examine the
extent to which patients’ information desire is dependent on the context in which it
is assessed.
In conclusion, this study conrms that many patients with advanced cancer wish to
receive detailed information on the benets and risks of palliative treatment options.
Oncologists were aware of this high information desire, but had some diculty
judging the information desire of individual patients. A stepped approach, possibly
facilitated by the use of DAs, may help to better meet patients’ information needs.
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Abstract
Few decision aids (DAs) are available to support patients with advanced cancer in
treatment decision-making.is randomised study evaluated safety and ecacy
of DAs on second-line chemotherapy for advanced breast or colorectal cancer. 45
patients were randomised to usual care and 83 patients to usual care plus a DA.
Using the DA, nurses oered information on adverse events, tumour response
and survival. Patients completed questionnaires to assess safety (primary outcome:
anxiety) and ecacy in terms of quality of the decision-making process and the
resulting choice.e DAs did not adversely aect patients’ well-being, including
anxiety. Patients in theDA group tended to bemore in favour of chemotherapy (96%
vs. 84%; p = 0.067), but eventually 88% and 84% of patients started chemotherapy
(p = 0.746). Patients in theDA group had stronger treatment preferences (3.0 vs. 2.5;
p = 0.030) and higher subjective knowledge (6.7 vs. 6.3; p = 0.022). No dierences
were seen in objective knowledge, risk perception or patient involvement. DAs with
outcome information on second-line treatment could be safely oered to patients.
Only some improvements in the quality of the decision-making process and the
resulting choice were found. Future studies might clarify whether this relative lack
of eects is common for palliative treatment decisions.
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Introduction
Introduction
Patients with advanced cancer beyond cure can be treated with palliative intent
to relieve symptoms and improve quality of life.1 ese goals can be achieved by
providing patients with best supportive care (BSC), whether or not complemented
by palliative chemotherapy in an attempt to stabilise or shrink the tumour. While
palliative chemotherapy can potentially prolong life, survival gains are usually in the
range of weeks or months. Furthermore, aer failure of a rst line of chemotherapy
given with palliative intent, benets of further lines of chemotherapy tend to be
more limited.e decision whether or not to add rst-line or further-line palliative
chemotherapy to BSC deserves proper consideration of the uncertain benets of
treatment against the risk of (severe) adverse events.
In recent studies from the US, 52% and 69–81% of patients receiving palliative
chemotherapy were apparently not aware that this treatment would not cure their
cancer.2,3 is is worrisome because accurate awareness of treatment goals, options,
benets and risks is needed to ensure that treatment decisions are aligned with
patients’ values.4 Admittedly, deciding about palliative chemotherapy —soon aer
hearing the bad news of either a diagnosis of metastatic disease or progression
of the disease— can be distressing and challenging for patients. Decision aids
(DAs) with information on the benets and risks of treatment options can support
patients in these dicult treatment choices.ere is solid evidence from diverse
healthcare settings that DAs can help to improve knowledge and realistic perception
of outcomes, and increase patients’ involvement in decision-making.5 Several DAs
have been developed to support decisions about palliative chemotherapy, most of
them pertaining to decisions about rst-line treatment.6–14 Benecial eects of these
DAs included improved knowledge9,10,12,14 and stronger treatment preferences.11
e aim of the present study is to evaluate the safety and ecacy of DAs in the set-
ting of second-line palliative chemotherapy for advanced breast or colorectal cancer,
using a randomised multicentre design.e DAs present numerical information
on benets and risks of chemotherapy, including information on expected survival.
Health professionals are oen concerned that providing survival information may
cause anxiety in patients with advanced cancer.15–17 While thus far, DAs have been
proven safe,5 some studies have indicated that prognostic discussions, better pro-
gnostic understanding, and encouragement to participate in decision-making were
associated with higher anxiety among patients receiving or eligible for palliative
chemotherapy.2,18,19 is also included patients who initially welcomed detailed
prognostic information.2 erefore, our primary aim is to evaluate the safety of the
DAs as compared with usual care, regarding patients’ well-being and specically
anxiety. Patients will be asked whether they wish to receive the various elements of
information from the DA. In addition, we explored whether the previously reported
benecial eects of DAs also apply to palliative treatment decisions.
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Methods
Study design
is randomised phase II study was conducted in 17 hospitals in the Netherlands.
e study was registered in the Netherlands Trial Registry (NTR1113), and the pro-
tocol has been published.20 In short, the target population consisted of patients with
advanced breast or colorectal cancer considering second-line palliative chemother-
apy. To identify these patients, we recruited patients receiving rst-line palliative
chemotherapy and patients who were in remission aer rst-line palliative chemo-
therapy for advanced incurable disease. Exclusion criteria were related to labile
personality structure (as assessed by the physician), a Karnofsky performance score
lower than 60, and insucient Dutch language prociency.e study was approved
by the regional ethics review committee and the research ethics committees of all
participating centres.
Recruitment
e medical oncologist or nurse assessed the potential eligibility of consecutive
patients. Eligible patients were approached by the health professional to ask permis-
sion for a researcher to contact them about a study testing a new way of providing
information to patients. Health professionals were instructed not to mention that
explicit information on survival could be provided in this study, to avoid losing
patients not desiring such information. All patients provided written informed
consent to participate.
Procedure
Patients were monitored for disease progression. If the ensuing decision whether
or not to start second-line chemotherapy arose, patients were randomly assigned to
receive (1) usual care from the oncologist (control group) or (2) usual care from
the oncologist followed by a DA from a nurse (intervention group), in a 1:2 ratio.
Unequal randomisation was employed because the control group was only needed
for the present evaluation of the DAs, while data from the intervention group were
also used to address questions on patients’ information desire.20 Randomisation
lists were computer generated per hospital and tumour type, using a block size of 3.
Treatment allocation was concealed using sealed envelopes which were opened by
the nurse aer the oncologist mentioned disease progression and oered second-
line treatment. For patients assigned to the intervention group the nurse scheduled
an appointment to administer the DA.is appointment was typically within a
week aer the oncologist mentioned disease progression and treatment options,
depending on local workow and patient preferences. At the end of the trial, the
randomisation order of patients was checked against the computer generated list.
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e DAs
e DAs were booklets with a description of the two treatment options and nu-
merical information on three items: (1) adverse events, (2) tumour response, and
(3) survival. DAs were developed for 11 chemotherapeutic regimens commonly
used as second-line treatment for advanced breast or colorectal cancer, based on
systematic reviews of the literature for the two tumour types.21,22 An example of a
summary page of a DA on second-line irinotecan is shown in Figure 7.1.e design
of the DAs was based on previous DAs for prostate cancer treatment, developed and
evaluated in our group, which showed benecial eects on objective knowledge,
risk perceptions, and patient involvement.23,24 We also followed guidance from the
International Patient Decision Aids Standards (IPDAS) where possible.
During the consultation the nurse rst introduced the DA and the two treatment
options (best supportive care with or without second-line palliative chemotherapy),
and presented an example of risk information.en information on benets and
risks was oered for the three separate items (adverse events, tumour response,
and survival). For each item, the nurse rst mentioned the type of information
that could be expected (e.g. implications of a severe adverse event, the temporary
nature of tumour response, and the concept of median survival) and then asked the
patient whether the information was desired or not. If desired, the information was
provided. At the end of the interview, the nurse mentioned that the information
could be used to support treatment decision-making. A booklet with information
tailored to the patient’s desire was available to take home.
Measures
Oncologists were asked to complete an inclusion form and nurses were asked to
complete a brief questionnaire about the interview. Patients were sent a baseline
questionnaire (T1) at inclusion, and two follow-up questionnaires one week (T2)
and eight weeks (T3) aer patients received the treatment-related information.
Sociodemographic variables and medical history
Patient’s gender and tumour type were extracted from the inclusion form. e
baseline questionnaire contained questions on age, marital status, having (grand)
children, working status, and education.
Intervention interview with the nurse using the DA
Aer delivering the DA, the nurse noted how the intervention went (1 ‘dicult’ to 5
‘good’).
Outcome measures
e primary outcome of this study was anxiety. Sample size calculation showed
that 70 patients were required in each group to detect a dierence of 2.2 on the
HADS anxiety scale (range 0–21) (power of 81%; two-sided α = 0.05).20 Since this
120
Ch
ap
te
r7
.
D
ec
isi
on
ai
ds
fo
rs
ec
on
d-
lin
ep
al
lia
tiv
ec
he
m
ot
he
ra
py
Without
chemotherapy
With
chemotherapy
ADVERSE EVENTS
Severe nausea
You are so nauseated that your intake of food
and uid is insucient
3 of 100 do
97 of 100 don’t
14 of 100 do
86 of 100 don’t
Severe vomiting
You have to vomit at least 6 times a day
sometimes intravenous uids and intraven-
ous feeding are needed
8 of 100 do
92 of 100 don’t
14 of 100 do
86 of 100 don’t
Severe diarrhoea
You have an increase of at least 7 stools per
day, and may also have problems controlling
your bowels
6 of 100 do
94 of 100 don’t
22 of 100 do
78 of 100 don’t
Severe hair loss
You lose all your hair (on your head)
0 of 100 do
100 of 100 don’t
44 of 100 do
56 of 100 don’t
Death
You die as a result of a severe adverse event
0 of 100 do
100 of 100 don’t
1 of 100 does
99 of 100 don’t
RESPONSE OF THE CANCER
e size of the cancer is reduced (white) 0 of 100 4 of 100
e size of the cancer remains stable (grey) 6 of 100 52 of 100
e size of the cancer is increased (black) 94 of 100 44 of 100
SURVIVAL
Aer this number of months
50 out of 100 people are still alive and
50 out of 100 people will have died
6months 9months
Figure 7.1: Example of the summary page of a decision aid for colorectal cancer
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is one of the rst randomised studies evaluating a DA on palliative chemotherapy,
we decided to explore a broad range of safety and ecacy outcomes.e primary
outcomemeasure anxiety was dened a priori, and all main and additional outcome
measures have been described beforehand in the publicly available study protocol.20
e outcomes of our exploratory analysis of additional outcome measures were
interpreted with appropriate caution, and any statistically signicant ndings will
need to be conrmed by future studies.25 Table 7.1 shows an overview of outcome
measures and operationalisation.
Main outcome measures
e primary outcome measure of this study was anxiety.26 Other measures on
patient well-being included general health, depression,26 cancer worries,27 and
health-related quality of life (HRQoL).28
Additional outcome measures
Coping Patients were asked questions on mental adjustment to cancer, including
the three coping strategies helplessness/hopelessness, ghting spirit, and avoid-
ance.29 In addition, questions were asked on perceived participation and perceived
involvement including the feeling of being oered a choice and the feeling that
patient’s opinion mattered.30,31
Information-related measures Patients were asked about the amount of treat-
ment-related information received and about receiving any undesired information.
Furthermore, questions were asked on satisfaction with the quality of information,
balanced presentation and potential negative experiences with the information
received.
Knowledge Patients rated their own subjective knowledge on cancer and benets
and risks of treatment, and were presented with ve statements to assess objective
knowledge. For subjective risk perception, patients were asked to rate the following
chances: (1) the chance of experiencing an adverse event, (2) the chance of experi-
encing a benecial eect on the tumour when having treatment with chemotherapy
and BSC, as compared with BSC alone, and (3) the chance of experiencing pain
when having treatment with chemotherapy and BSC, as compared with BSC alone.
Objective risk perception was assessed by asking for the chances of experiencing
severe diarrhoea and achieving partial or complete tumour response.
Decision-related measures e decision was evaluated with questions on de-
cision satisfaction and uncertainty, patient’s feeling of control regarding the treat-
ment choice, and weighing of pros and cons of treatment options.32 Patients were
asked for their treatment preference and, if applicable, the strength of this preference
(T2), and for the treatment received (T3).
Treatment attitudes Patients were asked to value each of the two treatment op-
tions and their satisfaction with the treatment received and the physical and emo-
tional eects of treatment.
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Table 7.1: Overview of outcome measures
Timing of measurements*
Measures Operationalisation
Baseline
T1
1 week
follow-up
T2
8 weeks
follow-up
T3
WELL-BEING
General health 0–10 (worst – best imaginable) × × ×
Anxiety and depression Hospital Anxiety and Depression Scale × × ×
Cancer Worries Adapted Lerman’s Cancer Worry Scale × × ×
Health-related quality of life EORTC QLQ-C15-PAL† × × ×
COPING
Helplessness/hopelessness Mental Adjustment to Cancer Scale × × ×
Fighting spirit Mental Adjustment to Cancer Scale × × ×
Avoidance Mental Adjustment to Cancer Scale × × ×
Perceived participation Problem-Solving Decision Making Scale × ×
Perceived involvement yes/no × ×
INFORMATION-RELATED MEASURES
Amount of information 1–7 (I received way too little – way too
much information)
× × ×
Undesired information yes/no ×
Satisfaction with quality of information 1–6 (not satisfied – very much satisfied) × ×
Balanced presentation of information 1–5 (clearly in favour of chemotherapy
plus BSC – clearly in favour of BSC alone)
×
Evaluation of information 1–5 (no negative experience –very negative
experience)
×
KNOWLEDGE
Subjective knowledge 1–10 (very bad – excellent) × ×
Objective knowledge five statements to be judged as right or wrong ×
Subjective risk perception 1–5 (very high – very low)‡ ×
1–7 (much higher – much lower)§
Objective risk perception 0–100%¶ ×
DECISION
Decision satisfaction-uncertainty Decision Evaluation Scales × ×
Decision control Decision Evaluation Scales × ×
Weighing pros and cons Decision Evaluation Scales × ×
Treatment choice chemotherapy+BSC / BSC alone / don’t know × ×
Strength of treatment preference 1–5 (not strong – very strong)∥ ×
TREATMENT ATTITUDES
Valuations 1–10 (very bad – excellent) × ×
Treatment satisfaction 1–6 (dissatisfied – very satisfied) ×
Abbreviations — BSC: best supportive care
* Baseline: at inclusion; follow-up: 1 and 8 weeks aer receiving the treatment-related information
† Including two functioning scales (physical and emotional), and seven symptom scales (fatigue, nausea
and vomiting, pain, dyspnoea, insomnia, appetite loss, and constipation)
‡ Question 1: ‘the chance of experiencing an adverse event’
§ Question 2: ‘the chance of experiencing a benecial eect on the tumour when having treatment with
chemotherapy and BSC, as compared with BSC alone’ and question 3 ‘the chance of experiencing
pain when having treatment with chemotherapy and BSC, as compared with BSC alone’
¶e absolute deviation between patient’s objective risk perception and the actual risk (as identied
in the literature reviews21,22 and presented in the DAs) was calculated.∥ For patients whose treatment choice was ‘undecided’, the strength of the treatment preference was
scored as zero
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Statistical Analysis
To examine selective attrition, the characteristics of randomised patients were com-
pared with inadvertently non-randomised patients, using independent samples
t-tests or Chi-Square tests. e safety and ecacy of the DAs were evaluated by
comparing the intervention group with the control group on an intention-to-treat
basis. In all analyses, scale values were calculated only if at least half of the items
were available, by imputing the mean of the available items. Nominal variables
were analysed using Chi-Square tests. Interval variables that were available for a
single follow-up measurement were analysed using independent samples t-tests,
Chi-Square tests or Fisher Exact Tests or, if a baseline measurement was available,
analysis of covariance (ANCOVA). Interval variables that were available for both
follow-upmeasurements were analysed using linear mixed models. In these models,
dependent variables were the two follow-up measurements (T2 and T3), and covari-
ates were the variables ‘group’, ‘time’, an interaction term between ‘group’ and ‘time’
and if available, ‘baseline measurement’. e covariates ‘group*time’, ‘time’, and
‘baseline measurement’ were stepwise removed from the model based on statistical
signicance. To accommodate the repeated measures we used a heterogeneous
compound symmetry error structure.
Results
Patients
Between February 2008 and April 2012, 441 patients were assessed for potential
eligibility (see Figure 7.2). Of these 441 patients, 55 (12%) did not meet the in-
clusion criteria, 31 (7%) were excluded, and 34 (8%) were not approached by the
oncologist and therefore the inclusion criteria could not be veried. Of the 321
patients approached to participate in this study, 263 (82%) gave informed consent.
From this group, 92 patients (35%) were not faced with the decision on second-line
chemotherapy and therefore did not belong to the target population of this study.
Another 43 patients (16%) faced the treatment decision but were not randomised
and dropped out of the study. e 128 randomised patients were similar to the
43 non-randomised patients at baseline with regard to gender (37 vs. 41% male;
p = 0.663), age (mean 62 vs. 59; p = 0.320), education (college education 25 vs.
25%; p = 0.959), information preferences (mean scores 8.5 vs. 8.3; p = 0.594), and
general health (mean scores 6.7 vs. 6.7; p = 0.884). Non-randomised patients
seemed more likely to have breast cancer, compared with randomised patients (43
vs. 27%; p = 0.060).
Of the 128 patients who experienced disease progression and were randomised, 45
were assigned to the control group, and 83 were assigned to the intervention group.
Table 7.2 shows the characteristics of the randomised patients.e two groups were
similar in baseline characteristics.
Consultation with oncologist during rst-line chemotherapy
Assessed for eligibility (n = 441)
Included in the study and monitored for disease progression
(n = 263)
Consultation with oncologist about second-line chemotherapy
Randomised (n = 128)
Excluded (n = 120)
• Did not meet inclusion criteria (n = 55)
• Labile personality structure (n = 12)
• Karnofsky score lower than 60 (n = 14)
• Insucient Dutch language prociency (n = 5)
• Other reasons (e.g. patient not asked in time) (n = 34)
• Declined to participate (n = 58)
Excluded (n = 135)
• Not faced with the decision on second-line
chemotherapy (n = 92)
– No disease progression within the follow-up of the
study (n = 40)
– Bad medical condition or died (n = 47)
– Already decided not to want any further
chemotherapy (n = 5)
• Not randomised (n = 43)
– Missed at disease progression (n = 35)
– Refused further participation in study (n = 6)
– Other reasons (e.g. went to another hospital) (n = 2)
Recruitment of patients who started rst-line palliative chemotherapy
Allocated to the intervention group (n = 83)
• Received the decision aid (n = 77)
Received information on:
– Adverse events (n = 74)
– Tumour response (n = 70)
– Survival (n = 57)
• Did not receive the decision aid (n = 6)
– No time before start of chemotherapy
(n = 2)
– Refusal patient (n = 4)
Lost to follow-up (n = 9)
Completed questionnaire 2 (n = 68)
Lost to follow-up (n = 10)
Completed questionnaire 3 (n = 58)
Allocated to the control group (n = 45)
Lost to follow-up (n = 5)
Completed questionnaire 2 (n = 40)
Lost to follow-up (n = 7)
Completed questionnaire 3 (n = 33)
Figure 7.2: Patient ow chart
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Table 7.2: Patient characteristics
Intervention group
(n = 83) Control group(n = 45)
Male gender, n (%) 31 (37%) 16 (36%)
Age, median (range) 62 (32–80) 64 (44–81)
Living with partner, n (%) 64 (77%) 37 (82%)
Employed, n (%) 25 (30%) 13 (29%)
Having children, n (%) 74 (89%) 38 (84%)
Having grandchildren, n (%) 44 (53%) 26 (58%)
College education or more, n (%) 24 (29%) 7 (16%)
Tumour characteristics
Colorectal cancer, n (%) 61 (73%) 32 (71%)
Breast cancer, n (%) 22 (27%) 13 (29%)
Intervention interview with the nurse using the DA
In the intervention group, 77 patients (93%) completed the intervention interview
with the nurse using the DA.e majority of patients chose to receive information
on adverse events (96%), tumour response (91%) and survival (74%) from the DA.
Nurses felt that 90% of the interviews went (very) well.
Outcomes
Table 7.3 provides a comparison of outcomes for the main outcomes measures and
additional outcomes measured at both follow-up moments (T2 and T3), analysed
using linear mixed models.e variable ‘group’ was retained in all models to assess
the eect of theDA. Table 7.4 provides a comparison of additional outcomes between
groups at a single follow-up moment (T2 or T3).
Main outcome measures
Receiving the DA was not related to any of the measures for well-being, including
the primary outcome anxiety (Table 7.3). In both groups, average anxiety scores
were approximately 6 on a 0–21 scale, and the dierence between the groups was
-0.1 (95% CI -1.1;0.9).
Additional outcome measures
Coping ere were no dierences between the groups regarding helplessness/
hopelessness, ghting spirit, avoidance, and perceived participation (Table 7.3) and
perceived involvement (Table 7.4).
Information-related measures No dierences were found between the groups
over time for the amount of information received and satisfaction with the quality
of the information (Table 7.3). Patients in both groups answered similarly on ques-
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Table 7.3: Comparison of outcomes over multiple time points (T2 and T3)
Linear mixed models
Measure (answer scale)*
Intervention
group†
Mean (SD)
Control
group†
Mean (SD)
Covariates
in model
Difference be-
tween groups‡
(95% CI)
Two-
sided
p value
WELL-BEING
General health (0–10) T1 6.5 ( 1.6) 7.1 ( 1.7) Group -0.2 ( -0.8; 0.5) 0.615
T2 5.7 ( 1.8) 6.1 ( 1.9) Baseline
T3 5.8 ( 2.0) 5.9 ( 1.7)
Anxiety (0–21 ) T1 5.7 ( 4.0) 5.6 ( 4.0) Group -0.1 ( -1.1; 0.9) 0.808
T2 6.6 ( 4.5) 6.1 ( 4.5) Baseline
T3 5.5 ( 4.1) 5.9 ( 4.6) Time
Depression (0–21) T1 5.1 ( 3.6) 4.1 ( 3.0) Group -0.7 ( -1.7; 0.3) 0.142
T2 5.6 ( 4.2) 5.6 ( 4.2) Baseline
T3 5.3 ( 3.6) 5.2 ( 3.5)
Cancer worries (1–4) T1 2.1 ( 0.6) 2.0 ( 0.6) Group -0.1 ( -0.3; 0.1) 0.192
T2 2.1 ( 0.5) 2.1 ( 0.6) Baseline
T3 2.1 ( 0.6) 2.2 ( 0.7)
HRQoL: physical functioning (0–100) T1 75.2 (22.3) 79.2 (18.1) Group -2.2 ( -9.2; 4.8) 0.536
T2 68.2 (22.5) 72.3 (21.0) Baseline
T3 67.9 (25.0) 71.1 (22.1)
HRQoL: emotional functioning (0–100) T1 81.0 (22.0) 80.5 (20.2) Group 3.5 ( -3.4;10.5) 0.318
T2 74.3 (22.0) 73.6 (27.1) Baseline
T3 79.7 (20.2) 75.5 (25.2)
HRQoL: fatigue (0–100) T1 36.8 (25.0) 31.3 (24.6) Group -2.6 (-10.9; 5.6) 0.526
T2 42.0 (24.7) 42.8 (28.3) Baseline
T3 41.6 (25.9) 43.1 (25.4)
HRQoL: nausea (0–100) T1 9.8 (17.2) 11.4 (23.0) Group -2.8 (-12.6; 7.0) 0.574
T2 20.4 (27.7) 22.5 (31.9) Baseline
T3 18.7 (29.5) 23.7 (30.3)
HRQoL: pain (0–100) T1 22.6 (26.1) 17.4 (25.9) Group -2.4 (-11.1; 6.2) 0.577
T2 30.4 (28.1) 27.5 (32.4) Baseline
T3 22.9 (28.9) 25.3 (23.2)
HRQoL: dyspnoea (0–100) T1 15.4 (22.3) 14.4 (25.3) Group 0.8 ( -6.2; 7.8) 0.842
T2 20.1 (25.8) 20.8 (25.8) Baseline
T3 20.7 (27.8) 20.2 (27.6)
HRQoL: insomnia (0–100) T1 22.8 (27.7) 22.7 (27.6) Group -1.2 (-10.9; 8.5) 0.810
T2 31.3 (31.2) 29.2 (33.9) Baseline
T3 25.9 (28.6) 30.3 (30.5)
HRQoL: loss of appetite (0–100) T1 17.1 (28.3) 17.4 (25.4) Group -1.2 (-12.0; 9.6) 0.826
T2 35.3 (33.5) 35.0 (35.4) Baseline
T3 31.0 (35.2) 37.4 (33.1)
HRQoL: constipation (0–100) T1 13.0 (25.0) 9.1 (18.1) Group -1.7 (-10.5; 7.1) 0.698
T2 13.2 (25.2) 16.7 (27.2) Baseline
T3 19.0 (26.6) 15.2 (22.2)
COPING
Helplessness/Hopelessness (1–4) T1 1.8 (0.6) 1.7 (0.5) Group 0.0 ( -0.1; 0.2) 0.759
T2 1.8 (0.6) 1.8 (0.5) Baseline
T3 1.9 (0.6) 1.8 (0.5)
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Table 7.3: (continued)
Linear mixed models
Measure (answer scale)*
Intervention
group†
Mean (SD)
Control
group†
Mean (SD)
Covariates
in model
Difference be-
tween groups‡
(95% CI)
Two-
sided
p value
Fighting Spirit (1–4) T1 2.9 (0.6) 3.2 (0.6) Group -0.0 ( -0.2; 0.1) 0.568
T2 2.7 (0.6) 3.0 (0.6) Baseline
T3 2.8 (0.7) 2.8 (0.7)
Avoidance (1–4) T1 2.5 (0.7) 2.6 (0.8) Group 0.1 ( -0.0; 0.3) 0.094
T2 2.5 (0.7) 2.6 (0.7) Baseline
T3 2.5 (0.7) 2.3 (0.7)
Perceived participation (1–5) T2 3.1 (1.0) 2.8 (0.9) Group 0.2 ( -0.2; 0.5) 0.395
T3 2.9 (1.0) 2.9 (0.8)
INFORMATION
Amount of information received (1–7) T1 3.8 (0.6) 3.9 (0.3) Group -0.1 ( -0.3; 0.0) 0.157
T2 3.8 (0.7) 4.0 (0.4) Baseline
T3 3.8 (0.5) 3.9 (0.3)
Satisfaction with quality of information (1–6)
Severe adverse events T2 4.8 (0.9) 4.8 (1.0) Group 0.0 ( -0.3; 0.4) 0.802
T3 4.5 (1.2) 4.4 (1.1) Time
Tumour response T2 4.5 (1.0) 4.4 (1.2) Group 0.1 ( -0.2; 0.5) 0.536
T3 4.3 (1.1) 4.2 (1.1)
Survival T2 4.0 (1.3) 4.0 (1.3) Group 0.1 ( -0.3; 0.6) 0.540
T3 4.0 (1.2) 3.6 (1.4)
DECISION
Decision satisfaction-uncertainty (1–5) T2 4.1 (0.6) 4.0 (0.7) Group 0.1 ( -0.1; 0.3) 0.155
T3 4.1 (0.6) 3.9 (0.4)
Decision control (1–5) T2 4.2 (0.7) 4.3 (0.6) Group -0.1 ( -0.3; 0.2) 0.617
T3 4.3 (0.6) 4.3 (0.6)
Weighing pros and cons (1–5) T2 4.2 (0.8) 3.9 (1.0) Group 0.2 ( -0.1; 0.5) 0.118
T3 4.0 (1.1) 3.8 (0.8)
TREATMENT ATTITUDES TOWARD BOTH OPTIONS
Valuations: chemotherapy + BSC (1–10) T2 7.5 (1.7) 7.2 (1.6) Group 0.1 ( -0.5; 0.7) 0.677
T3 7.1 (1.8) 7.3 (1.7)
Valuations: BSC alone (1–10) T2 3.7 (2.1) 4.3 (2.1) Group -0.4 ( -1.2; 0.3) 0.246
T3 4.1 (2.3) 4.6 (2.4)
KNOWLEDGE
Subjective knowledge§ T1 6.5 (1.2) 6.6 (1.0) Group 0.5 ( 0.1; 0.9) 0.022
T2 6.7 (1.2) 6.3 (1.3) Baseline
Abbreviations — SD: standard deviation, CI: condence interval, BSC: best supportive care
* More information on the scales can be found in Table 7.1.
† Intervention group: T1 n = 82, T2 n = 68, T3 n = 58 — Control group: T1 n = 44, T2 n = 40, T3
n = 33.
‡ Dierence between intervention and control group averaged over T2 and T3, adjusted for T1. Positive
numbers represent higher scores in the intervention group.
§ Analyzed using ANCOVA; dierence between intervention and control group at T2, adjusted for T1.
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Table 7.4: Comparison of outcomes at a single time point (T2 or T3)
Measure (answer scale)*
Intervention
group
N (%) or
mean (SD)
Control
group
N (%) or
mean (SD) p value
MEASUREMENTS AT T2 n = 68 n = 40
Coping: Involvement
Perceived involvement: perception of being offered a choice
(yes/no)†
45 (66%) 26 (67%) 0.959
Perceived involvement: perception whether patient’s opinion
mattered (yes/no)†
51 (75%) 30 (77%) 0.823
Information-related measures
Undesired information (yes/no) 6 (10%) 7 (18%) 0.244
Balanced presentation of information (1–5) 2.7 (0.7) 2.4 (1.1) 0.201
Evaluation of information on treatment options: unpleasant
(1–5)
2.1 (1.0) 2.2 (1.2) 0.679
Evaluation of information on treatment options: shocking (1–5) 2.3 (1.0) 2.3 (1.0) 0.958
Evaluation of information on treatment options: frightening
(1–5)
2.4 (0.9) 2.2 (1.0) 0.347
Evaluation of information on severe adverse events: threatening
(1–5)
2.5 (1.0) 2.7 (1.1) 0.358
Evaluation of information on tumour response: threatening
(1–5)
2.7 (1.1) 2.7 (1.0) 0.786
Evaluation of information on survival: threatening (1–5) 3.0 (1.3) 2.6 (1.3) 0.112
Knowledge
Objective knowledge (1–5) 3.4 (1.3) 3.5 (1.3) 0.684
Subjective risk perception: severe adverse events (1–5) 2.2 (0.7) 2.0 (0.8) 0.242
Subjective risk perception: tumour response (1–7) 1.8 (1.1) 2.1 (1.1) 0.219
Subjective risk perception: pain (1–7) 3.0 (1.2) 3.2 (1.3) 0.461
Objective risk perception: diarrhoea (0–100%)‡ 30.9 (22.1) 34.9 (22.1) 0.366
Objective risk perception: tumour response (0–100%)‡ 30.0 (20.8) 32.5 (14.3) 0.463
Decision-related measures
Treatment choice: undecided (vs. decided) 1 (2%) 4 (10%) 0.068
Treatment choice: chemotherapy (vs. no chemotherapy) 63 (96%) 31 (84%) 0.067
Strength of treatment preference (1–5) 3.0 (1.0) 2.5 (1.2) 0.030
MEASUREMENTS AT T3 n = 58 n = 33
Coping: Involvement
Perceived involvement: perception of being offered a choice
(yes/no)†
41 (71%) 20 (61%) 0.299
Perceived involvement: perception whether patient’s opinion
mattered (yes/no)†
47 (81%) 25 (76%) 0.525
Decision-related measures
Treatment received: chemotherapy and BSC (vs. BSC alone) 50 (88%) 26 (84%) 0.746
Treatment attitudes toward the treatment received
Treatment satisfaction: received treatment (1–6) 4.6 (1.3) 4.6 (1.0) 0.794
Treatment satisfaction: physical consequences of treatment (1–6) 3.8 (1.5) 3.5 (1.3) 0.372
Treatment satisfaction: emotional consequences of treatment
(1–6)
4.0 (1.4) 3.9 (1.3) 0.725
Abbreviations — SD: standard deviation, BSC: best supportive care
* More information on the scales can be found in Table 7.1
† Measured at T2 and T3
‡ Objective risk perception represents the absolute deviance between patient’s risk perception and
actual risk as presented in the DA, based on literature reviews21,22
129
D
iscussion
tions about undesired information, balanced presentation, and evaluation of the
information (Table 7.4).
Knowledge Subjective knowledge was signicantly higher in patients in the in-
tervention group (6.7 vs. 6.3; p = 0.022). Objective knowledge and subjective and
objective risk perceptions were similar between the groups (Table 7.4).
Decision-related measures e two groups did not score dierently on decision
satisfaction and uncertainty, decision control, and weighing of pros and cons
(Table 7.3). At T2, patients in the intervention group seemed more likely to have
formed a treatment preference (98% vs. 90%; p = 0.068), and more oen favoured
chemotherapy (96% vs. 84%; p = 0.067). In addition, a stronger treatment prefer-
ence was observed in the intervention group (3.0 vs. 2.5; p = 0.030). At T3, there
were no dierences in treatment received between the groups (Table 7.4).
Treatment attitudes Valuations of both treatment options were comparable be-
tween the groups (Table 7.3). In both groups, treatment with chemotherapy was on
average valued with a 7 while treatment with BSC alone was valued with a 4 (on a
scale of 1–10). Satisfaction with treatment received and the physical and emotional
consequences was similar between the groups (Table 7.4).
Discussion
When deciding about second-line palliative chemotherapy, patients and health
professionals have to weigh the uncertain benets of treatment against potential
toxicity. is study showed that DAs with outcome information could safely be
oered to patients with advanced cancer considering second-line treatment, which
was supported by favourable evaluations of the interviews by nurses. e safety
of DAs has previously been demonstrated in diverse healthcare settings.5 How-
ever, concerns had been raised about the safety of DAs for palliative treatment
decisions.2,15,16,18 e one randomised study of a DA on rst-line chemotherapy
and two pilot studies showed that the use of a DA did not increase anxiety or dis-
tress, or take away hope.6,14,33 e current study consistently showed that the use of
DAs did not increase anxiety, cancer worries or hopelessness in patients deciding
about second-line treatment, and in addition, the use of DAs did not result in more
patients receiving undesired information, or reporting negative experiences with
the information received.
With regard to ecacy, patients in the intervention group were found to have higher
subjective knowledge and stronger treatment preferences — the latter also seems
to be reected in fewer patients being undecided. ese are important benets,
nevertheless, other benets regarding objective knowledge, risk perception, and
involvement in decision-making, reported in reviews34–36 and earlier studies from
our group23,24 were anticipated but not found. One explanation could be that not
all patients received full information from the DAs, since the nurse followed the
patient’s desire. However, it would be undesirable to force unwanted information
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on patients. Another explanation could be that the DAs were oered by 20 dierent
nurses and aer the consultation with the oncologist; timing was tailored to local
workows and DAs may have been oered relatively late in the decision-making
process. Yet another explanation may relate to the population of patients with
advanced cancer. All patients in this study had experience with chemotherapy,
possibly reducing the added value of the DAs. Furthermore, patients may not have
perceived the option to refrain from active treatment as a realistic option.37 is
was exemplied by the very low valuations for best supportive care alone, and one
patient who opted for chemotherapy wrote down ‘I do not have a choice’ on the rst
follow-up questionnaire. It is known that an important reason to opt for second-
line chemotherapy is to maintain hope and believe in positive outcomes.17,38,39 In
our interpretation, a similar relative absence of eects was reported in the single
randomised study evaluating a DA on rst-line palliative chemotherapy; a positive
eect was reported on objective knowledge but only at T3, and no positive eects
were found on decisional conict or satisfaction, or achievement of involvement
preferences.14
Future studies might explore patients’ perceptions of palliative treatment choices,
including ways to make patients aware that best supportive care without chemother-
apy is a realistic treatment option. Studies might aim to close the decision support
loop by scheduling a consultation with the oncologist aer the DA is oered, to
allow patients time to think and an opportunity to discuss the treatment decision
with their oncologist. e development of DAs could be made more ecient by
developing (and updating) DAs alongside clinical practice guidelines because both
draw on the same evidence base.40 Developers of future DAs should also consider
the most recent evidence on the presentation of risk information, for example on
visual formats41 and the presentation of three survival scenarios (best case, worst
case, and typical survival) instead of median survival.42 If more denitive evidence
is obtained about the benecial eects of DAs for palliative treatment decisions,
attention should be devoted to identify factors inuencing the implementation
in daily practice. So far, implementation of DAs has been limited,43 and several
barriers and facilitators have been identied.44
One of the strengths of this study is that we performed one of the few randomised
evaluations of a DA for patients with advanced cancer, and the rst for second-line
treatment options. A further strength is that we facilitated generalisability of the
results by recruiting patients from a large number of hospitals, by recruiting patients
receiving rst-line chemotherapy or in remission aer rst-line chemotherapy
while applying few exclusion criteria, and by instructing health professionals not
to tell patients beforehand that detailed risk information would be oered. A
satisfactory informed consent rate of 82% was achieved.orough attention was
paid to including evidence-based information in the DAs, by performing systematic
reviews which were subjected to peer-review.21,22
Noteworthy limitations include multiple testing and statistical power. A total of 52
comparisons between the intervention and control group were performed, of which
two (4%) reached statistical signicance at the level p < 0.05.ese two ndings
need to be interpretedwith caution.e lack of statistically signicant resultsmay be
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related to statistical power. However, none of the remaining dierences between the
groups appears large enough to be clinically relevant. Another limitation inherent
to the nature of DAs is that complete blinding was not possible. Nevertheless,
oncologists were not aware of the allocation prior to randomisation and our analysis
showed no dierences between randomised and non-randomised patients.
In conclusion, decision aids on second-line palliative chemotherapy could be oered
to patients with advanced cancer by a nurse in a safe and acceptable way. ese
decision support tools can help to provide standardised information about benets
and risks of palliative chemotherapy, which was desired by the majority of patients
and was found to slightly improve the quality of both the decision process and the
resulting choice. However, other previously reported benecial eects, including
improvements in objective knowledge, risk perception and involvement in decision-
making, were not conrmed for the decision aids in this study. Future studies might
clarify whether this relative absence of eects is common in the palliative treatment
setting.
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Abstract
Background Decision aids (DAs) eectively support patient decision making,
but are rarely used in daily practice.
Objective To explore nurses’ and oncologists’ views on routinely oering DAs
on palliative chemotherapy to patient by nurses. Most interviewees had clinical
experience with the DAs, which were booklets administered to patients by nurses.
Methods e study was guided by 3 theoretical implementation models of innov-
ations in clinical practice, including factors related to the innovation, the profes-
sionals (nurses and oncologists), the patient, and the organization. Semistructured
interviews were conducted among 12 nurses and 14 oncologists. Interviews were
audio taped and fully transcribed.
Results e main barriers to routinely oering DAs to patients were found in
nurses’ and oncologists’ opinions and attitudes (eg, concerns about the impact in
this vulnerable population) and in the logistics of organizations (eg, the decision
is already made before the nurse sees the patient). Twenty-two of 26 interviewees
were open to the future use of the DAs. Disseminating information to professionals
(eg, about positive eects of DAs) and embedding DAs in the existing workow
would facilitate implementation.
Conclusions Most nurses and oncologists were open to the future use of the
DAs by nurses, provided that certain barriers, particularly related to professionals’
opinions and attitudes and logistical procedures in the organization, could be
overcome.
Implications for practice ese ndings can inform a tailored strategy to imple-
ment DAs on palliative chemotherapy. Implementation should start with interven-
tions to motivate professionals, for example, educational meetings.
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Introduction
Introduction
Over the last decades, there has been a growing awareness of the importance of
determining patients’ preferences, especially for treatment decisions where no best
treatment option exists and a trade-o between benets and risks has to be made.1–3
For these kinds of decisions, the model of shared decision-making (SDM) can be
helpful. is model denes that at least 2 participants —health professional and
patient— are involved, and that information is shared, treatment preferences are
expressed, and consensus is reached on the preferred treatment.4 e goal of SDM
is improving the quality of care by ensuring that medical decisions are aligned with
patients’ preferences.
e exchange of information on treatment options and the potential risks and
benets of each option can be facilitated by decision aids (DAs). Decision aids
are used to complement the information from the health professional and are
proven to be eective at stimulating patients to take a more active role in decision
making,5,6 lowering decisional conict,5,7 decreasing the proportion of people
remaining undecided,5 and improving patients’ knowledge regarding treatment
options.5,7
In oncological practice, despite the available evidence of benecial eects, treatment
decisions are not routinely supported by DAs.5,8,9 Limiting factors include the avail-
ability of DAs, particularly for treatment decisions in the palliative phase,2,10 and
the low degree of implementation of DAs in daily practice.11 e few reported imple-
mentation studies in the eld of oncology include a survey from the United States12
and 4 qualitative studies from the United States13–15 and the United Kingdom,16
all related to curative treatment decisions and focusing on stand-alone video or
DVD-based DAs.
In a previous study, DAs in the form of booklets were developed to support the de-
cision whether to start second-line chemotherapy for advanced breast or colorectal
cancer.17 ese DAs were to be oered to patients by nurses, who usually spend
more time with patients than physicians and who may already be highly involved
in supporting treatment decisions.18,19 However, even experienced nurses would
not always have complete knowledge of all aspects of treatment options,18 and DAs
can support them by providing an overview of the most important benets and
risks, including numerical estimates.
Nurses and medical oncologists in 19 hospitals have gained experience with these
DAs in a clinical trial (NTR1113).e aim and research questions of this trial are
presented in Figure 8.1. Alongside the trial, insight into the factors inuencing the
implementation of these DAs for palliative treatment decisions in daily clinical prac-
tice is needed.is qualitative study used interviews with nurses and oncologists to
address the following research question: “What are nurses’ and oncologists’ views
on routinely oering DAs for second-line palliative chemotherapy to patients, and
what are their views on the DAs being administered by nurses?”
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is qualitative study was added to a clinical trial exploring the feasibility
of shared decision-making for treatment decisions in the palliative phase of
cancer. Research questions addressed in the trial pertained to (1) patients’
desire to receive treatment-related information; (2) the possibility to predict
this desire based on patient characteristics or the oncologist’s judgment; and
(3) the eect of the information on patients’ well-being and the quality of the
decision process and the resulting choice.e qualitative study as described
in this article was undertaken to inform the potential implementation of
the decision aids in daily practice.
Figure 8.1: Overview of the accompanying clinical trial
Methods
Study Design
In this qualitative study, interviews were conducted among nurses and medical
oncologists in the Netherlands to explore their views regarding routinely oering
the DAs to patients by nurses. e study was guided by 3 theoretical models on
implementation of innovations in clinical practice.20–22 On the basis of thesemodels,
we dened 5 domains related to the implementation of the DAs: “the decision aids”
(the innovations to be implemented), “the nurse” (who oers the DAs to patients),
“the oncologist” (responsible for managing the patient’s care), “the patient” (as a
recipient of the DAs), and “the organization” (in which the DAs are used). e
semi-structured interview guide was developed to represent these 5 domains, with
questions including the dierent steps in the use of the DAs from a perspective
of daily clinical practice and the intended future use of the DAs and inuencing
factors.e 4 interview parts and illustrative questions for every part are shown
in Figure 8.2. e guide was exible, combining a pre-determined set of open
questions with the opportunity to bring up new questions.
Setting
In the accompanying trial,17 we evaluated DAs for 11 dierent chemotherapeutic
drugs commonly used for second-line treatment of patients with advanced breast or
colorectal cancer.23,24 Oncologists provided the usual treatment-related information.
Patients received the DA in a subsequent consultation with a nurse. e nurse
oered patients step-by-step information on adverse events, tumour response, and
survival, asking patients whether each information item was desired.e desired
information was presented on laminated cards, showing the risk information in
numbers and in a pie chart to visualize risk.25 Patients were given a brochure with
the desired information to take home.
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Interview parts Illustrative questions
1 Introductory questions How much experience do you have in working with cancer
patients?
2 Use of the decision aids
2.1 Identication of eligible patients How would this work out in your hospital?
What is your experience with this step?
What do you expect from this?
What goes well and what can be improved?
2.2 Presentation of the DAs by nurses How would this work out in your hospital?
What is your experience with this step?
What do you expect from this?
What goes well and what can be improved?
2.3 Reaction of patients to the DAs How would this work out in your hospital?
What is your experience with this step?
What do you expect from this?
What goes well and what can be improved?
3 Future use Would you use/keep using this decision aid in the future?
Which factors did you weigh in arriving at this decision?
What is needed for you to start/keep using the decision aids?
What changes would you like to be made to the decision aids?
4 Other Do you have any other opinions or experiences that we did not
talk about yet?
Figure 8.2: Interview parts and illustrative questions
Interviews
Figure 8.3 shows the selection of nurses and oncologists from both hospitals that
participated in the trial (high and low patient enrolment) and hospitals that declined
participation.e 33 selected professionals were sent an information letter and a
copy of a DA and were then contacted over the phone. A researcher conducted
the interviews at the hospitals between May and September 2011.e researcher
had received training including a pilot interview. Interviews were expected to last
about 30 minutes and were tape recorded.e interviewer continued to perform
interviews until saturation was reached, that is, until no new factors inuencing
implementation were emerging from subsequent interviews.
Data Analysis
All interviews were fully transcribed and imported in Atlas.ti, which is a soware
program to support the systematic analysis of qualitative data, for example, by
providing tools to code phrases, modify and group codes, perform queries on
coded data, and display relations between phrases or codes. Phrases in which
potential barriers or facilitators were described were selected and labeled using
open coding.ese codes were then combined and redened in an iterative process
(axial hierarchical coding). Many of the factors mentioned by professionals were
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Hospitals approached for participation in the trial
(n = 36)
Hospitals participating in the trial
evaluating the DAs (n = 19) Hospitals declining participation in the trialevaluating the DAs (n = 17)
Selection of 5 hospitals
with high patient
enrolment in the triala
Selection of 9 hospitals
with low patient
enrolment in the triala
Selection of 5 hospitalsa
Per hospital: selection
of the nurse and
oncologist who had
been the contact
persons for the trial
(n = 10; 5 nurses
and 5 oncologists)
Per hospital: selection
of the nurse and
oncologist who had
been the contact
persons for the trial
(n = 18; 9 nurses
and 9 oncologists)
Per hospital: selection
of the oncologist
who had declined
trial participation
(n = 5; 5 oncologists)b
Total number of health professionals invited
(n = 33; 14 nurses and 19 oncologists)
Figure 8.3: Selection of participants
aSelection was aimed at including professionals from hospitals from dierent regions in the
Netherlands and both university and community hospitals
bDecisions on trial participationwere taken by oncologists; therefore, this sample did not comprise
nurses
bidirectional and could be either classied as barrier or facilitator, depending on
the emphasis given. For example, multiple professionals stated that “DAs are most
opportune when oncologists actually oer patients a treatment choice, but this
is not always daily practice.” To obtain the fullest possible overview of potential
barriers, and unambiguously convey the way in which a factor would inuence
implementation, labels were worded negatively, describing bidirectional factors as
barriers. For instance, the previously mentioned factor was labeled as the potential
barrier “the oncologist does not oer patients a choice whether or not to have
chemotherapy.”
e rst author performed the analysis and three coauthors each veried a third of
the coded interviews.ereaer, the rst author met with each of the 3 coauthors
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Findings
Table 8.1: Participant characteristics
Variable Nurses Oncologists
PARTICIPATION
Invited, n 14 19
Agreed, n (%) 14 (100) 15 (79)
Interviewed, n (%) 12 ( 86) 14 (74)
PARTICIPANTS (n = 26)
Age, mean (range), y 41 (30–47) 49 (39–62)
Gender, n (%)
Female 11 ( 92) 9 (64)
Male 1 ( 8) 5 (36)
Type of practice, n (%)
University 1 ( 8) 2 (14)
Community 11 ( 92) 12 (86)
Duration of the interview, mean (range), min 31 (23–46) 28 (11–42)
in person to discuss the coding and resolve disagreement by discussion. Final
codes were determined in a consensus meeting with all authors involved in the
coding process. Quotations were selected to illustrate the most important factors.
A qualitative comparison was made between the views of nurses and oncologists.
Findings
Participants
All 14 invited nurses, who all participated in the accompanying trial in which
the DAs were used, agreed to be interviewed. Only 12 interviews were conducted
because data saturationwas reached. Eleven of 12 nurses were specialized inworking
with cancer patients; the other nurse had a more general role as a patient educator.
A total of 19 oncologists from 19 hospitals were invited. Of the 14 who participated
in the trial in which the DAs were used, 13 agreed to be interviewed; with one of
these oncologists an appointment could not be scheduled within the study period.
Of the 5 oncologists who had not participated in the trial, 2 agreed to be interviewed.
Data saturation was reached aer 14 interviews. Table 8.1 presents the participation
rate and characteristics of the participants.
Barriers
In the analysis, 356 phrases from nurses and 310 phrases from oncologists describing
a potential barrier were selected and labeled.ese phrases were combined into 69
potential barriers; 30 were mentioned by nurses and oncologists, 28 only by nurses,
and 11 only by oncologists. Table 8.2 presents all 69 potential barriers in 5 domains,
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with reference to the professional whomentioned the barrier. For purpose of brevity,
only barriers mentioned by at least half of the nurses (marked with a superscript a)
or half of the oncologists (marked with a superscript b) are elaborated. For these
barriers, a denition and illustrative quote from the interviews are presented in
Table 8.3.
In the domain of the DAs, 13 barriers were found regarding the content, format,
and eect of the DAs (Table 8.2). Most nurses and oncologists mentioned that the
DAs present numerical information that is group based and not always helpful for
patients (Table 8.3).
In the nurse domain, barriers were found regarding the knowledge and skills (n = 3)
and the opinions and attitudes (n = 11) of the nurse. Most nurses mentioned that
they need to gain practical experience with the DAs and that they have doubts about
the added value of the DAs for patients.
In the oncologist domain, professionals mentioned 2 barriers related to the know-
ledge and skills and 13 barriers related to the opinions and attitudes of the oncologist.
e majority of oncologists said that they want the liberty to tailor the information
to an individual patient, that they want to remain involved in the decision, that
the information in the DAs may have a negative impact, and that they have doubts
about the added value of the DAs for patients.
In the patient domain, professionals mentioned 5 barriers in patients’ knowledge
and skills and 9 barriers in patients’ opinions and attitudes. Most of the nurses
mentioned that many patients do not perceive having a choice, because active
treatment is desired.
With regard to the organization domain, barriers concerned resources (n = 2),
logistics (n = 8) and the social setting (n = 3).emajority of nurses and oncologists
mentioned that the nurse has insucient time to oer the DAs, that the patient
is already well informed by dierent sources, and that the treatment decision is
already made before the patient is seen by the nurse.
Future Use
Twenty-two out of 26 professionals (85%) were open to keep or start using the
DAs, provided that certain barriers would be overcome. Professionals stated that
the DAs can help to clearly explain the 2 options and the possible consequences,
visualize information, deepen the consultation, and support patients to make a
more deliberate decision.
Facilitators
e interviews yielded 212 phrases from nurses and 185 phrases from oncologists
describing a facilitator. Most facilitators were mentioned following the questions
on future use.
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Table 8.2: Potential barriers to the implementation of the DAs
Domain Mentioned by Barrier
1 “THE DECISION AIDS”
Content Both professions The DAs offer information on rare adverse events.
Both professions The DAs offer too explicit information on survival.
Both professions The DAs do not offer all relevant information.
Nurses The DAs offer more information than recommended by another study.
Nurses The DAs need to be updated regularly.
Format Both professions*,† The numerical information is group-based and not always helpful for patients.
Both professions The laminated cards with the information are difficult to use.
Oncologists The DAs present the disadvantages of chemotherapy first, followed by the advantages.
Nurses The DAs consist of a rigid structure for the nurse to follow.
Nurses The written information can be more confronting than the usual oral information.
Nurses The DAs consist of a large booklet with different versions.
Effect Oncologists The effect of the DAs is not apparent to the oncologist.
Nurses The effect of the DAs is not apparent to the nurse.
2 “THE NURSE”
Knowledge
and skills
Both professions The nurse lacks the skills to offer the DAs to patients.
Nurses* The nurse needs to gain practical experience with the use of DAs.
Nurses The nurse forgets to administer the DAs.
Opinions
and attitudes
Both professions The nurse believes the oncologist should support patients in decision making.
Both professions The nurse is not motivated to offer the DAs.
Nurses* The nurse has doubts about the added value of the DAs for patients.
Nurses The nurse finds it difficult to provide confronting information about prognosis.
Nurses The nurse wants the liberty to tailor the information to the individual patient.
Nurses The nurse believes the information in the DAs needs further explanation.
Nurses The nurse believes the information in the DAs may have a negative impact.
Nurses The nurse does not agree with the treatment choice in the DAs.
Nurses The nurse considers to use the DAs only for a subgroup of patients.
Nurses The nurse believes that not all patients have a need for the DAs.
Nurses The nurse believes it is difficult for patients to refrain from further chemotherapy.
3 “THE ONCOLOGIST”
Knowledge
and skills
Both professions The oncologist is insufficiently familiar with the DAs.
Nurses The oncologist forgets to refer patients to the nurse to receive the DAs.
Opinions
and attitudes
Both professions† The oncologist wants the liberty to tailor the information to the individual patient.
Both professions† The oncologist wants to remain involved in the decision.
Both professions The oncologist does not offer patients a choice whether to have chemotherapy.
Oncologists† The oncologist believes the information in the DAs may have a negative impact.
Oncologists† The oncologist has doubts about the added value of the DAs for patients.
Oncologists The oncologist believes the information in the DAs is too much and too explicit.
Oncologists The oncologist does not agree with the treatment choice in the DAs.
Oncologists The oncologist considers using the DAs only for a subgroup of patients.
Oncologists The oncologist believes that not all patients want the DAs.
Oncologists The oncologist believes that the DAs may lead to more questions from patients.
Oncologists The oncologist believes it is undesirable that many patients decline chemotherapy.
Nurses The oncologist does not approve of the DAs.
Nurses The oncologist does not offer the patient enough preparatory information on survival.
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Table 8.2: (continued)
Domain Mentioned by Barrier
4 “THE PATIENT”
Knowledge
and skills
Both professions The patient is not able to indicate the amount of information desired.
Both professions The patient can handle only a limited amount of information.
Both professions The patient cannot handle the numerical group-based information in the DAs.
Both professions For the patient, it is difficult to make a treatment choice.
Nurses The patient is not used to DAs and does not know what to expect.
Opinions
and attitudes
Both professions* The patient does not perceive a choice, as active treatment is desired.
Both professions The patient does not need the information in the DAs.
Both professions The patient has already made a treatment choice.
Both professions The patient wants to leave decision making to the oncologist.
Oncologists The patient wants to get all information during the initial consult with the oncologist.
Nurses The patient wants the nurse to give the information quickly and without fuss.
Nurses The patient is not willing to have an extra appointment in the hospital to receive a DA.
Nurses The patient finds the laminated cards of the DAs childish.
Nurses The patient can become emotionally distressed by the information in the DAs.
5 “THE ORGANIZATION”
Resources Both professions*,† The nurse has insufficient time to offer the DAs.
Both professions The professionals pay insufficient attention to the DAs due to competing activities.
Logistics Both professions*,† Patients are already well informed by different sources.
Both professions*,† The treatment decision is already made before the patient is seen by the nurse.
Both professions Eligible patients for the DAs need to be identified.
Both professions The information is usually given in stages.
Both professions The DAs need to be integrated into the routine consultation with the nurse.
Both professions There is little time to make a choice as treatment with chemotherapy will start soon.
Nurses When the DAs are given directly after the bad news, the patient can be too upset.
Nurses Patients are referred to multiple nurses who all need to be equipped to offer the DAs.
Social setting Both professions The team of oncologists and nurses needs to approve the use of the DAs.
Both professions There is a lack of communication between oncologist and nurse.
Nurses The information desire of the patient deviates from the desire of the family.
Abbreviations — DAs: decision aids
* mentioned by at least 50% of nurses
† mentioned by at least 50% of oncologists
In the DA domain, nurses suggested that the DAs could be made more user-friendly
(eg, more compact booklets or computer-based DAs). Professionals thought that
encouraging trial results would facilitate their use of the DAs.
In the nurse domain, oncologists told us that nurses could be supported by training
to increase their knowledge, skills, and self-ecacy. Nurses thought that positive
experiences or positive reactions from patients would promote their use of the DAs.
In the oncologist domain, nurses thought that the use of DAs would be facilitated
when oncologists would havemore knowledge about SDMandDAs.e oncologists
themselves reported that a positive experience with the DAs would promote use.
In the patient domain, oncologists expected patients to become more open to the
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Table 8.3: Barriers mentioned by the majority of professionals
Domain Barrier Definition and quote
1 “The decision aids” The numerical
information is
group based and
not always
helpful for
patients.
Professionals mentioned that numerical information at the group level is dif-
ficult to apply individually. Fundamental uncertainty remains (“will I get the
adverse effect or not”), questioning the value of risk information for the pa-
tient, who may require a different type of information.
“. . . and always be honest, you don’t know what it will be like for the indi-
vidual patient, these are but data at the group level, so you don’t know. [. . . ]
But you don’t know, it says nothing about the person in front of you, who
can think ‘well, I will probably be in the lucky group”’
— Oncologist 3, trial participant
2 “The nurse” The nurse needs
to gain practical
experience with
the use of DAs.
The nurses have to get used to offering this type of information, using the
laminated cards with information, incorporating this in their conversation.
“. . . You had to be shown once and find out for yourself how you should do
it. . . with the cards. . . and that was something to get used to in the beginning”
— Nurse 11
The nurse has
doubts about
the added value
of the DAs for
patients.
The nurses doubted whether the DAs would add additional information, make
patients feel better, or influence their treatment choice.
“. . . and I don’t know whether it would yield much more information to the
patients when it is visualized, compared with how we normally conduct an
informative consultation”
— Nurse 6
3 “The oncologist” The oncologist
wants the liberty
to tailor the
information to
the individual
patient.
The oncologists want to adapt the amount, content, wording, and timing of
the information to an individual patient’s characteristics, such as information
needs, emotional state, skills, and medical history.
“. . . at least I believe that I, as a specialist, can feel. . . well. . . to this patient I
should not give any more information now, it is enough. And with another
patient I can have the feeling that I should revert to a subject the next time,
to be discussed more extensively. And. . . it is not as clear-cut as ‘this patient
wants a lot of information, that one wants few information. . . ’ Sometimes
it depends on the moment”
— Oncologist 11, trial participant
The oncologist
wants to remain
involved in the
decision.
The oncologists consider it their job to give the relevant information to the
patient and to share the treatment decision with the patient.
“. . . in the end, the decision should be made by the doctor and the patient, so
one could imagine that this is something that, in fact, a doctor should offer”
— Oncologist 7, trial participant
The oncologist
believes the
information in
the DAs may
have a negative
impact.
According to the oncologists, the information in the DAs can be confronting
and may thwart hope or heighten anxiety or depression.
“Well, there are a number of people, who think that they want to know, but
if they hear it, actually see the numbers, they get really frightened”
— Oncologist 1, trial participant
The oncologist
has doubts
about the added
value of the DAs
for patients.
The oncologists doubted whether the DAs would add additional information,
improve patients’ well-being, or influence their treatment choice.
“The question is, to some extent, that if you take sufficient time and space
for the conversation, and let such a conversation be repeated or let it be
reiterated, or ask patients whether they have understood it correctly, by a
nurse or a case manager, then for me it is questionable, to some extent,
whether such a paper decision aid plays a role”
— Oncologist 13, trial participant
4 “The patient” The patient
does not
perceive a
choice, as active
treatment is
desired.
The nurses, and also some of the oncologists, told us that many patients want
to do something, desiring to have active treatment to extend their life.
“Then again, we see few people who say that they won’t do anything. Very
few people. The majority of people really want, yes, to proceed. Yes. And
then they will quit later on when the adverse events are too severe, but you
see few people who say in advance that they don’t want to do it, that they
quit, that it stops for them.”
— Nurse 11
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Table 8.3: (continued)
Domain Barrier Definition and quote
5 “The organization” The nurse has
insufficient
time to offer the
DAs.
The professionals reported that nurses have insufficient time to see all patients
or to offer the DAs to the patients within their usual time slot.
“. . . but you have to keep to your schedule, you have fixed schedules, so I say,
scheduled at an hour, and it is of course annoying if each time you use this
[the DA] you would run half an hour overtime”
— Nurse 6
Patients are
already well
informed by
different
sources.
Patients have already received a lot of information, verbally and in writing,
from the oncologists and nurses and they may also have sought information
themselves.
“. . . so that people have already received so much information about a certain
topic that they, yes. . . that it would be superfluous to offer the DA after that”
— Oncologist 13, trial participant
The treatment
decision is
already made
before the
patient is seen
by the nurse.
In practice, it is often the case that the patient, alone or together with the
oncologist, has already made a treatment decision before the nurse sees the
patient to offer the DA.
“. . . the difficulty is that often the oncologist communicates the bad news
and immediately comes with a proposal. And that is. . . ‘you should do some-
thing about that’. It is better to say. . . ‘well you have two choices and we can
inform you about that using. . . ’. He should offer something like that and
not immediately. . . well. . . discuss both options, without making the decision
right away. Because, let’s face it, that happens quickly.”
— Nurse 2
DAs once they get used to DAs in general. Nurses reported that patients’ opinions
may become more positive if patients nd the additional information useful and
appreciate the explicitness.
In the organization domain, nurses and oncologists emphasized the importance
of repeatedly disseminating information about the DAs (eg, in hospitals, in nurse
education, and on a Web site with oncological guidelines).e use of DAs would
also be facilitated by determining the optimal moment in time to oer the DAs,
improving the coordination of information provided by nurses and oncologists, and
allowing sucient time to make a treatment choice. Professionals also suggested
that the DAs could be better integrated into daily practice by adjusting the DAs to
match the format of current written information and by developing more DAs for
other palliative treatment decisions.
Comparing the Views of Nurses and Oncologists
In the domains of the nurse and the oncologist, participants mentioned barriers
and facilitators regarding their own profession and less frequently referred to the
other profession. Compared with oncologists, nurses mentioned more barriers
and facilitators in the domains of the DAs, the patients, and the organization.e
question on future use was answered comparably by nurses and oncologists.
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Discussion
In this qualitative study, factors inuencing the routine oer of 11 DAs on palliative
treatment decisions to patients by nurses were studied by interviewing 26 nurses and
oncologists who had gained prior experiencewith theDAs. Important barriers to the
future use of these DAs were found in professionals’ opinions and attitudes toward
the DAs and in the current logistical procedures of the organizations regarding
information giving and decision making. Important facilitators were found to be
dissemination of information and better integration of the DAs in the organization.
ere were no substantial dierences between the views of nurses and oncologists.
Nurses mentionedmore factors related to the DAs, patients and organization, which
seems reasonable because nurses worked with the DAs and were therefore more
familiar with the DAs, the reactions of patients, and the use within the organization.
e present study yielded several barriers and facilitators specic to these particular
DAs.e context of palliative treatment decisions raised particular barriers about
the impact of the information on this vulnerable patient group and about the
intricacy of the decision to refrain from further chemotherapy.ese barriers could
be overcome by providing professionals with educational materials regarding the
benets of DAs.e fact that the nurse oers the DAs raised issues regarding the
necessary extra appointment for the patient, nurses’ skills, and the distribution of
tasks and communication between nurses and oncologists. Interestingly, a study on
discussing “do not resuscitate” orders with patients at the end of life showed that
nurses, as compared with physicians, were more condent in their ability to discuss
the topic and expressed more positive attitudes, thereby raising questions about the
division of responsibilities between nurses and physicians.26
Facilitators would be training of nurses and organizing a meeting with nurses and
oncologists in each hospital to discuss the use of the DAs. In addition to these new
ndings, barriers and facilitators found in this study in the palliative treatment phase
correspond with the ndings of previous qualitative studies on curative treatment
decisions.13–16 Likewise, these studies reported that important barriers included
the lack of physician awareness and support of the DAs,13–16 and that key resources
included an informed sta14,15 and the incorporation of DAs into routine patient
ow.13–16
Strengths and Limitations
e most obvious strength is that this is the rst study to explore implementation of
DAs in the eld of palliative oncology. A further strength is that most participants
had previously gained experience with the DAs, enabling them to speak from
experience. While these professionals may have had a favorable attitude toward the
DAs, interviews with 2 oncologists who had declined trial participation did not yield
new insights. Most participants were already acquainted with the interviewer.is
pre-existing relationship may have evoked more candid responses, but it may also
have led to more socially acceptable answers.e generalizability of our ndings
to other countries needs further study. However, many of the identied factors
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are not specically related to the Dutch setting, and the correspondence between
our ndings and the ndings of studies from the United States13–15 and the United
Kingdom16 is encouraging. For future work, a valuable extension would be to
explore patients’ views on the implementation of the DAs.
Conclusions and Practice Implications
is study added knowledge on barriers and facilitators inuencing the routine
oer of DAs to patients by nurses in the eld of palliative oncology. Most nurses and
oncologists were open to the future use of the DAs, provided that certain barriers
could be overcome, in particular barriers related to the opinions and attitudes of
professionals and to the logistical procedures in the organizations.
e ndings from this study can be used to develop a tailored implementation
strategy to bring the benets of these DAs to patients with advanced cancer.e
overall intended benet of implementing SDM in the palliative treatment phase
is that treatment decisions, including decisions where one of the options implies
refraining from active treatment, are aligned with patients’ preferences. Decision
aids can play a role to inform patients about treatment goals, options, and benets
and risks of each alternative.
When starting to implement the DAs, changing the opinions and attitudes of both
nurses and oncologists is a necessary precondition to enable changes in the logistics
of organizations. Interventions that can be used to motivate professionals include
the education of professionals, for example, by organizing educational meetings
to improve knowledge in combination with workshops to develop SDM skills.27,28
Furthermore, the education of future professionals could be targeted to ensure that
nurses and oncologists become accustomed to using DAs. Professionals can be
engaged in planning the implementation in their hospital, for example, by involving
them in discussing the distribution of tasks between nurses and oncologists, and
dening the optimal moment in time —before the decision is made— to deliver
the DAs. e DAs can be made available through a Web site with information
about the use and eects of the DAs (eg, an online tutorial and a forum to share
experiences). Another way of motivating professionals would be to create a demand
among patients, by informing patients about the availability and benets of the
DAs.
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Introduction
e main objective of the research project described in this thesis was to study the
necessity and feasibility of introducing shared decision-making (SDM) and decision
aids (DAs) in the eld of advanced cancer, thereby focusing on the treatment de-
cision whether or not to add second-line palliative chemotherapy to best supportive
care (BSC). Research questions 1 and 2 were related to gathering evidence about the
benets and risks of second-line chemotherapy for advanced colorectal (Chapter 3)
and breast cancer (Chapter 4). Questions 3 and 4 pertained to the wish of patients
with advanced cancer to share treatment-related information and the possibility to
predict an individual patient’s information desire based on patient characteristics
(Chapter 5), or based on the judgement of the oncologist (Chapter 6). Furthermore,
question 5 was related to the eects that treatment information in DAs may have on
patients (Chapter 7), and question 6 was related to the factors that would inuence
the implementation of DAs in daily clinical practice (Chapter 8).
In this chapter, we will address the research questions one by one and critically
examine the results in the light of methodological considerations and other studies.
In the last part of this chapter we will discuss the implications of our study for
clinical practice and future research.
Looking back: addressing the research questions and critically
examining the results
Overviews of benets and risks of second-line palliative chemotherapy
Colorectal cancer
In the systematic review on benets and risks of second-line irinotecan for advanced
colorectal cancer (Chapter 3), 25 phase II and 5 phase III studies were identied.
Data on severe (grade 3–4) adverse events, tumour response, and survival were
extracted from the studies. Only one of these studies performed a direct random-
ised comparison between patients receiving BSC plus second-line irinotecan, and
patients receiving BSC alone.1
Breast cancer
Since many chemotherapeutic regimens can be used for second-line treatment in
advanced breast cancer, we inventoried which regimens were commonly used in
the hospitals participating in the trial.is inventory yielded eight dierent regi-
mens: (1) capecitabine; (2) liposomal doxorubicin; (3) gemcitabine; (4) docetaxel;
(5) paclitaxel; (6) vinorelbine; (7) combination therapy with cyclophosphamide,
methotrexate, and 5-uorouracil (CMF); and (8) combination therapy with doxor-
ubicin and cyclophosphamide (AC). In the vast body of literature on second-line
chemotherapy for breast cancer, no randomised studies comparing any of the eight
second-line regimens to BSC alone were found. Information on severe adverse
events, tumour response and survival with chemotherapy was extracted; no dif-
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ferences in eectiveness were found between the eight regimens. e data were
published in a review, albeit with a focus on monotherapy for patients who had
been pretreated with anthracyclines and taxanes. As a result, the published review
focused on four regimens: capecitabine, liposomal doxorubicin, gemcitabine, and
vinorelbine. e information for BSC had to be derived from indirect evidence.
We extracted information about severe adverse events and tumour response from
randomised studies on other tumour types, comparing BSC plus second-line che-
motherapy with BSC alone.e impact of second-line chemotherapy on survival
remains unknown. In the DAs, the median expected survival of 12 months with
chemotherapy was presented together with a question mark for expected survival
without chemotherapy, and an explanation that it is not known whether, or in
what way, the survival of patients who are treated with BSC alone is inuenced by
second-line chemotherapy.
Developing the DAs
e data on benets and risks obtained in the systematic reviews were used to
develop the DAs. e design of the DAs was based on DAs for prostate cancer
previously developed and evaluated in our group.2,3 We involved clinicians, an
expert on SDM and DAs, and two methodologists, and several lay people to review
the comprehensibility of the DAs. Clinicians from all participating hospitals were
sent a copy of a DA to review before the start of the trial.
e International Patient Decision Aids Standards (IPDAS) collaboration recom-
mends a systematic development process for DAs, comprising steps as scoping
and design, development of a prototype, and ‘alpha’ and ‘beta’ testing.4 Our re-
search questions pertained to the necessity and feasibility of introducing SDM and
DAs in the eld of advanced cancer. If the DAs are to be used beyond the current
project, there are several opportunities to improve the DAs.4 ese comprise con-
sultation of patients and additional experts including patient educators and policy
makers, and use of a theoretical framework, such as the Ottawa Decision Support
Framework.5 Furthermore, the quality of the evidence on treatment outcomes could
be assessed critically, for instance by using the Grading of Recommendations As-
sessment, Development, and Evaluation (GRADE) approach.6 e results of this
quality assessment could then be described in the DAs, together with information
on the likely expiration date of the DAs, and the update and monitoring policy.
For the treatment decision in our study, no existing reviews or guidelines were
available; therefore we performed our own systematic reviews of the literature,
which were subjected to peer review. If we intend to continue using the DAs,
these reviews will require timely updates to keep up with the newest evidence. A
much more ecient approach would be to develop DAs alongside clinical practice
guidelines, because both draw on the same evidence base, and updating of the DAs
could then be performed together with an update of the guideline.7 Linking DAs
to guidelines would ensure uniformity of the treatment-related information, and
could possibly promote the uptake of DAs. Interestingly, one of the objectives of the
MAGIC project (MAking Grade the Irresistible Choice; www.magicproject.org)
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is to develop a model for semi-automated production of electronic DAs based
on the evidence collected for guidelines, which can then be directly linked to
electronic guidelines for use during clinical consultations.8 It is worth keeping track
of the progress of MAGIC to explore possible opportunities for DAs in the eld of
advanced cancer.
Oering DAs with treatment-related information to patients in a clinical trial
Summary of trial results
In the clinical trial, 77 patients with advanced breast or colorectal cancer were
oered a DA by a nurse. When the treatment-related information was oered, 96%
of patients wished to see information on adverse events, 91% wished information
on tumour response, and 74% wished information on survival. When patients were
askedwhether any information on the three items in theDAwas previously provided
by the oncologist, 73%, 54%, and 28% of patients answered armatively. Apparently,
many patients received less information from the oncologist than desired. Chapter 5
showed that it is not possible to identify those patients who desire survival informa-
tion on the basis of clinical or psychosocial characteristics. Chapter 6 demonstrated
that oncologists were adequately aware of the high information desire of this patient
population, but they had diculty judging the information desire of individual
patients. Based on these ndings, we recommend that oncologists do not base their
information provision on implicit assumptions of information desire, but explicitly
ask patients what information is desired. Chapter 7 showed that the DAs could
be safely oered to patients with advanced breast or colorectal cancer, without
any negative impact on patients’ well-being. Benecial eects of the DAs on the
quality of both the decision-making process and the resulting choice were found
(stronger treatment preferences and better subjective knowledge). However, no
improvements in objective knowledge, risk perception, or patient involvement in
decision-making were found. is absence of anticipated eects can possibly be
attributed to the DAs themselves, to the setting of advanced cancer, where patients
may feel that treatment provides the last hope or option,9,10 or to the nurses who
independently decided when and how to oer the information aer the consultation
with the oncologist.
Study methodology
Our approach to measure patients’ desire for treatment-related information closely
resembled the way information is provided in clinical practice, by actually providing
information at the point of decision-making. In hindsight, it would have been
worthwhile to also ask the patients in the control group about their desire for
information, without oering the information, to examine the extent to which
patients’ information desire is dependent on the context in which it is assessed.
Patient questionnaires comprised several measures to evaluate the DAs.e IPDAS
collaboration distinguishes two constructs for evaluating the eectiveness of DAs:
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(1) the quality of the decision-making process and (2) the quality of the resulting
choice.11 e measures included in the questionnaires represented both of these
constructs, andmany have previously been used by studies included in theCochrane
review on eectiveness of DAs.12 Several studies have also employed the Decisional
Conict Scale;12,13 however, a validation study of the Dutch version of this scale in
a sample of patients with cancer could not conrm the original three subscales.14
While other measures (e.g. value congruence with the chosen option) may have
been valuable additions to our study, we were careful not to overburden this patient
population with overly long questionnaires.
All of the measures in our study were patient-reported. It could be valuable to
add clinician-reported measures, or observational measures of patients’ behaviour
and interaction with clinicians.15 e use of observational measures can provide
additional insights, but researchers need to bear in mind that asking patients for
consent to record consultations may have a detrimental eect on recruitment, and
patients and clinicians may alter their behaviour due to the observer eect.
Generalisability of the trial results
e clinical trial in which the DAs were used was conducted in 17 hospitals in the
Netherlands, and included patients with advanced breast or colorectal cancer, in
the setting of second-line palliative treatment with chemotherapy. It is not clear
whether the results can be generalised to other countries, patients with dierent
tumour types, or other palliative treatment decisions.
Since the 1950s, studies from the UK, USA, Australia and Canada have consistently
shown that patients in these countries prefer to hear the truth about a diagnosis of
cancer.16 When asking for preferences on the communication of prognosis, patients
with advanced disease from the UK, USA, Australia, Sweden, and Japan were found
to report higher information preferences than patients from Greece and Spain.17 It
seems that patients from countries without an Anglo-Saxon cultural background
prefer less information. In some of these countries, information may be provided to
family members, who may request that information is withheld from the patient.18
It is important to realise that health professionals have to handle the delicate balance
between legal aspects of sharing information and providing the best possible care,
while coping respectfully with these cultural dierences and preferences.
Our study only included patients with advanced breast or colorectal cancer, tumour
types that were selected because of their high incidence. In both of these patient
groups, a substantial majority of patients desired survival information (61% vs. 78%,
respectively). Similarly high needs for survival information were reported in a
survey among patients with advanced lung cancer,19 and a survey among patients
with advanced breast, colorectal, prostate, lung, melanoma, and ovarian cancer.20
Other surveys among heterogeneous samples of patients with advanced cancer
showed that 78% and 85% of patients wanted full information.21,22 Based on these
studies, there are no indications that information desire will be largely dierent for
other tumour types, but this needs to be conrmed by further studies.
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Other studies in the eld of advanced cancer, not related to decisions about palliative
chemotherapy, have shown similar results for patients’ information desire and the
eect of sensitive information. In a study of patients with advanced cancer referred
for palliative care, patients who received a question prompt list (QPL) asked more
prognostic questions and discussedmore prognostic and end-of-life issueswith their
physician.23 ese ndings illustrate patients’ need for information on these issues;
furthermore, no negative impact was found on patient anxiety. In a population of
patients with dierent forms of advanced cancer, a video about cardiopulmonary
resuscitation could safely be shown to patients to support decision making.24
Exploring the use of the DAs in daily clinical practice
While many DAs have been proven benecial in randomised studies, few to none
are routinely used in daily clinical practice. To obtain insight in potential imple-
mentation issues of the DAs, we interviewed oncologists and nurses who had been
involved in this project, most of whom had gained clinical experience with the DAs.
Most barriers to the use of the DAs in daily practice were found in the opinions
and attitudes of the oncologists and nurses (e.g. concerns about the impact of the
information in this vulnerable population) and in the logistics of organisations
(e.g. the decision is already made before the nurse sees the patient). Many of the
clinicians were open to the future use of the DAs, and facilitators to implement the
DAs were also mentioned (e.g. education and training of clinicians).ese results
can be used to develop a tailored implementation strategy. is strategy would
need to address the full range of barriers, but to facilitate logistical changes, the rst
challenge is to motivate clinicians to get them committed to implement the DAs
in daily practice. While our study focused on one specic treatment decision and
DAs in the form of a booklet which were oered by a nurse, many of the identied
factors will also apply to other contexts in the eld of advanced cancer. Indeed,
several ndings corresponded with ndings for the implementation of other (video
or DVD based) DAs for curative cancer-related decisions, reported in studies from
the USA and the UK.25–28 Importantly, several barriers and facilitators specic to
these particular DAs were found, including the intricacy of the decision to refrain
from further active treatment, and the distribution of tasks between nurses and
oncologists.
Looking ahead: Implications for clinical practice and future
research
Implications for clinical practice
Providing treatment-related information
e results from the trial encourage candid discussions of treatment options, includ-
ing the benets and risks of each option. Since an individual patient’s information
desire cannot be predicted, discussions should start by eliciting the patient’s in-
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formation desire, for which recommendations have been published.29,30 e use
of open-ended questions can help to elicit a patient’s most important questions
and concerns as well as the preferred level of candidness, to guide the provision of
information by the clinician.30 For example, a physician might ask ‘What types of
information would you like?’ or more specically ‘Would you like me to talk about
the prognosis for this kind of cancer? What kind of information do you want me to
cover?’.30,31
eDAs developed in this study can be used to oer information on a few predened
items relevant to the treatment decision. Aer giving patients a preview of the
information, the patient can be asked whether or not this information is desired. If
desired, the DA can be used to provide numerical information, including visual
aids.is stepped approach of providing information (‘preview-ask-tell’) resembles
the principle of ‘ask-tell-ask’, which has been recommended to facilitate a two-way
exchange of information.32 Following this principle, aer providing the information
to the patient, the clinician can ask what the patient understands and feels about
the information given. It should be pointed out that many existing DAs may be
too rigid to accommodate the variable information needs of patients. Ideally, DAs
should be exible and interactive, for example in the form of Apps to be used on an
iPad, as recently launched by the NHS.33
e online teaching module Oncotalk provides recommendations about how to dis-
cuss palliative treatment options.34 Figure 9.1 shows what this procedure could look
like when discussing second-line palliative chemotherapy and we have indicated
where a DA could be used. Aer discussing the treatment options and the benets
and risks of each of these options, the clinician can oer to make a recommendation.
Aer all, the SDMmodel not only describes a two-way exchange of information, but
also an exchange of treatment preferences.35 Another important issue is to negotiate
a realistic time frame to make the decision. It became apparent from our interviews
with oncologists and nurses that on several occasions a treatment decision had
already been made in the consultation with the oncologist.is is not recommen-
ded because patients may need time to consider the treatment options and discuss
them with others, before returning with their questions at the next consultation.36
However, if the decision is made just aer the treatment options are discussed, the
only window of opportunity to use a DA would be to have the oncologist oering it
during the consultation. A better solution would be to give patients more time to
make a decision. When patients are deciding about participation in a clinical trial,
there is a legal obligation that aer the patient is properly informed, the patient is
allowed a sucient period of reection, to reach a carefully considered decision
about the requested consent.37 We believe that this should be no dierent when
obtaining informed consent for standard treatment.
Our reasons to have nurses oer the DAs to patients included the considerations
that nurses usually spendmore time with patients than physicians do, and that some
nurses are already highly involved in supporting treatment decisions.38,39 Interviews
with nurses revealed that some nurses believed that the oncologist should break
prognosis and support patients in decision-making (Chapter 8). e DECIDE
study on barriers and facilitators to improve communication and decision-making
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Negotiate an agenda for the visit▸ Ask what the patient wants to discuss▸ Tell the patient that you want to discuss treatment options following rst-line
chemotherapy▸ Ask the patient to commit to that agenda
Briey recap the clinical situation▸ Recap the test results (disease progression) and implications (no further rst-
line chemotherapy)▸ Consider to explore patient’s current understanding of the illness▸ Ask whether the patient wants to discuss prognosis, but do not force it on the
patient
Outline themedically reasonable treatment options, then discuss the pros and
cons of each▸ Mention and explain the two options: (1) BSC plus second-line chemotherapy
and (2) BSC alone, and ask whether these options are clear*▸ Go through the pros and cons of each option*▸ Ask for the patient’s reaction▸ Reinforce accurate understanding▸ Ask about the desire for numerical information*▸ Ask about the desire to talk about prognosis for both treatment options*▸ Ask about the desire to receive a recommendation▸ Ask whether the patient and/or the family has any remaining questions
Respond to the patient’s emotions (using the NURSE method)40
Talk explicitly about your commitment to the patient▸ Be clear about your interest in the patient’s well-being, your recognition of
hopes, and your commitment to support the patient
Negotiate a realistic time frame to make a decision▸ Ask how much time the patient needs to nish making a decision▸ Ask what other people (like family, friends and/or the general practitioner)
the patient may want to talk with during the decision making process▸ Ask if any other information would assist them in the decision making▸ Verify that the patient’s proposed time frame is reasonable (depending on the
urgency of starting any treatment with chemotherapy)
Summarise the plan of care and make concrete plans for the next step▸ Including next visit and contact information
*A decision aid can be used to support this step
Figure 9.1: Applying Oncotalk teachingmodule 5 to the decision about second-line palliative
chemotherapy34
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about goals of care similarly showed that nurses did not want to interfere in the
physician-patient dyad.41 is could be a serious barrier to the administration of
DAs by nurses. However, instead of ‘interfering’ with the dyad, the role of the nurses
would be to support this dyad.
Use of the DAs in daily clinical practice
e implementation of the DAs appears to be most strongly inuenced by the
opinions and attitudes of clinicians and by the logistics of health care organisations.
An essential precondition to eectuate any changes in the logistics of an organisation
would be to get the commitment of clinicians. A commitment to implement the
DAs and SDM can be based on either a belief in the inherent benets, a sense of
obligation, or the recognition that not implementing the DAs would have negative
repercussions.42 When commitment is based on ‘want to’ motives rather than ‘ought
to’ or ‘have to’, clinicians can be expected to be more cooperative. erefore, any
implementation strategy or intervention should aim to reach this highest level of
commitment.
Several interventions to improve physicians’ adoption of SDM have been described,
including (1) the distribution of printed educational materials, (2) educational meet-
ings, (3) audit and feedback, (4) reminders, and (5) patient-mediated interventions.43
Of ve randomised studies evaluating these interventions, only two (a DA and
a multifaceted intervention employing educational materials and meetings, and
audit and feedback) resulted in statistically signicant higher ratings of SDM by
observers.44 More studies are needed to elucidate eectiveness of various inter-
ventions or combinations of interventions. A rather successful implementation
eort of the Group Health Research Institute employed audits by project managers
to monitor implementation processes and progress, feedback on the distribution
of DAs in comparison with other providers and clinics, and agging of patient
records by sta to remind physicians about the DA.45 Notwithstanding these eorts
to distribute DAs to patients, the authors reckoned that distribution alone is not
enough, and that clinicians need to be engaged to truly change decision-making.
ey suggested that clinician engagement could be improved by discussing the
purpose of the DAs and the benets expected with clinicians, and providing them
with training in SDM. It would probably be most eective to simultaneously employ
an intervention for patients to raise their awareness about SDM and DAs.46,47
Educating health professionals about SDM and DAs
Worldwide, at least 54 training programs in SDM for health professionals have been
developed, which are characterised by a wide range of approaches, restriction of
most programs to physicians only, and lack of proper assessment of eectiveness.48
In a recent randomised trial evaluating a training program for oncologists, disap-
pointingly, 52 of the 86 oncologists (60%) dropped out during the study and hardly
any eects were found.49 e authors surmised that the high dropout rates were
related to the nature of the 12-hour training, and are now setting up a new trial
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in which individual and online training programs will be evaluated. Another ran-
domised trial based on individual training of oncologists is currently underway.50
Communication about chemotherapy with elderly patients was successfully im-
proved by providing nurses with access to one of their videotaped consultations
including a reection task, educational material, a 1-day training session including
role play, peer review, and a half day follow-up meeting.51
Many of the training programs in communication skills and SDM target licensed
physicians in an eort to shi their style of decision-making towards SDM. By tar-
geting the education of future health professionals (e.g. through implementing the
CanMEDS competency framework),52 SDM can become the norm. Participation
of health professionals in these training programs can be fostered by mandatory
training for future professionals, and providing incentives for licensed professionals
in the form of accreditation credits for continued medical education (CME).
Educating patients and the general public about SDM and DAs
Patient-mediated interventions to improve the use of SDM and DAs could involve
educational materials, instruments such as QPLs or DAs, and training. Providing
a QPL to elderly patients successfully increased the number of questions asked
and slightly improved patient recall of information.51 e interactive web-based
communication aid CONNECT, comprising an assessment of patients’ preferences
and values and a 15-minutes communication skills training, helped patients with
advanced cancer to reach treatment decisions and improved their satisfaction with
communication and decisions.53
e MAGIC (MAking Good decisions In Collaboration) program has used a mar-
keting campaign to raise patients’ awareness of SDM and encourage them to ‘Ask 3
Questions’ (see Figure 9.2). Both health professionals and patients have responded
positively to this campaign, but have also indicated that additional actions, including
better information and reinforcement by clinicians, are needed to activate patients
for SDM.54 We feel that the approach could be taken further upstream by targeting
the general public with messages about SDM, as was done in the ‘Great Patient’
Campaign (see Figure 9.3). All these interventions can help to raise awareness of
SDM and activate people to become more involved in their own health care, which
would help to open the way to bring this approach to the eld of advanced cancer.
Other changes required
In an extensive project to implement DAs in primary care, the project team went
through all the eorts to appoint physician and sta champions, involve health
professionals in selecting DAs and tailoring DA distribution to the workow of each
clinic, organise lunch presentations and training sessions, provide support materials,
and reward high distribution rates of DAs with incentives such as lunch bags.55
In addition, promotional brochures and posters were used to increase patients’
interest in DAs. In spite of all these eorts, the distribution of DAs was only low to
modest. Clearly, more cultural and structural changes will be needed to change the
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Figure 9.2: Ask 3 Questions poster from the
MAGIC program
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opinions and attitudes of health professionals and to overcome barriers in health
care organisations. One of the proposed changes by the authors was to reward
health professionals for their eorts to practise SDM and use DAs, by reimbursing
any extra time it may take to fully involve patients, and emphasising that patient
involvement should be considered as routine component of care by imposing a
quality indicator for SDM. Another change would be to support physicians in
their eorts by also involving other health professionals, such as nurses, and by
employing ICT solutions to identify eligible patients for DAs based on electronic
health records.
Implications for future research
Improving the current DAs
e DAs improved the quality of the decision-making process and the result-
ing choice, but not objective knowledge, risk perception, or patient involvement
(Chapter 7). One of the possible explanations for this lack of eect was that the DAs
were also employed as a tool to assess information desire. Possible amendments
suggested by health professionals (Chapter 8) include reconsidering the selection of
information, such as omitting rare adverse events. Adapting the current booklets
to create computer- or web-based versions would improve user-friendliness by
facilitating the distribution of the DAs, and creating the opportunity of tailoring the
presentation of the information (e.g. the order of the items). Health professionals
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also expressed reservations about the explicit numerical information about survival
in the form of a median. A possible amendment is the presentation of three survival
scenarios (best case, worst case, and typical survival) instead of median survival.56
ese scenarios would better convey the variation in survival duration, and help
patients to hope for the best, while planning for the worst. We feel that further study
is merited to assess the acceptability and eectiveness of these scenarios among
patients at the point of decision-making. Another amendment would be to broaden
the treatment choice, by including a comparison amongst the available chemothera-
peutic regimens. For example, while no dierences were found in eectiveness
between the various second-line regimens for advanced breast cancer, patients may
prefer a regimen based on the toxicity prole.
Developing additional DAs
ere are many more preference-sensitive decisions in the eld of advanced cancer
that could be supported by DAs.ese include other lines of palliative chemother-
apy, chemotherapy for other tumour types, and treatment decisions about other
treatment modalities, including targeted therapy. When selecting topics for addi-
tional DAs, the views of clinicians and patients can be taken into account, as well as
the availability of a recent relevant systematic review, preferably in the context of
guideline development.e availability of more DAs would also aid implementa-
tion, since DAs can then increasingly be regarded as a standard part of care, instead
of an isolated initiative for a specic treatment decision.
Particularities of palliative treatment decisions
In this population of patients with advanced breast or colorectal cancer, almost all
patients (91%) preferred treatment with second-line chemotherapy, and nearly all
(87%) ended up having second-line chemotherapy. A similar strong tendency to
start chemotherapy was previously reported among patients with advanced breast or
colorectal cancer deciding about rst- or second-line palliative chemotherapy.10,57
An important reason to start second-line chemotherapy was that the treatment
oered hope.10 An exploration of treatment attitudes among patients with advanced
cancer showed that about one third of patients could be categorised as striving for
quality of life, another third as striving for length of life, and the remaining third
had no clear preference.58 e same categorisation holds true for the patients in
our study. However, patients’ predominant preference for chemotherapy seems to
contradict previous ndings that striving for quality of life and less for length of life
was associated with lower preferences for palliative chemotherapy.10
It will be an important task for future research to explore patients’ treatment attitudes
and their perceptions of the treatment choice regarding palliative chemotherapy.
Interviews with health professionals indicated that many patients do not perceive
having a choice, because active treatment is desired. In a study among patients
with early breast cancer deciding about adjuvant chemotherapy, as many as 78%
of patients perceived no choice.59 Many of these patients felt that doing nothing
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was not an option. Another study on the same treatment decision reported that
patients thought that choosing between ‘doing something’ and ‘doing nothing’ was
not a meaningful choice between equivalent treatment options.60 While data from
our trial showed that 66% of patients feel that they were oered a treatment choice,
this does not imply that patients also perceived to have a choice, because they
may be inclined to at least try every available treatment to ‘ght’ cancer.59 In the
abovementioned study about adjuvant chemotherapy, another frequently reported
reason for not perceiving a choice was that patients chose to follow the doctor’s
advice.59 It has been suggested that oncologists tend to support patients’ wish to
have active treatment. While striving for open and candid discussions with patients,
oncologists are also reportedly keen to maintain patients’ hope by oering active
treatment.61 Patients provided several information- and decision-related comments
in the follow-up questionnaires (see Figure 9.4).ese comments highlight a need
for information about the option of BSC alone and the eect of chemotherapy
on survival, as well as the potential value of DAs. Furthermore, the comments of
some patients illustrate that they were not involved in decision-making, and others
expressed a strong preference for chemotherapy, precluding them to consider the
alternative option of BSC alone.
Patients’ awareness of supportive care could be raised by routinely scheduling
an appointment with a palliative care team soon aer the diagnosis of advanced
disease. Knowing what supportive care has to oer may help patients to recognise
that refraining from active treatment would not imply doing nothing or being
abandoned by health professionals, and it may prompt patients to think ahead
about the point of ceasing active treatment. Early involvement of a palliative care
team alongside standard oncological treatment may also improve both quality of
life and survival.62
Exploring other aspects of SDM in the eld of advanced cancer
While this thesis has focused on the sharing of treatment-related information
between clinicians and patients, SDM also entails steps to discuss the preferred
treatment and reach agreement. An indication that these steps can be improved is
provided by a series of audiotaped consultations on rst-line palliative chemother-
apy, in which only 29% of patients were oered a treatment choice.63 However, it is
known that not all patients prefer to be involved in treatment decision-making.64
In our trial, 76% of patients preferred to share the decision with the physician or to
have an active role in treatment decision-making, while 24% of patients preferred
a more passive role. It is worth noting that not being involved in the treatment
decision may not have negative consequences in itself, as long as this passive role
is in line with the patient’s preferred role. For patients who prefer a passive role,
aer sharing information, physicians can aim to make a treatment choice in line
with the patient’s values and preferences (physician-as-agent model).35 However,
this prior sharing of information would be crucial, since physicians are no better
in identifying patients’ treatment preferences than they are in identifying inform-
ation preferences, an issue that has been referred to as ‘the silent misdiagnosis of
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INFORMATION-RELATED COMMENTS
“I have not received information about what will happen when no chemotherapy is provided”
— patient from control group, T2
“I have not received the information with or without chemotherapy”
— patient from control group, T2
“e information was good and sucient”
— patient from intervention group, T2
“I was not told anything about survival [by the oncologist]”
— patient from intervention group, T2
“e information from the decision aid was clearer than the information from the physician. How-
ever, it was still too generic”
— patient from intervention group, T2
“e information from the decision aid was very valuable, I would have appreciated receiving this
earlier”
— patient from intervention group, T2
“I already knew most information”
— patient from intervention group, T2
“I am very satised with both the format and the content of the information”
— patient from intervention group, T2
DECISION-RELATED COMMENTS
“I do not have a say in treatment with chemotherapy, that is decided by others”
— patient from control group, T2
“I feel that this decision is made without me”
— patient from intervention group, T2
“I cannot value the appropriateness of BSC, because I have not discussed it or thought about it”
— patient from intervention group, T2
“I do not have a choice”
— patient from intervention group, T2,
commenting on a question about balanced presentation of information
“e only thing that matters is the eect of the chemotherapy, adverse events do not matter to me”
— patient from control group, T3
NOTE: all patients from the intervention group cited here have received the full decision aid
T2: one week aer receiving treatment-related information
T3: eight weeks aer receiving treatment-related information
Figure 9.4: Information- and decision-related comments from the follow-up questionnaires
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patient preferences’.65 Future studies are needed to explore the process of treatment
decision-making between clinicians and patients with advanced cancer. It would
be interesting to investigate the role of the treatment recommendation made by
the physician, which is an integral part of shared decision-making, but can also
strongly inuence a patient’s decision.66
Conclusion
e studies in this thesis indicated the necessity and feasibility of shared decision-
making in the eld of advanced cancer. Many patients with advanced breast or
colorectal cancer wished to receive treatment-related information when deciding
about second-line palliative chemotherapy. Since a patient’s information desire
could not be predicted, recommendations for clinicians include eliciting each indi-
vidual patient’s desire, for which we suggest using a stepped approach (‘preview-
ask-tell-ask’). Importantly, the information could be oered to patients in a safe
and acceptable way, using decision aids. More studies are needed to elucidate the
eects of decision aids for palliative treatment decisions, in particular when one of
two treatment options implies refraining from active treatment.e development
and maintenance, and possibly also uptake, of decision aids can be facilitated by
establishing a link with clinical guidelines.e implementation of shared decision-
making and decision aids in the daily care for patients with advanced cancer needs
more attention, including eorts to commit and support health professionals.
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Summary
In the Netherlands, each year approximately 50,000 patients with cancer are told
that their disease cannot be cured (anymore).ese patients can be provided with
best supportive care to relieve and prevent symptoms, and to improve quality of
life. In addition, anticancer therapy such as palliative chemotherapy can be oered
in an attempt to stabilise or shrink the tumour, which can improve quality of life
and potentially increase length of life. However, these benets of treatment are
uncertain and there is a very real risk of experiencing (severe) adverse events.
For these preference-sensitive decisions, the model of shared decision-making
can help to reach a treatment decision that is aligned with a patient’s values and
preferences. According to this model, clinician and patient (and possibly other
participants) work together to share information, take steps to build consensus about
the preferred treatment, and reach an agreement.e exchange of information on
treatment options and the benets and risks of each of the options can be supported
by decision aids.ese tools take a variety of forms and are used to complement
the information from the clinician. Decision aids have been proven benecial, for
example in stimulating patients to take a more active role in decision-making and
improving patients’ knowledge regarding the treatment options, without inicting
any negative eects.
e concept of shared decision-making and decision aids ts with the increased
focus on patient-centred care. However, its introduction in the eld of advanced
cancer may raise some issues. Possible issues include doubts about the desire of
patients with advanced cancer to share information on treatment options, and
the ability of clinicians to tailor their information provision to the information
preferences of individual patients. Clinicians have also expressed concerns about
the consequences of providing patients with advanced cancer with treatment-related
information. Finally, implementing shared decision-making and decision aids in
daily clinical practice will require conscious eort.
e main objective of this thesis is to study the necessity and feasibility of intro-
ducing shared decision-making and decision aids in the eld of advanced cancer.
More specically, the thesis focuses on the treatment decision whether or not to
have second-line palliative chemotherapy in addition to best supportive care.e
project started o with the development of decision aids on second-line palliative
chemotherapy (Part I) which were oered to patients in a clinical trial (Part II).
In addition, a qualitative study was conducted to explore the implementation of
the decision aids (Part III).e results of these studies are examined in the general
discussion (Part IV).
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Part I: Setting the stage
Chapter 1 provides a general introduction on the topic of this thesis, comprising a
description of the palliative treatment setting, the model of shared decision-making,
and decision aids. Furthermore, the study aim, research questions and design
are described. Chapter 2 gives more details about the study design, including the
development of the decision aids and the methodology used in the clinical trial.
Chapter 3 presents a systematic review of the literature on second-line treatment for
advanced colorectal cancer. In this setting, irinotecan is the main chemotherapeutic
agent. We extracted information on benets and risks from 30 studies. Only one
of these studies presented a randomised comparison between best supportive care
alone and treatment with chemotherapy in addition to best supportive care.
InChapter 4we describe our systematic review on benets and risks of second-line
treatment for advanced breast cancer. A total of eight dierent monotherapy and
combination regimens were used in the hospitals participating in the trial. e
published review focused on four of these regimens, which were monotherapy
options for patients who had been pretreated with anthracyclines and taxanes. To
develop the decision aids, we extracted data on benets and risks from 99 studies on
second-line chemotherapy, but we did not nd any studies in which a randomised
comparison was made with best supportive care alone. erefore, evidence of
adverse events and tumour response with best supportive care alone was indirectly
derived from randomised studies on other tumour types.e impact of second-line
chemotherapy on survival remains unknown.
Part II: Using the decision aids in the context of a clinical trial
In Chapter 5, we investigate how many and which patients desire information
on expected survival. e 57 patients desiring survival information (74%) were
compared with the 20 patients not desiring this information, using a multitude of
clinical and psychosocial patient characteristics.e resulting prediction model,
which included four patient characteristics, yielded correct predictions for 60 out of
72 patients with complete data (83%). To enable these predictions, each patient’s past
experience with chemotherapy, cancer coping style and deliberation style would
need to be assessed. Although the predictive performance seems fairly good at
rst glance, the simple assumption that all patients would wish to see survival
information already yields correct predictions in 55 patients (76%). erefore,
we concluded that it is not useful to identify those patients who desire survival
information on the basis of clinical or psychosocial patient characteristics.
In Chapter 6, we further explore patients’ information desire and the ability of
oncologists to judge this desire.e results showed that oncologists were adequately
aware of the high information desire of this patient population. However, they had
diculty judging what information an individual patient wants to see. Based on
these ndings, we recommend that oncologists do not base their information
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provision on judgements of what a patient would or would not wish to know, but
explicitly ask patients what information is desired and act accordingly.
In Chapter 7, the eects of the treatment-related information in the decision aids
are evaluated by comparing the 83 patients randomly assigned to receive a decision
aid with a group of 45 patients randomly assigned to receive only usual care.is
evaluation showed that the decision aids on second-line palliative chemotherapy
could be safely oered to patients with advanced breast or colorectal cancer, without
any negative impact on patients’ well-being. e decision aids improved some
aspects of the quality of the decision-making process and the resulting choice, but
not objective knowledge, risk perception, or patient involvement.e absence of
these anticipated eects can possibly be attributed to the decision aids themselves,
to the setting of advanced cancer, where chemotherapy may represent hope, or to
the nurses who independently decided when and how to provide the information
aer the consultation with the oncologist.
Part III: Exploring the use of the decision aids in daily clinical
practice
Chapter 8 describes a qualitative study on the implementation of the decision aids in
daily clinical practice. Wemade use of the experience of 14 oncologists and 12 nurses
who participated in the trial to identify factors inuencing the implementation of
decisions aids for palliative treatment decisions. In our interviews, the opinions and
attitudes of the oncologists and nurses were found to play a key role in successful
implementation, and the logistics of organisation also played a major role.
Part IV: General discussion and summaries
Chapter 9 addresses the research questions one by one and critically examines the
results in the light ofmethodological considerations and other studies. Furthermore,
the implications of the results for clinical practice and future research are discussed.
Recommendations for clinicians include eliciting the information preferences of
each individual patient, for which we suggest using a stepped approach (‘preview-
ask-tell-ask’). Patients should then be allowed sucient time to make a treatment
decision. However, it is questionable whether patients with advanced cancer per-
ceive that refraining from active treatmentwith chemotherapy is a realistic treatment
option. Future studies are needed to explore patients’ perceptions and possible ways
to raise patients’ awareness of this treatment decision and the equivalence of both
treatment options.
e implementation of decision aids to support palliative treatment decisions re-
quires a tailored strategy.e current decision aids need to be kept up to date with
evidence. Development of additional decision aids for other palliative treatment
decisions can help to promote these instruments as a standard part of care. Both
development and maintenance of decision aids can be facilitated by linking these
tools to guidelines. An essential condition for implementation is the commitment
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of health professionals, to be achieved by a belief in the benets of shared decision-
making and decision aids.is may be realised by education of both partners in
the decision-making process, namely current and future health professionals and
current and future patients. Furthermore, cultural and structural changes can help
to incentivise and support health professionals.
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Samenvatting
Jaarlijks krijgen in Nederland ongeveer 50.000 patiënten met kanker te horen dat
genezing voor hen niet (meer) mogelijk is. Deze patiënten kunnen gebaat zijn
bij een algemeen ondersteunend beleid dat erop gericht is om symptomen van de
ziekte te verminderen of te voorkómen en de kwaliteit van leven te optimaliseren.
Aanvullend kan ook nog een behandelingworden ingezet die zich direct op de tumor
richt, zoals palliatieve chemotherapie. Indien de behandeling met chemotherapie
de tumor tijdelijk weet te verkleinen of tot stilstand laat komen kan dit een positieve
uitwerking hebben op de kwaliteit van leven en mogelijk ook in beperkte mate
op de duur van het leven. Het blij echter ongewis of deze positieve eecten ook
daadwerkelijk zullen optreden, terwijl de behandeling met chemotherapie een reëel
risico op (ernstige) bijwerkingen met zich meebrengt.
Wat hier de beste behandeloptie is hangt af van de voorkeuren van de patiënt. Het
zogenaamde model voor gezamenlijke besluitvorming kan worden aangewend om
een behandelkeuze te maken die in overeenstemming is met de normen, waarden
en voorkeuren van de patiënt. Dit model denieert dat clinicus en patiënt (mogelijk
in samenspraak met andere betrokkenen) samenwerken. Beide partijen wisselen
informatie uit, waarbij de clinicus de patiënt informeert over de behandelmogelijk-
heden en de mogelijke uitkomsten en de patiënt de clinicus informeert over zijn
of haar voorkeuren, verwachtingen en zorgen. Vervolgens kunnen zij gezamenlijk
stappen zetten om tot een consensus te komen over de te verkiezen behandeloptie
om daarna gezamenlijk een beslissing te nemen en een plan op te stellen. Het
uitwisselen van informatie over behandelopties en de voor- en nadelen van elk
van deze opties kan ondersteund worden door het gebruik van keuzehulpen. Deze
instrumenten zijn beschikbaar in verschillende vormen en worden gebruikt ter
aanvulling op de informatie van de clinicus. Keuzehulpen zijn bewezen eectief
in onder andere het stimuleren van patiënten om een meer actieve rol te spelen in
de besluitvorming en het verbeteren van de kennis van patiënten, zonder daarbij
negatieve eecten teweeg te brengen.
Het model voor gezamenlijke besluitvorming en het gebruik van ondersteunende
keuzehulpen passen goed in het huidige gedachtegoed van patiëntgerichte zorg. Er
zijn echter wel kanttekeningen te plaatsen bij de toepassing in de zorg voor patiënten
met gevorderde kanker. Zo zijn er twijfels ten aanzien van de wens van deze
patiënten om informatie over de behandelopties te ontvangen en het vermogen van
clinici om de informatievoorziening aan de voorkeuren van de individuele patiënt
aan te passen. Daarnaast hebben clinici zorgen geuit over de mogelijke schadelijke
gevolgen die het aanbieden van behandelgerelateerde informatie aan patiënten met
gevorderde kanker met zich mee kan brengen. Tenslotte blijkt het daadwerkelijk
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inbedden van gezamenlijke besluitvorming en het gebruik van keuzehulpen in de
dagelijkse praktijk niet eenvoudig.
De hoofddoelstelling van dit proefschri is het bestuderen van de noodzaak en
haalbaarheid van gezamenlijke besluitvorming en keuzehulpen in de zorg voor pa-
tiënten met gevorderde kanker. Hierbij is speciek gekeken naar de behandelkeuze
om wel of niet tweedelijns palliatieve chemotherapie in te zetten als aanvulling op
een algemeen ondersteunend beleid. Het project ging van start met het ontwik-
kelen van keuzehulpen voor tweedelijns chemotherapie (deel I), die vervolgens
aangeboden werden aan patiënten in een klinische studie (deel II). Daarnaast zijn
de mogelijkheden voor implementatie van de keuzehulpen onderzocht in een kwa-
litatieve studie (deel III). Ter afsluiting worden de verkregen resultaten besproken
in een algemene discussie (deel IV).
Deel I: Voorwerk voor de klinische studie
Hoofdstuk 1 biedt een algemene inleiding op het onderwerp van dit proefschri,
waarbij achtereenvolgens het terrein van palliatieve behandelkeuzes en het model
van gezamenlijke besluitvorming inclusief ondersteunende keuzehulpen aan de
orde komen. Vervolgens beschrij dit hoofdstuk het doel van de studie, de onder-
zoeksvragen en het ontwerp van de studie. In hoofdstuk 2 wordt verder ingegaan
op het ontwerp van de studie, waaronder het ontwikkelen van de keuzehulpen en
de methodologie voor de klinische studie.
Hoofdstuk 3 beschrij een systematische literatuurstudie naar de voor- en nadelen
van tweedelijns chemotherapie van gevorderde dikkedarmkanker. Doorgaans wordt
hierbij het cytostaticum irinotecan ingezet. De literatuurstudie leverde 30 studies op
waaruit informatie over de voor- en nadelenwerd geëxtraheerd. Slechts één van deze
studies betrof een gerandomiseerde vergelijking van het algemeen ondersteunend
beleid versus de behandeling met tweedelijns chemotherapie in aanvulling op het
algemeen ondersteunend beleid.
In hoofdstuk 4 wordt een tweede systematische literatuurstudie beschreven die is
uitgevoerd om de voor- en nadelen van tweedelijns chemotherapie voor gevorderde
borstkanker in kaart te brengen. Clinici uit de deelnemende ziekenhuizen gaven aan
gebruik te maken van in totaal acht verschillende mono- en combinatietherapieën
voor tweedelijns chemotherapie. De gepubliceerde literatuurstudie spitst zich toe
op vier van deze mogelijkheden, namelijk monotherapieën voor patiënten die in
het verleden al eens behandeld zijn met anthracyclines en taxanen. Uit de veelheid
aan publicaties over tweedelijns chemotherapie kon voldoende informatie over
bijwerkingen, respons van de tumor en overleving worden geëxtraheerd. Niet één
van deze studies bood een gerandomiseerde vergelijking ten aanzien van het eect
van tweedelijns chemotherapie als aanvulling op een algemeen ondersteunend
beleid. De kans op bijwerkingen en het eect op tumorgrootte moest dan ook
indirect worden verkregen uit gerandomiseerde studies voor andere tumortypes
en het eect van tweedelijns chemotherapie op de overleving van patiënten blij
onbekend.
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Deel II: Het gebruik van de keuzehulpen binnen een klinische studie
In hoofdstuk 5 onderzoeken we hoeveel en welke patiënten informatie willen over
de te verwachten levensduur. De 57 patiënten (74%) die deze informatie wilden
ontvangen werden vergeleken met de 20 patiënten die deze informatie niet wensten
te ontvangen, op basis van een breed scala aan klinische en psychosociale kenmerken
van de patiënt. Het resulterende predictiemodel met vier patiëntkenmerken leidde
tot juiste voorspellingen voor 60 van de 72 patiënten waarvoor complete gegevens
beschikbaar waren (83%). Om deze voorspellingen mogelijk te maken is informatie
nodig over de ervaringen van de patiënt met eerdere chemotherapie, de wijze
waarop de patiënt met de ziekte omgaat en de wijze waarop de patiënt beslissingen
neemt. Hoewel het model de informatiebehoee van de patiënt op het eerste gezicht
redelijk lijkt te voorspellen, laat een vergelijking zien dat simpelweg aannemen dat
iedere patiënt de overlevingsinformatie wenst te zien ook al leidt tot een juiste
voorspelling voor 55 patiënten (76%). We concluderen dan ook dat het niet zinvol is
om op basis van klinische of psychosociale kenmerken te voorspellen of een patiënt
de informatie over overleving wel of niet wenst te ontvangen.
Hoofdstuk 6 gaat dieper in op de informatiebehoee van de patiënt en relateert
deze aan de inschatting van deze behoee door de oncoloog. Oncologen bleken
goed op de hoogte te zijn van de hoge informatiebehoee in deze patiëntengroep.
Zij bleken daarentegen niet goed in staat om de behoee van een individuele patiënt
te voorspellen. Onze aanbeveling luidt dan ook om de informatievoorziening over
tweedelijns chemotherapie niet te baseren op aannames over de informatiebehoee
van een patiënt, maar om deze behoee bij de patiënt uit te vragen en hiernaar te
handelen.
Hoofdstuk 7 omvat een evaluatie van het aanbieden van behandelgerelateerde
informatie in de keuzehulpen. Hierbij werden de 83 patiënten die middels loting
waren toegewezen om de keuzehulp te ontvangen vergeleken met een groep van 45
patiënten die middels loting alleen de gebruikelijke informatie hadden ontvangen.
Deze vergelijking wees uit dat de keuzehulpen met informatie over tweedelijns
chemotherapie veilig konden worden aangeboden aan patiënten met gevorderde
dikkedarm- of borstkanker, zonder enig nadelig eect op het welbevinden van de
patiënt. Daarbij bleek er ook sprake te zijn van een aantal positieve eecten ten
aanzien van de kwaliteit van het besluitvormingsproces en de beslissing zelf, maar er
werden geen eecten gevonden ten aanzien van objectieve kennis, risicoperceptie,
of betrokkenheid van de patiënt bij de behandelkeuze. Het feit dat deze eecten
niet konden worden bevestigd kan te maken hebben met de keuzehulpen zelf, met
de specieke besluitvorming rondom gevorderde kanker, waarbij chemotherapie
hoop kan bieden, of met de verpleegkundigen die zelfstandig konden besluiten op
welk tijdstip en hoe ze de informatie aanboden, als vervolg op het consult van de
patiënt met de oncoloog.
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Deel III: Een verkenning van het gebruik van keuzehulpen in de
dagelijkse klinische praktijk
Hoofdstuk 8 beschrij een kwalitatieve studie waarin de uitdagingen van de im-
plementatie van de keuzehulpen in de dagelijkse praktijk onder de loep worden
genomen. Hierbij werd gebruik gemaakt van de ervaringen die 14 oncologen en 12
verpleegkundigen opgedaan hadden met de keuzehulpen in de klinische studie. In-
terviews met deze clinici wezen uit dat de mening en houding van zowel oncologen
als verpleegkundigen een sleutelrol spelen in een succesvolle implementatie en dat
daarnaast ook de rol van logistieke processen aandacht behoe.
Deel IV: Algemene discussie
In hoofdstuk 9 wordt ingegaan op de afzonderlijke onderzoeksvragen, waarbij de
resultaten kritisch tegen het licht worden gehouden ten aanzien van de gebruikteme-
thodologie en de resultaten van andere studies. Aansluitend worden de implicaties
voor de klinische praktijk en voor vervolgonderzoek besproken.
De aanbevelingen voor clinici behelzen onder andere het onderzoeken van de infor-
matiebehoee van iedere patiënt, waarbij we aanbevelen volgens een stappenplan te
werk te gaan. Volgens dit stappenplan wordt patiënten eerst meer inzicht geboden
in de beschikbare informatie, waarna hen gevraagd wordt of zij behoee hebben
aan deze informatie. Indien gewenst wordt de informatie daarna verstrekt, waarna
de clinicus middels navraag kan controleren of de informatie goed begrepen is. Het
is belangrijk dat patiënten daarna voldoende tijd krijgen om een keuze te maken.
Tegelijkertijd is het nog maar de vraag of de mogelijkheid om af te zien van verdere
chemotherapie wel als een volwaardig alternatief beschouwd wordt door patiënten
met gevorderde kanker. Toekomstige studies zouden kunnen verhelderen hoe pati-
ënten tegen deze keuze aankijken en of en hoe het mogelijk is om patiënten beter
bewust te maken van deze keuze en de volwaardigheid van beide alternatieven.
De implementatie van de keuzehulpen om het proces van gezamenlijke besluitvor-
ming te ondersteunen behoe een op maat gesneden aanpak. Het is van belang dat
de huidige keuzehulpen actueel blijven. Het ontwikkelen van nieuwe keuzehulpen
voor andere palliatieve behandelkeuzes kan helpen om deze instrumenten neer te
zetten als een standaard onderdeel van de zorg. Een koppeling van keuzehulpenmet
richtlijnen zou zowel de ontwikkeling als het onderhoud van deze instrumenten ten
goede komen. Verder is het essentieel dat clinici zich engageren om gezamenlijke
besluitvorming en keuzehulpen te introduceren. Dit kan onder andere bereikt
worden door goede voorlichting aan beide partners in het proces van medische
besluitvorming, namelijk huidige en toekomstige clinici en huidige en toekomstige
patiënten. Daarnaast kunnen culturele en structurele veranderingen helpen om
clinici te motiveren en te ondersteunen.
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List of abbreviations
5-FU 5-uorouracil
HER2 human epidermal growth factor receptor 2
QLQ-C15-PAL quality of life questionnaire core 15 palliative
QLQ-C30 quality of life questionnaire core 30
AC combination therapy with doxorubicin and cyclophosphamide
ANCOVA analysis of covariance
ANOVA analysis of variance
BSC best supportive care
CanMEDS Canadian medical education directives for specialists
CI condence interval
CME continued medical education
CMF cyclophosphamide, methotrexate, and 5-uorouracil
CMO commissiemensgebonden onderzoek [committee on research involving
human subjects]
CONSORT consolidated standards of reporting trials
CTCAE Common Terminology Criteria for Adverse Events v3.0
DA decision aid
DCR disease control rate
DECIDE decision-making about goals of care for hospitalized medical patients
EORTC European Organisation for Research and Treatment of Cancer
FOLFIRI 5-uorouracil (5-FU), leucovorin (LV), and irinotecan
FOLFOX 5-FU, LV, and oxaliplatin
GRADE Grading of Recommendations Assessment, Development, and Evalu-
ation
HADS hospital anxiety and depression scale
HRQoL health-related quality of life
IPDAS International Patient Decision Aids Standards
IQR interquartile range
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LV leucovorin
MADS Michigan assessment of decision style
MAGIC (1) MAking Grade the Irresistible Choice
MAGIC (2) MAking Good decisions In Collaboration
N/A not eligible/not assessable
NR not reported
NTR Netherlands Trial Registry
NURSE naming, understanding, respecting, supporting, exploring
OR (1) odds ratio
OR (2) overall response
OS overall survival
PD progressive disease
PFS progression-free survival
PRISMA preferred reporting items for systematic reviews and meta-analyses
QoL quality of life
QPL question prompt list
QQQuestionnaire quality quantity questionnaire
RECIST response evaluation criteria in solid tumours
SD (1) standard deviation
SD (2) stable disease
SDM shared decision-making
SNS subjective numeracy scale
SPSS statistical package for the social sciences
TTP time to progression
WHO world health organisation
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C Symposia & congresses
Symposium Methodology and Ethics, Nijmegen 2011 0.3
RIHS PhD Retreat, Wageningen (poster presentation) 2011 0.3
RIHS PhD Retreat, Wageningen (oral presentation) 2012 0.3
International Shared Decision Making conference (ISDM), Maastricht 2011 0.9
American Society of Clinical Oncology (ASCO) Annual Meeting, Chicago, USA (poster
discussion session)
2012 1.5
Annual Meeting of the Society for Medical Decision Making (SMDM), Phoenix, USA
(two poster presentations)
2012 1.2
Network meeting of the Platform Shared Decision Making, Utrecht (poster presentation) 2012 0.3
International Shared Decision Making conference (ISDM), Lima, Peru (poster
presentation and oral presentation)
2013 1.2
D Other
Weekly epidemiology journal club at the Department for Health Evidence, Radboudumc 2007–2013 5.4
Chairing PhD meetings at the Department for Health Evidence 2010–2011 —
TEACHING ACTIVITIES
E Lecturing
Teacher in BSc course Research Methodology 1 (5OMB1), Biomedical Sciences,
Radboud University
2010–2011 —
Teacher in BSc course on basic training in research methodology, (MPV2), Medicine,
Radboud University
2013 —
F Supervision of internships / other
Co-supervisor of a BSc internship, Biomedical Sciences, Radboud University 2011 —
Supervision of a group of BSc students during a 2-week exploratory research internship
(OMB2), Biomedical Sciences, Radboud University
2010–2012 —
Supervision of a group of BSc students in writing a research proposal (5OMB4),
Biomedical Sciences, Radboud University
2011 —
Supervision of a group of BSc students in a module on Cancer Research (MED5DIF1),
Biomedical Sciences, Radboud University
2012 —
Supervision of a group of BSc students during a 2-week small study on risk assessment
(MG01), Radboud University
2011–2012 —
TOTAL 31.0
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Dankwoord
Geef me de kalmte om de dingen te accepteren die ik niet kan veranderen,
de moed om te veranderen wat ik wel kan veranderen,
en de wijsheid om het onderscheid tussen die twee te weten.
Franciscus van Assisi
In oktober 2013 legde ik de laatste hand aan de discussie van dit proefschri, na
een bijzonder enerverend jaar. Naast de gebruikelijke drukte rond het afronden
van een promotietraject besloten Kenneth en ik ook nog eens de stap te wagen om
naar Engeland te verhuizen. Vlak na die verhuizing ging ik op pad naar Peru om
daar de resultaten van onze studie te presenteren (en gelukkig ook van een jne
vakantie te genieten). Ondanks al deze drukte en bezigheden heb ik het schrijven
aan het proefschri toch als een prettige periode ervaren. Dat is ook wel eens
anders geweest. Zo’n twee jaar nadat ik verwachtingsvol van start ging met mijn
promotietraject wilde het rekruteren van patiënten voor ons onderzoek nog niet
vlotten en de door mij zo gewenste publicaties bleven ook nog even uit. Daarnaast
werd bij mijn schoonvader Rob een niet te genezen hersentumor ontdekt, waardoor
werk en privéleven wel erg met elkaar verweven raakten. In deze lastige periode
werd ik gelukkig door heel wat mensen gesteund. Allereerst natuurlijk door mijn
(co-)promotoren en daarnaast wil ik ook graag de extra steun van Gerhard Zielhuis,
Frank Roos en Monique Jans noemen. Samen hebben jullie er aan bijgedragen om
me weer op het juiste spoor te zetten, waarna het gelukkig weer de goede kant uit
ging. Erg bedankt voor jullie steun en vertrouwen.
Beste Peep, erg bedankt voor al je begeleiding en wijze woorden. We moesten
even aan elkaar wennen, maar ik ben je ontzettend gaan waarderen en ik moet
eerlijk bekennen dat ik je begeleiding nog wel eens miste toen ik op afstand aan
het proefschri werkte. Als ik je weer eens één van mijn documenten stuurde, kon
ik rekenen op een snelle reactie waarin je de vinger precies op de zere plek wist te
leggen. Bedankt voor je kritische blik, het hee me geholpen om mijn werk naar
een hoger niveau te tillen. Beste Nelleke, bedankt voor je stimulans om altijd het
beste uit ons werk te willen halen. Zonder jouw aanmoediging had ik er nooit
van durven dromen om een artikel in te sturen naar de Lancet Oncology. En het
werd nog gepubliceerd ook! Ook moedigde je me aan om mijn werk op allerlei
bijeenkomsten te presenteren, wat uiteindelijk nog een posterprijs opleverde. Ook
bedankt voor je klinische blik, als aanvulling op mijn academische blik. Beste
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Winette, ook jij zorgde voor de aanvullende klinische kennis en een brede blik op
het onderzoeksveld. Daarnaast wist je me altijd advies te geven hoe we ons werk
het beste konden presenteren. Beste Gert Jan, wij kennen elkaar al vanuit mijn
studententijd waarin je één van mijn eerste stages begeleidde en nu je ook mijn
promotor bent maakt dat voor mij de cirkel rond.
Daarnaast waren er nog heel wat andere mensen betrokken bij de totstandkoming
van dit proefschri. Pieternel en Rogier, bedankt voor jullie methodologische en
statistische ondersteuning. Bij de dataverzameling waren achtereenvolgens drie
student-assistenten betrokken: Eva Volmeijer, Mirte Sprengers en Sanne Hobbelink.
Bedankt voor al jullie inspanningen! Deze data had natuurlijk nooit verzameld
kunnenworden zonder demedewerking van alle patiënten. Ik vind het erg bijzonder
dat zoveel patiënten bereid waren om mee te werken aan ons onderzoek. Hierbij
moet ook zeker de rol van alle artsen en verpleegkundigen in de deelnemende
ziekenhuizen genoemd worden. Een aantal van deze clinici was daarnaast ook
als co-auteur betrokken bij één of meerdere artikelen. De kwalitatieve studie in
hoofdstuk 8 was voor mij een heel nieuwe onderzoeksdiscipline. De kundige en
vaak ook snelle feedback van Rosella Hermens hee me erg geholpen om ook dit
onderdeel tot een goed einde te brengen. Daarbij kreeg ik ook nog eens hulp van
Frouke Nijhuis bij het onder de knie krijgen van de analyse en Nicole Ketelaar hielp
me met de beginselen van het programma Atlas. Marlies Peters raakte bij mijn
project betrokken door het aanbieden van één van de keuzehulpen aan een patiënt.
Later kreeg je zelfs de hoofdrol in een voorlichtingslmpje over het gebruik van
keuzehulpen, en nu ben je ook nog als co-auteur betrokken bij hoofdstuk 8. Marcia
en Julia, ik vond het erg jn om af en toemet jullie van gedachten te kunnenwisselen
over keuzehulpen en alles daaromheen. Tim Ignacio leverde als bachelorstudent
een bijdrage aan de analyse van de eerste vragenlijsten.
Ik wil ook graag alle collega’s van de afdeling Health Evidence bedanken voor de
prettige werkomgeving. Ik heb me erg thuis gevoeld op de afdeling. Op het werk
deelden we koe- en lunchpauzes, refereersessies en overleggen, en we gingen
op PhD retraite naar Wageningen. Buiten het werk waren er dagjes uit, gingen
we bowlen, speelden we een pubquiz, kakkerlakkenpoker, of dobbelspelletjes met
Sinterklaas en leefden we ons uit met karaoke. Ik denk hier met heel veel plezier
aan terug (al hoop ik hier niet teveel foto’s van terug te zien op de dag van mijn
promotie. . . )!
Een onmisbare factor was Sandra. Je was mijn ideale kamergenoot en secretaresse
en we hebben dan ook heel wat gedeeld, van werkgerelateerde zaken tot dezelfde
outt voor jouw promotie (onafhankelijk van elkaar gekocht!). Jouw tijd hier in
Engeland ging helaas veel te snel voorbij, maar ik hoop dat we elkaar blijven zien,
of dat nu op Skype of aan mijn of jouw kant van de Noordzee is. Het is voor mij
vanzelfsprekend dat je straks als paranimf naast me staat als het dan eindelijk ook
voor mij zover is,.
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Naast Sandra heb ik nog een aantal andere kamergenoten gehad. Janine, erg bedankt
voor je gezelligheid en ook voor je steun in moeilijke tijden. Ram, ik denk nog
regelmatig terug aan je advies om na de verhuizing “niet alles tegelijk te willen”,
als ik weer eens wens dat dingen sneller gaan. Tja, het kost nu eenmaal tijd om te
wennen in een nieuwe omgeving en om in vloeiend Engels mee te kunnen praten
met je nieuwe collega’s, maar langzaam aan kom ik er wel!
Tijdens mijn promotietraject heb ik ook heel wat congressen mogen bezoeken. Het
begon met een bezoekje aanMaastricht en daarna volgden buitenlandse congressen
in Chicago, Phoenix en Lima. Tijdens deze congressen presenteerde ik mijn eigen
werk en leerde andere onderzoekers en hun werk kennen. Daarnaast waren deze
congressen vaak ook erg gezellig. Vanuit Phoenix ging ik met Peep, Paul en Sander
met een huurauto op pad naar Sedona en stondenwe ’s avonds in de woestijn naar de
sterrenhemel te kijken. In Lima was het erg gezellig met KimKuipers-van de Heuvel
en Ingrid Nota. Ingrid, nog bedankt voor het proeezen van het discussiehoofdstuk.
Dr David Wellsted and Dr Marie Anne-Durand, thank you so much for giving me
the opportunity to nish my PhD thesis at the University of Hertfordshire. You
made settling in to life in a foreign country so much easier for me! I really enjoyed
working with you and broadening my view of the eld of shared decision-making
and patient engagement.
To allmy colleagues at the LouisDundas Centre atUniversity College London, thank
you so much for listening to all my stories about the Dutch PhD system. I would
like to thank Professor Myra Bluebond-Langner for giving me the opportunity to
continue my research in the eld of palliative treatment decisions.
En dan waren er familie, schoonfamilie en vrienden die meeleefden met dit hele
promotietraject en ook de nodige aeiding boden. Papa, mama en Jeroen, jullie
hebben van dichtbij mijn ontwikkeling van kleine wijsneus naar jonge doctor mee-
gemaakt. Ik hoop dat jullie trots kunnen zijn op dit eindresultaat. Ik verheug me er
op om iedereen op 20 mei nog eenmaal kort en krachtig te kunnen vertellen waar
ik me al die jaren mee bezig heb gehouden. Bedankt voor jullie interesse, ook als
het soms misschien moeilijk voor te stellen was wat promoveren nu precies inhoudt
of waarom ik dat überhaupt zou willen,.
Alfred, ik ben heel blij dat je me op 20 mei wilt bijstaan als paranimf. Ik ken je nu
ongeveer de hel van mijn leven (wat worden we oud!). Het begon met dansles bij
Vieberink in Doetinchem, later gingen we met een groep stappen in de Radstake of
in Tilburg en tegenwoordig spreken we af met z’n vieren. Al zien we elkaar niet zo
vaak, het is altijd weer vertrouwd en gezellig en eigenlijk is er in al die jaren maar
weinig veranderd.
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Ik had het geluk dat ik mijn ervaringen thuis kon delen met Kenneth, die mijn
passie voor het onderzoek deelt en aan wie ik nooit hoefde uit te leggen hoe blij je
kunt zijn met een publicatie of hoe het is om kritisch commentaar van reviewers
te krijgen. Lieve Kenneth, ik hoop dat je ook zonder dit dankwoord al weet wat je
voor mij betekend hebt de afgelopen jaren. Jouw steun en vertrouwen, en op zijn
tijd de nodige relativering hebben me erg geholpen. Nu deze periode tot een einde
komt kijk ik uit naar een nieuwe periode, waarin we als Dr & Dr Rovers verder
zullen gaan met ons leven hier.
St Albans,
15 maart 2015
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